



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |   |  |
|--|---|--|
| <b>(51) International Patent Classification <sup>7</sup>:</b><br><b>C07K 14/195, C12N 15/31, 1/21, 5/10,</b><br><b>A01H 5/00, 5/10, C12N 15/82</b>   | <b>A3</b>   | <b>(11) International Publication Number:</b> <b>WO 00/20452</b><br><b>(43) International Publication Date:</b> 13 April 2000 (13.04.00) |
| <b>(21) International Application Number:</b> PCT/US99/23181<br><b>(22) International Filing Date:</b> 5 October 1999 (05.10.99)<br><br><b>(30) Priority Data:</b><br>60/103,050 5 October 1998 (05.10.98) US<br><br><b>(71) Applicant:</b> EDEN BIOSCIENCE CORPORATION [US/US];<br>11816 North Creek Parkway N., Bothell, WA 98011-8205<br>(US).<br><br><b>(72) Inventors:</b> WEI, Zhong-Min; 8230 125th Court, Kirkland, WA<br>98034 (US). FAN, Hao; 19712 6th Drive S.E., Bothell,<br>WA 98012 (US). NIGGEMEYER, Jennifer, L.; 21315 2nd<br>Avenue S.E., Bothell, WA 98021 (US).<br><br><b>(74) Agents:</b> GOLDMAN, Michael, L. et al.; Nixon Peabody LLP,<br>Clinton Square, P.O. Box 1051, Rochester, NY 14603 (US).  | <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG,<br>BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB,<br>GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,<br>KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,<br>MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,<br>SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW,<br>ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ,<br>UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD,<br>RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK,<br>ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI<br>patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR,<br>NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i><br><br><b>(88) Date of publication of the international search report:</b><br>6 July 2000 (06.07.00) |  |
| <b>(54) Title:</b> HYPERSENSITIVE RESPONSE ELICITOR FRAGMENTS WHICH ARE ACTIVE BUT DO NOT ELICIT A HYPERSEN-<br>SITIVE RESPONSE<br><br><b>(57) Abstract</b><br><br>The present invention is directed to isolated active fragments of a hypersensitive response elicitor protein or polypeptide which fragment does not elicit a hypersensitive response in plants. Also disclosed are isolated DNA molecules which encode such fragments. Isolated fragments of hypersensitive response elicitor proteins or polypeptides in accordance with the present invention and the isolated DNA molecules that encode them have the following activities: imparting disease resistance to plants, enhancing plant growth, and/or controlling insects on plants. This can be achieved by applying the fragments of a hypersensitive response elicitor in a non-infectious form to plants or plant seeds under conditions effective to impart disease resistance, to enhance plant growth, and/or to control insects on plants or plants grown from the plant seeds. Alternatively, transgenic plants or plant seeds transformed with a DNA molecule encoding the fragment can be provided and the transgenic plants or plants resulting from the transgenic plant seeds are grown under conditions effective to impart disease resistance, to enhance plant growth, and/or to control insects on plants or plants grown from the plant seeds. |   |  |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali   | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger  | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakstan                                | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |  |    |  |    |                          |

SEP 28 2000

## **HYPERSENSITIVE RESPONSE ELICITOR FRAGMENTS WHICH ARE ACTIVE BUT DO NOT ELICIT A HYPERSENSITIVE RESPONSE**

This application claims benefit of U.S. Provisional Patent Application  
5 Serial No. 60/103,050, filed October 5, 1998.

### **FIELD OF THE INVENTION**

The present invention relates to active fragments of a hypersensitive  
10 response elicitor which fragments do not elicit a hypersensitive response.

### **BACKGROUND OF THE INVENTION**

Interactions between bacterial pathogens and their plant hosts generally  
15 fall into two categories: (1) compatible (pathogen-host), leading to intercellular  
bacterial growth, symptom development, and disease development in the host plant;  
and (2) incompatible (pathogen-nonhost), resulting in the hypersensitive response, a  
particular type of incompatible interaction occurring, without progressive disease  
symptoms. During compatible interactions on host plants, bacterial populations  
20 increase dramatically and progressive symptoms occur. During incompatible  
interactions, bacterial populations do not increase, and progressive symptoms do not  
occur.

The hypersensitive response is a rapid, localized necrosis that is  
associated with the active defense of plants against many pathogens (Kiraly, Z.,  
25 "Defenses Triggered by the Invader: Hypersensitivity," pages 201-224 in: Plant  
Disease: An Advanced Treatise, Vol. 5, J.G. Horsfall and E.B. Cowling, ed.  
Academic Press New York (1980); Klement, Z., "Hypersensitivity," pages 149-177  
in: Phytopathogenic Prokaryotes, Vol. 2, M.S. Mount and G.H. Lacy, ed. Academic  
Press, New York (1982)). The hypersensitive response elicited by bacteria is readily  
30 observed as a tissue collapse if high concentrations ( $\geq 10^7$  cells/ml) of a limited  
host-range pathogen like *Pseudomonas syringae* or *Erwinia amylovora* are infiltrated  
into the leaves of nonhost plants (necrosis occurs only in isolated plant cells at lower  
levels of inoculum) (Klement, Z., "Rapid Detection of Pathogenicity of  
Phytopathogenic Pseudomonads," Nature 199:299-300; Klement, et al.,

- 2 -

"Hypersensitive Reaction Induced by Phytopathogenic Bacteria in the Tobacco Leaf," Phytopathology 54:474-477 (1963); Turner, et al., "The Quantitative Relation Between Plant and Bacterial Cells Involved in the Hypersensitive Reaction," Phytopathology 64:885-890 (1974); Klement, Z., "Hypersensitivity," pages 149-177 in Phytopathogenic Prokaryotes, Vol. 2., M.S. Mount and G.H. Lacy, ed. Academic Press, New York (1982)). The capacities to elicit the hypersensitive response in a nonhost and be pathogenic in a host appear linked. As noted by Klement, Z., "Hypersensitivity," pages 149-177 in Phytopathogenic Prokaryotes, Vol. 2., M.S. Mount and G.H. Lacy, ed. Academic Press, New York, these pathogens also cause physiologically similar, albeit delayed, necroses in their interactions with compatible hosts. Furthermore, the ability to produce the hypersensitive response or pathogenesis is dependent on a common set of genes, denoted *hrp* (Lindgren, P.B., et al., "Gene Cluster of *Pseudomonas syringae* pv. 'phaseolicola' Controls Pathogenicity of Bean Plants and Hypersensitivity on Nonhost Plants," J. Bacteriol. 168:512-22 (1986); Willis, D.K., et al., "*hrp* Genes of Phytopathogenic Bacteria," Mol. Plant-Microbe Interact. 4:132-138 (1991)). Consequently, the hypersensitive response may hold clues to both the nature of plant defense and the basis for bacterial pathogenicity.

The *hrp* genes are widespread in Gram-negative plant pathogens, where they are clustered, conserved, and in some cases interchangeable (Willis, D.K., et al., "*hrp* Genes of Phytopathogenic Bacteria," Mol. Plant-Microbe Interact. 4:132-138 (1991); Bonas, U., "*hrp* Genes of Phytopathogenic Bacteria," pages 79-98 in: Current Topics in Microbiology and Immunology: Bacterial Pathogenesis of Plants and Animals - Molecular and Cellular Mechanisms, J.L. Dangl, ed. Springer-Verlag, Berlin (1994)). Several *hrp* genes encode components of a protein secretion pathway similar to one used by *Yersinia*, *Shigella*, and *Salmonella* spp. to secrete proteins essential in animal diseases (Van Gijsegem, et al., "Evolutionary Conservation of Pathogenicity Determinants Among Plant and Animal Pathogenic Bacteria," Trends Microbiol. 1:175-180 (1993)). In *E. amylovora*, *P. syringae*, and *P. solanacearum*, *hrp* genes have been shown to control the production and secretion of glycine-rich, protein elicitors of the hypersensitive response (He, S.Y., et al. "Pseudomonas Syringae pv. Syringae HarpinPss: a Protein that is Secreted via the Hrp Pathway and Elicits the Hypersensitive Response in Plants," Cell 73:1255-1266 (1993), Wei, Z.-H.,



- 3 -

et al., "HrpI of *Erwinia amylovora* Functions in Secretion of Harpin and is a Member of a New Protein Family," J. Bacteriol. 175:7958-7967 (1993); Arlat, M. et al.

"PopA1, a Protein Which Induces a Hypersensitive-like Response on Specific Petunia Genotypes, is Secreted via the Hrp Pathway of *Pseudomonas solanacearum*," EMBO J. 13:543-553 (1994)).

The first of these proteins was discovered in *E. amylovora* Ea321, a bacterium that causes fire blight of rosaceous plants, and was designated harpin (Wei, Z.-M., et al., "Harpin, Elicitor of the Hypersensitive Response Produced by the Plant Pathogen *Erwinia amylovora*," Science 257:85-88 (1992)). Mutations in the encoding *hrpN* gene revealed that harpin is required for *E. amylovora* to elicit a hypersensitive response in nonhost tobacco leaves and incite disease symptoms in highly susceptible pear fruit. The *P. solanacearum* GMI1000 PopA1 protein has similar physical properties and also elicits the hypersensitive response in leaves of tobacco, which is not a host of that strain (Arlat, et al. "PopA1, a Protein Which Induces a Hypersensitive-like Response on Specific Petunia Genotypes, is Secreted via the Hrp Pathway of *Pseudomonas solanacearum*," EMBO J. 13:543-53 (1994)). However, *P. solanacearum* *popA* mutants still elicit the hypersensitive response in tobacco and incite disease in tomato. Thus, the role of these glycine-rich hypersensitive response elicitors can vary widely among Gram-negative plant pathogens.

Other plant pathogenic hypersensitive response elicitors have been isolated, cloned, and sequenced. These include: *Erwinia chrysanthemi* (Bauer, et. al., "*Erwinia chrysanthemi* Harpin<sub>Ech</sub>: Soft-Rot Pathogenesis," MPMI 8(4): 484-91 (1995)); *Erwinia carotovora* (Cui, et. al., "The RsmA<sup>-</sup> Mutants of *Erwinia carotovora* subsp. *carotovora* Strain Ecc71 Overexpress *hrpN*<sub>Ecc</sub> and Elicit a Hypersensitive Reaction-like Response in Tobacco Leaves," MPMI 9(7): 565-73 (1996)); *Erwinia stewartii* (Ahmad, et. al., "Harpin is not Necessary for the Pathogenicity of *Erwinia stewartii* on Maize," 8th Int'l. Cong. Molec. Plant-Microb. Inter. July 14-19, 1996 and Ahmad, et. al., "Harpin is not Necessary for the Pathogenicity of *Erwinia stewartii* on Maize," Ann. Mtg. Am. Phytopath. Soc. July 27-31, 1996); and *Pseudomonas syringae* pv. *syringae* (WO 94/26782 to Cornell Research Foundation, Inc.).

The present invention seeks to identify fragments of hypersensitive response elicitor proteins or polypeptides, which fragments do not elicit a hypersensitive response but are active when utilized in conjunction with plants.

5

## SUMMARY OF THE INVENTION

The present invention is directed to isolated fragments of an *Erwinia* hypersensitive response elicitor protein or polypeptide which fragments do not elicit a hypersensitive response in plants but are otherwise active when utilized in conjunction with plants. Also disclosed are isolated DNA molecules which encode such fragments.

10

The fragments of hypersensitive response elicitors according to the present invention have the following activity when utilized in conjunction with plants: imparting disease resistance to plants, enhancing plant growth and/or controlling insects. This involves applying the fragments in a non-infectious form to plants or plant seeds under conditions effective to impart disease resistance, to enhance plant growth, and/or to control insects on plants or plants grown from the plant seeds.

15

As an alternative to applying the fragments to plants or plant seeds in order to impart disease resistance, to enhance plant growth, and/or to control insects on plants, transgenic plants or plant seeds can be utilized. When utilizing transgenic plants, this involves providing a transgenic plant transformed with a DNA molecule encoding a fragment of a hypersensitive response elicitor protein or polypeptide in accordance with the present invention and growing the plant under conditions effective to impart disease resistance, to enhance plant growth, and/or to control insects in the plants or plants grown from the plant seeds. Alternatively, a transgenic plant seed transformed with the DNA molecule encoding such a fragment can be provided and planted in soil. A plant is then propagated under conditions effective to impart disease resistance, to enhance plant growth, and/or to control insects on plants or plants grown from the plant seeds.

20

25

30

### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 shows truncated proteins of the hypersensitive response elicitor protein or polypeptide.

5                   Figure 2 shows a list of synthesized oligonucleotide primers for construction of truncated harpin proteins. N represents the N-terminus (5' region), and C represents the C-terminus (3' region). The primers correspond to the indicated sequence identification numbers for the present application: N1 (SEQ. ID. No. 1), N76 (SEQ. ID. No. 2), N99 (SEQ. ID. No. 3), N105 (SEQ. ID. No. 4), N110 (SEQ. ID. No. 5), N137 (SEQ. ID. No. 6), N150 (SEQ. ID. No. 7), N169 (SEQ. ID. No. 8),  
10                   N210 (SEQ. ID. No. 9), N267 (SEQ. ID. No. 10), N343 (SEQ. ID. No. 11), C75 (SEQ. ID. No. 12), C104 (SEQ. ID. No. 13), C168 (SEQ. ID. No. 14), C180 (SEQ. ID. No. 15), C204 (SEQ. ID. No. 16), C209 (SEQ. ID. No. 17), C266 (SEQ. ID. No. 18), C342 (SEQ. ID. No. 19), and C403 (SEQ. ID. No. 20).

15

### **DETAILED DESCRIPTION OF THE INVENTION**

The present invention is directed to isolated fragments of a hypersensitive response elicitor protein or polypeptide where the fragments do not  
20                   elicit a hypersensitive response but have other activity in plants. Also disclosed are DNA molecules encoding such fragments as well as expression systems, host cells, and plants containing such molecules. Uses of the fragments themselves and the DNA molecules encoding them are disclosed.

The fragments of hypersensitive response elicitor polypeptides or  
25                   proteins according to the present invention are derived from hypersensitive response elicitor polypeptides or proteins of a wide variety of fungal and bacterial pathogens. Such polypeptides or proteins are able to elicit local necrosis in plant tissue contacted by the elicitor. Examples of suitable bacterial sources of polypeptide or protein  
30                   elicitors include *Erwinia*, *Pseudomonas*, and *Xanthomonas* species (e.g., the following bacteria: *Erwinia amylovora*, *Erwinia chrysanthemi*, *Erwinia stewartii*, *Erwinia carotovora*, *Pseudomonas syringae*, *Pseudomonas solanacearum*, *Xanthomonas campestris*, and mixtures thereof).

- 6 -

An example of a fungal source of a hypersensitive response elicitor protein or polypeptide is *Phytophthora*. Suitable species of *Phytophthora* include *Phytophthora parasitica*, *Phytophthora cryptogea*, *Phytophthora cinnamomi*, *Phytophthora capsici*, *Phytophthora megasperma*, and *Phytophthora citrophthora*.

5 The hypersensitive response elicitor polypeptide or protein from *Erwinia chrysanthemi* has an amino acid sequence corresponding to SEQ. ID. No. 21 as follows:

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |    |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| 10 | Met | Gln | Ile | Thr | Ile | Lys | Ala | His | Ile | Gly | Gly | Asp | Leu | Gly | Val | Ser | 1   | 5   | 10  | 15 |
|    | Gly | Leu | Gly | Ala | Gln | Gly | Leu | Lys | Gly | Leu | Asn | Ser | Ala | Ala | Ser | Ser | 20  | 25  | 30  |    |
|    | Leu | Gly | Ser | Ser | Val | Asp | Lys | Leu | Ser | Ser | Thr | Ile | Asp | Lys | Leu | Thr | 35  | 40  | 45  |    |
| 15 | Ser | Ala | Leu | Thr | Ser | Met | Met | Phe | Gly | Gly | Ala | Leu | Ala | Gln | Gly | Leu | 50  | 55  | 60  |    |
|    | Gly | Ala | Ser | Ser | Lys | Gly | Leu | Gly | Met | Ser | Asn | Gln | Leu | Gly | Gln | Ser | 65  | 70  | 75  |    |
| 20 | Phe | Gly | Asn | Gly | Ala | Gln | Gly | Ala | Ser | Asn | Leu | Leu | Ser | Val | Pro | Lys | 85  | 90  | 95  |    |
|    | Ser | Gly | Gly | Asp | Ala | Leu | Ser | Lys | Met | Phe | Asp | Lys | Ala | Leu | Asp | Asp | 100 | 105 | 110 |    |
|    | Leu | Leu | Gly | His | Asp | Thr | Val | Thr | Lys | Leu | Thr | Asn | Gln | Ser | Asn | Gln | 115 | 120 | 125 |    |
| 25 | Leu | Ala | Asn | Ser | Met | Leu | Asn | Ala | Ser | Gln | Met | Thr | Gln | Gly | Asn | Met | 130 | 135 | 140 |    |
|    | Asn | Ala | Phe | Gly | Ser | Gly | Val | Asn | Asn | Ala | Leu | Ser | Ser | Ile | Leu | Gly | 145 | 150 | 155 |    |
| 30 | Asn | Gly | Leu | Gly | Gln | Ser | Met | Ser | Gly | Phe | Ser | Gln | Pro | Ser | Leu | Gly | 165 | 170 | 175 |    |
|    | Ala | Gly | Gly | Leu | Gln | Gly | Leu | Ser | Gly | Ala | Gly | Ala | Phe | Asn | Gln | Leu | 180 | 185 | 190 |    |
|    | Gly | Asn | Ala | Ile | Gly | Met | Gly | Val | Gly | Gln | Asn | Ala | Ala | Leu | Ser | Ala | 195 | 200 | 205 |    |
| 35 | Leu | Ser | Asn | Val | Ser | Thr | His | Val | Asp | Gly | Asn | Asn | Arg | His | Phe | Val | 210 | 215 | 220 |    |
|    | Asp | Lys | Glu | Asp | Arg | Gly | Met | Ala | Lys | Glu | Ile | Gly | Gln | Phe | Met | Asp | 225 | 230 | 235 |    |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 240 |    |

[illegible]

15 This hypersensitive response elicitor polypeptide or protein has a molecular weight of 34 kDa, is heat stable, has a glycine content of greater than 16%, and contains substantially no cysteine. The *Erwinia chrysanthemi* hypersensitive response elicitor polypeptide or protein is encoded by a DNA molecule having a nucleotide sequence  
20 corresponding to SEQ. ID. No. 22 as follows:

|    |            |            |            |            |            |            |     |
|----|------------|------------|------------|------------|------------|------------|-----|
|    | CGATTTTACC | CGGGTGAACG | TGCTATGACC | GACAGCATCA | CGGTATTGCA | CACCGTTACG | 60  |
|    | GCGTTTATGG | CCGCGATGAA | CCGGCATCAG | GCGGCGCGCT | GGTCGCGGCA | ATCCGGCGTC | 120 |
|    | GATCTGGTAT | TTCAGTTTGG | GGACACCGGG | CGTGAACTCA | TGATGCAGAT | TCAGCCGGGG | 180 |
| 25 | CAGCAATATC | CCGGCATGTT | GCGCACGCTG | CTCGCTCGTC | GTTATCAGCA | GGCGGCAGAG | 240 |
|    | TGCGATGGCT | GCCATCTGTG | CCTGAACGGC | AGCGATGTAT | TGATCCTCTG | GTGGCCGCTG | 300 |
|    | CCGTCGGATC | CCGGCAGTTA | TCCGCAGGTG | ATCGAACGTT | TGTTTGAACT | GGCGGGAATG | 360 |
|    | ACGTTGCCGT | CGCTATCCAT | AGCACCGACG | GCGCGTCCGC | AGACAGGGAA | CGGACGCGCC | 420 |
|    | CGATCATTA  | GATAAAGGCG | GCTTTTTTTA | TTGCAAAACG | GTAACGGTGA | GGAACCGTTT | 480 |
| 30 | CACCGTCGGC | GTCACTCAGT | AACAAGTATC | CATCATGATG | CCTACATCGG | GATCGGCGTG | 540 |
|    | GGCATCCGTT | GCAGATACTT | TTGCGAACAC | CTGACATGAA | TGAGGAAACG | AAATTATGCA | 600 |
|    | AATTACGATC | AAAGCGCACA | TCGGCGGTGA | TTTGGGCGTC | TCCGGTCTGG | GGCTGGGTGC | 660 |
|    | TCAGGGACTG | AAAGGACTGA | ATTCCGCGGC | TTCATCGCTG | GGTTCCAGCG | TGGATAAACT | 720 |
|    | GAGCAGCACC | ATCGATAAGT | TGACCTCCGC | GCTGACTTCG | ATGATGTTTG | GCGGCGCGCT | 780 |
| 35 | GGCGCAGGGG | CTGGGCGCCA | GCTCGAAGGG | GCTGGGGATG | AGCAATCAAC | TGGGCCAGTC | 840 |

|    |            |            |            |            |            |            |      |
|----|------------|------------|------------|------------|------------|------------|------|
|    | TTTCGGCAAT | GGCGCGCAGG | GTGCGAGCAA | CCTGCTATCC | GTACCGAAAT | CCGGCGGCGA | 900  |
|    | TGCGTTGTCA | AAAATGTTTG | ATAAAGCGCT | GGACGATCTG | CTGGGTCATG | ACACCGTGAC | 960  |
|    | CAAGCTGACT | AACCAGAGCA | ACCAACTGGC | TAATTCAATG | CTGAACGCCA | GCCAGATGAC | 1020 |
|    | CCAGGGTAAT | ATGAATGCGT | TCGGCAGCGG | TGTGAACAAC | GCACTGTGCT | CCATTCTCGG | 1080 |
| 5  | CAACGGTCTC | GGCCAGTCGA | TGAGTGGCTT | CTCTCAGCCT | TCTCTGGGGG | CAGGCGGCTT | 1140 |
|    | GCAGGGCCTG | AGCGGCGCGG | GTGCATTCAA | CCAGTTGGGT | AATGCCATCG | GCATGGGCGT | 1200 |
|    | GGGGCAGAAT | GCTGCGCTGA | GTGCGTTGAG | TAACGTCAGC | ACCCACGTAG | ACGGTAACAA | 1260 |
|    | CCGCCACTTT | GTAGATAAAG | AAGATCGCGG | CATGGCGAAA | GAGATCGGCC | AGTTTATGGA | 1320 |
|    | TCAGTATCCG | GAAATATTCG | GTAACCGGA  | ATACCAGAAA | GATGGCTGGA | GTTCCCGGAA | 1380 |
| 10 | GACGGACGAC | AAATCCTGGG | CTAAAGCGCT | GAGTAAACCG | GATGATGACG | GTATGACCGG | 1440 |
|    | CGCCAGCATG | GACAAATTCC | GTCAGGCGAT | GGGTATGATC | AAAAGCGCGG | TGGCGGGTGA | 1500 |
|    | TACCGGCAAT | ACCAACCTGA | ACCTGCGTGG | CGCGGGCGGT | GCATCGCTGG | GTATCGATGC | 1560 |
|    | GGCTGTCTGC | GGCGATAAAA | TAGCCAACAT | GTCGCTGGGT | AAGCTGGCCA | ACGCCTGATA | 1620 |
|    | ATCTGTGCTG | GCCTGATAAA | GCGGAAACGA | AAAAAGAGAC | GGGGAAGCCT | GTCTCTTTTC | 1680 |
| 15 | TTATTATGCG | GTTTATGCGG | TTACCTGGAC | CGGTTAATCA | TCGTCATCGA | TCTGGTACAA | 1740 |
|    | ACGCACATTT | TCCCGTTCAT | TCGCGTCTGT | ACGCGCCACA | ATCGCGATGG | CATCTTCTCT | 1800 |
|    | GTCGCTCAGA | TTGCGCGGCT | GATGGGGAAC | GCCGGGTGGA | ATATAGAGAA | ACTCGCCGGC | 1860 |
|    | CAGATGGAGA | CACGTCTGCG | ATAAATCTGT | GCCGTAACGT | GTTTCTATCC | GCCCCTTTAG | 1920 |
|    | CAGATAGATT | GCGGTTTCGT | AATCAACATG | GTAATGCGGT | TCCGCCTGTG | CGCCGGCCGG | 1980 |
| 20 | GATCACCACA | ATATTCATAG | AAAGCTGTCT | TGCACCTACC | GTATCGCGGG | AGATACCGAC | 2040 |
|    | AAAATAGGGC | AGTTTTTGCG | TGGTATCCGT | GGGGTGTTC  | GGCCTGACAA | TCTTGAGTTG | 2100 |
|    | GTTCTGCATC | ATCTTTCTCC | ATCTGGGCGA | CCTGATCGGT | T          |            | 2141 |

30 Met Ser Leu Asn Thr Ser Gly Leu Gly Ala Ser Thr Met Gln Ile Ser  
1 5 10 15  
Ile Gly Gly Ala Gly Gly Asn Asn Gly Leu Leu Gly Thr Ser Arg Gln  
20 25 30

- 9 -

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Asn | Ala | Gly | Leu | Gly | Gly | Asn | Ser | Ala | Leu | Gly | Leu | Gly | Gly | Gly | Asn |  |
|    |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |  |
|    | Gln | Asn | Asp | Thr | Val | Asn | Gln | Leu | Ala | Gly | Leu | Leu | Thr | Gly | Met | Met |  |
|    |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |  |
| 5  | Met | Met | Met | Ser | Met | Met | Gly | Gly | Gly | Gly | Leu | Met | Gly | Gly | Gly | Leu |  |
|    | 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |  |
|    | Gly | Gly | Gly | Leu | Gly | Asn | Gly | Leu | Gly | Gly | Ser | Gly | Gly | Leu | Gly | Glu |  |
|    |     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |  |
| 10 | Gly | Leu | Ser | Asn | Ala | Leu | Asn | Asp | Met | Leu | Gly | Gly | Ser | Leu | Asn | Thr |  |
|    |     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |  |
|    | Leu | Gly | Ser | Lys | Gly | Gly | Asn | Asn | Thr | Thr | Ser | Thr | Thr | Asn | Ser | Pro |  |
|    |     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |  |
|    | Leu | Asp | Gln | Ala | Leu | Gly | Ile | Asn | Ser | Thr | Ser | Gln | Asn | Asp | Asp | Ser |  |
|    |     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |  |
| 15 | Thr | Ser | Gly | Thr | Asp | Ser | Thr | Ser | Asp | Ser | Ser | Asp | Pro | Met | Gln | Gln |  |
|    | 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |  |
|    | Leu | Leu | Lys | Met | Phe | Ser | Glu | Ile | Met | Gln | Ser | Leu | Phe | Gly | Asp | Gly |  |
|    |     |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     | 175 |     |  |
| 20 | Gln | Asp | Gly | Thr | Gln | Gly | Ser | Ser | Ser | Gly | Gly | Lys | Gln | Pro | Thr | Glu |  |
|    |     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |  |
|    | Gly | Glu | Gln | Asn | Ala | Tyr | Lys | Lys | Gly | Val | Thr | Asp | Ala | Leu | Ser | Gly |  |
|    |     |     | 195 |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |  |
|    | Leu | Met | Gly | Asn | Gly | Leu | Ser | Gln | Leu | Leu | Gly | Asn | Gly | Gly | Leu | Gly |  |
|    |     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |  |
| 25 | Gly | Gly | Gln | Gly | Gly | Asn | Ala | Gly | Thr | Gly | Leu | Asp | Gly | Ser | Ser | Leu |  |
|    | 225 |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |  |
|    | Gly | Gly | Lys | Gly | Leu | Gln | Asn | Leu | Ser | Gly | Pro | Val | Asp | Tyr | Gln | Gln |  |
|    |     |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |     |  |
| 30 | Leu | Gly | Asn | Ala | Val | Gly | Thr | Gly | Ile | Gly | Met | Lys | Ala | Gly | Ile | Gln |  |
|    |     |     | 260 |     |     |     |     |     | 265 |     |     |     |     | 270 |     |     |  |
|    | Ala | Leu | Asn | Asp | Ile | Gly | Thr | His | Arg | His | Ser | Ser | Thr | Arg | Ser | Phe |  |
|    |     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |     |     |     |  |
|    | Val | Asn | Lys | Gly | Asp | Arg | Ala | Met | Ala | Lys | Glu | Ile | Gly | Gln | Phe | Met |  |
|    |     | 290 |     |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |  |
| 35 | Asp | Gln | Tyr | Pro | Glu | Val | Phe | Gly | Lys | Pro | Gln | Tyr | Gln | Lys | Gly | Pro |  |
|    | 305 |     |     |     |     | 310 |     |     |     |     | 315 |     |     |     |     | 320 |  |
|    | Gly | Gln | Glu | Val | Lys | Thr | Asp | Asp | Lys | Ser | Trp | Ala | Lys | Ala | Leu | Ser |  |
|    |     |     |     |     | 325 |     |     |     |     | 330 |     |     |     |     | 335 |     |  |
|    | Lys | Pro | Asp | Asp | Asp | Gly | Met | Thr | Pro | Ala | Ser | Met | Glu | Gln | Phe | Asn |  |

- 10 -

[illegible]

This hypersensitive response elicitor polypeptide or protein has a molecular weight of about 39 kDa, has a pI of approximately 4.3, and is heat stable at 100°C for at least 10 minutes. This hypersensitive response elicitor polypeptide or protein has substantially no cysteine. The hypersensitive response elicitor polypeptide or protein derived from *Erwinia amylovora* is more fully described in Wei, Z.-M., R. J. Laby, C. H. Zumoff, D. W. Bauer, S.-Y. He, A. Collmer, and S. V. Beer, "Harpin, Elicitor of the Hypersensitive Response Produced by the Plant Pathogen *Erwinia amylovora*," Science 257:85-88 (1992), which is hereby incorporated by reference. The DNA molecule encoding this polypeptide or protein has a nucleotide sequence corresponding to SEQ. ID. No. 24 as follows:

|    |            |            |             |            |            |            |     |
|----|------------|------------|-------------|------------|------------|------------|-----|
| 20 | AAGCTTCGGC | ATGGCACGTT | TGACCGTTGG  | GTCGGCAGGG | TACGTTTGAA | TTATTCATAA | 60  |
|    | GAGGAATACG | TTATGAGTCT | GAATACAAGT  | GGGCTGGGAG | CGTCAACGAT | GCAAATTTCT | 120 |
|    | ATCGGCGGTG | CGGGCGGAAA | TAACGGGTTG  | CTGGGTACCA | GTCGCCAGAA | TGCTGGGTTG | 180 |
|    | GGTGGCAATT | CTGCACTGGG | GCTGGGCGGC  | GGTAATCAAA | ATGATACCGT | CAATCAGCTG | 240 |
|    | GCTGGCTTAC | TCACCGGCAT | GATGATGATG  | ATGAGCATGA | TGGGCGGTGG | TGGGCTGATG | 300 |
| 25 | GGCGGTGGCT | TAGGCGGTGG | CTTAGGTAAT  | GGCTTGGGTG | GCTCAGGTGG | CCTGGGCGAA | 360 |
|    | GGACTGTCTG | ACGCGCTGAA | CGATATGTTA  | GGCGGTTCGC | TGAACACGCT | GGGCTCGAAA | 420 |
|    | GGCGGCAACA | ATACCACTTC | AACAACAAAT  | TCCCCGCTGG | ACCAGGCGCT | GGGTATTAAC | 480 |
|    | TCAACGTCCC | AAAACGACGA | TTCCACCTCC  | GGCACAGATT | CCACCTCAGA | CTCCAGCGAC | 540 |
|    | CCGATGCAGC | AGCTGCTGAA | GATGTTTCAGC | GAGATAATGC | AAAGCCTGTT | TGGTGATGGG | 600 |
| 30 | CAAGATGGCA | CCCAGGGCAG | TTCCTCTGGG  | GGCAAGCAGC | CGACCGAAGG | CGAGCAGAAC | 660 |
|    | GCCTATAAAA | AAGGAGTCAC | TGATGCGCTG  | TCGGGCCTGA | TGGGTAATGG | TCTGAGCCAG | 720 |
|    | CTCCTTGGA  | ACGGGGGACT | GGGAGGTGGT  | CAGGGCGGTA | ATGCTGGCAC | GGGTCTTGAC | 780 |
|    | GGTTTCGTCG | TGGGCGGCAA | AGGGCTGCAA  | AACCTGAGCG | GGCCGGTGGA | CTACCAGCAG | 840 |



- 11 -

TTAGGTAACG CCGTGGGTAC CGGTATCGGT ATGAAAGCGG GCATTCAGGC GCTGAATGAT 900  
 ATCGGTACGC ACAGGCACAG TTCAACCCGT TCTTTCGTCA ATAAAGGCGA TCGGGCGATG 960  
 GCGAAGGAAA TCGGTTCAGTT CATGGACCAG TATCCTGAGG TGTTCGGCAA GCCGCAGTAC 1020  
 CAGAAAGGCC CGGGTCAGGA GGTGAAAACC GATGACAAAT CATGGGCAAA AGCACTGAGC 1080  
 5 AAGCCAGATG ACGACGGAAT GACACCAGCC AGTATGGAGC AGTTCAACAA AGCCAAGGGC 1140  
 ATGATCAAAA GGCCCATGGC GGGTGATACC GGCAACGGCA ACCTGCAGGC ACGCGGTGCC 1200  
 GGTGGTTCTT CGCTGGGTAT TGATGCCATG ATGGCCGGTG ATGCCATTAA CAATATGGCA 1260  
 CTTGGCAAGC TGGGCGCGGC TTAAGCTT 1288

10

Another potentially suitable hypersensitive response elicitor from  
*Erwinia amylovora* is disclosed in U.S. Patent Application Serial No. 09/120,927,  
 which is hereby incorporated by reference. The protein is encoded by a DNA  
 molecule having a nucleic acid sequence of SEQ. ID. No. 25 as follows:

15 ATGTCAATTC TTACGCTTAA CAACAATACC TCGTCCTCGC CGGGTCTGTT CCAGTCCGGG 60  
 GGGGACAACG GGCTTGGTGG TCATAATGCA AATTCTGCGT TGGGGCAACA ACCCATCGAT 120  
 20 CGGCAAACCA TTGAGCAAAT GGCTCAATTA TTGGCGGAAC TGTTAAAGTC ACTGCTATCG 180  
 CCACAATCAG GTAATGCGGC AACCGGAGCC GGTGGCAATG ACCAGACTAC AGGAGTTGGT 240  
 AACGCTGGCG GCCTGAACGG ACGAAAAGGC ACAGCAGGAA CCACTCCGCA GTCTGACAGT 300  
 25 CAGAACATGC TGAGTGAGAT GGGCAACAAC GGGCTGGATC AGGCCATCAC GCCCGATGGC 360  
 CAGGGCGGCG GGCAGATCGG CGATAATCCT TTAAGTAAAG CCATGCTGAA GCTTATTGCA 420  
 30 CGCATGATGG ACGGCCAAAG CGATCAGTTT GGCCAACCTG GTACGGGCAA CAACAGTGCC 480  
 TCTTCCGGTA CTTCTTCATC TGGCGGTTCC CCTTTTAAAG ATCTATCAGG GGGGAAGGCC 540  
 CCTTCCGGCA ACTCCCCTTC CGGCAACTAC TCTCCCGTCA GTACCTTCTC ACCCCCATCC 600  
 35 ACGCCAACGT CCCCTACCTC ACCGCTTGAT TTCCCTTCTT CTCCCACCAA AGCAGCCGGG 660  
 GGCAGCACGC CGGTAACCGA TCATCCTGAC CCTGTTGGTA GCGCGGGCAT CGGGGCCGGA 720  
 40 AATTCCGTGG CTTTCAACAG CGCCGGCGCT AATCAGACGG TGCTGCATGA CACCATTACC 780  
 GTGAAAGCGG GTCAGGTGTT TGATGGCAAA GGACAAACCT TCACCGCCGG TTCAGAATTA 840  
 GGCAGTGGCG GCCAGTCTGA AAACCAGAAA CCGCTGTTTA TACTGGAAGA CGGTGCCAGC 900  
 45 CTGAAAAACG TCACCATGGG CGACGACGGG GCGGATGGTA TTCATCTTTA CGGTGATGCC 960  
 AAAATAGACA ATCTGCACGT CACCAACGTG GGTGAGGACG CGATTACCGT TAAGCCAAAC 1020  
 50 AGCGCGGGCA AAAAATCCCA CGTTGAAATC ACTAACAGTT CTTTCGAGCA CGCCTCTGAC 1080  
 AAGATCCTGC AGCTGAATGC CGATACTAAC CTGAGCGTTG ACAACGTGAA GGCCAAAGAC 1140

- 12 -

TTTGGTACTT TTGTACGCAC TAACGGCGGT CAACAGGGTA ACTGGGATCT GAATCTGAGC 1200  
 CATATCAGCG CAGAAGACGG TAAGTTCTCG TTCGTTAAAA GCGATAGCGA GGGGCTAAAC 1260  
 5 GTCAATACCA GTGATATCTC ACTGGGTGAT GTTGAAAACC ACTACAAAGT GCCGATGTCC 1320  
 GCCAACCTGA AGGTGGCTGA ATGA 1344

10

See GenBank Accession No. U94513. The isolated DNA molecule of the present invention encodes a hypersensitive response elicitor protein or polypeptide having an amino acid sequence of SEQ. ID. No. 26 as follows:

15 Met Ser Ile Leu Thr Leu Asn Asn Asn Thr Ser Ser Ser Pro Gly Leu  
 1 5 10 15  
 Phe Gln Ser Gly Gly Asp Asn Gly Leu Gly Gly His Asn Ala Asn Ser  
 20 20 25 30  
 Ala Leu Gly Gln Gln Pro Ile Asp Arg Gln Thr Ile Glu Gln Met Ala  
 35 40 45  
 25 Gln Leu Leu Ala Glu Leu Leu Lys Ser Leu Leu Ser Pro Gln Ser Gly  
 50 55 60  
 Asn Ala Ala Thr Gly Ala Gly Gly Asn Asp Gln Thr Thr Gly Val Gly  
 65 70 75 80  
 30 Asn Ala Gly Gly Leu Asn Gly Arg Lys Gly Thr Ala Gly Thr Thr Pro  
 85 90 95  
 Gln Ser Asp Ser Gln Asn Met Leu Ser Glu Met Gly Asn Asn Gly Leu  
 100 105 110  
 35 Asp Gln Ala Ile Thr Pro Asp Gly Gln Gly Gly Gly Gln Ile Gly Asp  
 115 120 125  
 Asn Pro Leu Leu Lys Ala Met Leu Lys Leu Ile Ala Arg Met Met Asp  
 130 135 140  
 40 Gly Gln Ser Asp Gln Phe Gly Gln Pro Gly Thr Gly Asn Asn Ser Ala  
 145 150 155 160  
 45 Ser Ser Gly Thr Ser Ser Ser Gly Gly Ser Pro Phe Asn Asp Leu Ser  
 165 170 175  
 Gly Gly Lys Ala Pro Ser Gly Asn Ser Pro Ser Gly Asn Tyr Ser Pro  
 180 185 190  
 50 Val Ser Thr Phe Ser Pro Pro Ser Thr Pro Thr Ser Pro Thr Ser Pro  
 195 200 205  
 55 Leu Asp Phe Pro Ser Ser Pro Thr Lys Ala Ala Gly Gly Ser Thr Pro  
 210 215 220

- 13 -

|    |   |             |
|----|---|-------------|
|    | Val Thr Asp His Pro Asp Pro Val Gly Ser Ala Gly Ile Gly Ala Gly |             |
|    | 225   | 230 235 240 |
| 5  | Asn Ser Val Ala Phe Thr Ser Ala Gly Ala Asn Gln Thr Val Leu His |             |
|    |   | 245 250 255 |
|    | Asp Thr Ile Thr Val Lys Ala Gly Gln Val Phe Asp Gly Lys Gly Gln |             |
|    |   | 260 265 270 |
| 10 | Thr Phe Thr Ala Gly Ser Glu Leu Gly Asp Gly Gly Gln Ser Glu Asn |             |
|    |   | 275 280 285 |
|    | Gln Lys Pro Leu Phe Ile Leu Glu Asp Gly Ala Ser Leu Lys Asn Val |             |
| 15 |   | 290 295 300 |
|    | Thr Met Gly Asp Asp Gly Ala Asp Gly Ile His Leu Tyr Gly Asp Ala |             |
|    | 305   | 310 315 320 |
| 20 | Lys Ile Asp Asn Leu His Val Thr Asn Val Gly Glu Asp Ala Ile Thr |             |
|    |   | 325 330 335 |
|    | Val Lys Pro Asn Ser Ala Gly Lys Lys Ser His Val Glu Ile Thr Asn |             |
|    |   | 340 345 350 |
| 25 | Ser Ser Phe Glu His Ala Ser Asp Lys Ile Leu Gln Leu Asn Ala Asp |             |
|    |   | 355 360 365 |
|    | Thr Asn Leu Ser Val Asp Asn Val Lys Ala Lys Asp Phe Gly Thr Phe |             |
| 30 |   | 370 375 380 |
|    | Val Arg Thr Asn Gly Gly Gln Gln Gly Asn Trp Asp Leu Asn Leu Ser |             |
|    | 385   | 390 395 400 |
| 35 | His Ile Ser Ala Glu Asp Gly Lys Phe Ser Phe Val Lys Ser Asp Ser |             |
|    |   | 405 410 415 |
|    | Glu Gly Leu Asn Val Asn Thr Ser Asp Ile Ser Leu Gly Asp Val Glu |             |
|    |   | 420 425 430 |
| 40 | Asn His Tyr Lys Val Pro Met Ser Ala Asn Leu Lys Val Ala Glu     |             |
|    |   | 435 440 445 |

45 This protein or polypeptide is acidic, rich in glycine and serine, and lacks cysteine. It is also heat stable, protease sensitive, and suppressed by inhibitors of plant metabolism. The protein or polypeptide of the present invention has a predicted molecular size of ca. 4.5 kDa.

Another potentially suitable hypersensitive response elicitor from *Erwinia amylovora* is disclosed in U.S. Patent Application Serial No. 09/120,663 which is hereby incorporated by reference. The protein is encoded by a DNA molecule having a nucleic acid sequence of SEQ. ID. No. 27 as follows:

- 14 -

|    |  |      |
|----|--|------|
|    | ATGGAATTAA AATCACTGGG AACTGAACAC AAGGCGGCAG TACACACAGC GGCGCACAAAC | 60   |
|    | CCTGTGGGGC ATGGTGTGTC CTTACAGCAG GGCAGCAGCA GCAGCAGCCC GCAAAATGCC  | 120  |
| 5  | GCTGCATCAT TGGCGGCAGA AGGCAAAAAT CGTGGGAAAA TGCCGAGAAT TCACCAGCCA  | 180  |
|    | TCTACTGCGG CTGATGGTAT CAGCGCTGCT CACCAGCAAA AGAAATCCTT CAGTCTCAGG  | 240  |
| 10 | GGCTGTTTGG GGACGAAAAA ATTTTCCAGA TCGGCACCGC AGGGCCAGCC AGGTACCACC  | 300  |
|    | CACAGCAAAG GGGCAACATT GCGCGATCTG CTGGCGCGGG ACGACGGCGA AACGCAGCAT  | 360  |
|    | GAGGCGGCCG CGCCAGATGC GGCGGTTTG ACCCGTTCGG GCGGCGTCAA ACGCCGCAAT   | 420  |
| 15 | ATGGACGACA TGGCCGGGCG GCCAATGGTG AAAGTGCGCA GCGGCGAAGA TAAGGTACCA  | 480  |
|    | ACGCAGCAAA AACGGCATCA GCTGAACAAT TTTGGCCAGA TGCGCCAAAC GATGTTGAGC  | 540  |
| 20 | AAAATGGCTC ACCCGGCTTC AGCCAACGCC GCGGATCGCC TGCAGCATTC ACCGCGCAC   | 600  |
|    | ATCCCGGGTA GCCACCACGA AATCAAGGAA GAACCGGTTG GCTCCACCAG CAAGGCAACA  | 660  |
|    | ACGCGCCACG CAGACAGAGT GGAAATCGCT CAGGAAGATG ACGACAGCGA ATTCCAGCAA  | 720  |
| 25 | CTGCATCAAC AGCGGCTGGC GCGCGAACGG GAAAATCCAC CGCAGCCGCC CAAACTCGGC  | 780  |
|    | GTTGCCACAC CGATTAGCGC CAGGTTTCAG CCCAACTGA CTGCGGTTGC GGAAAGCGTC   | 840  |
| 30 | CTTGAGGGGA CAGATACCAC GCAGTCACCC CTTAAGCCGC AATCAATGCT GAAAGGAAGT  | 900  |
|    | GGAGCCGGGG TAACGCCGCT GGCGGTAACG CTGGATAAAG GCAAGTTGCA GCTGGCACC   | 960  |
|    | GATAATCCAC CCGCGCTCAA TACGTGTTG AAGCAGACAT TGGGTAAAGA CACCCAGCAC   | 1020 |
| 35 | TATCTGGCGC ACCATGCCAG CAGCGACGGT AGCCAGCATC TGCTGCTGGA CAACAAAGGC  | 1080 |
|    | CACCTGTTTG ATATCAAAAG CACCGCCACC AGCTATAGCG TGCTGCACAA CAGCCACCCC  | 1140 |
| 40 | GGTGAGATAA AGGGCAAGCT GGCGCAGGCG GGTACTGGCT CCGTCAGCGT AGACGGTAAA  | 1200 |
|    | AGCGGCAAGA TCTCGCTGGG GAGCGGTACG CAAAGTCACA ACAAACAAT GCTAAGCCAA   | 1260 |
|    | CCGGGGGAAG CGCACCGTTC CTTATTAACC GGCATTTGGC AGCATCCTGC TGGCGCAGCG  | 1320 |
| 45 | CGGCCGAGG GCGAGTCAAT CCGCCTGCAT GACGACAAA TTCATATCCT GCATCCGAG     | 1380 |
|    | CTGGGCGTAT GGCAATCTGC GGATAAAGAT ACCCACAGCC AGCTGTCTCG CCAGGCAGAC  | 1440 |
| 50 | GGTAAGCTCT ATGCGCTGAA AGACAACCGT ACCCTGCAAA ACCTCTCCGA TAATAAATCC  | 1500 |
|    | TCAGAAAAGC TGGTCGATAA AATCAAATCG TATTCCGTTG ATCAGCGGGG GCAGGTGGCG  | 1560 |
|    | ATCCTGACGG ATACTCCCGG CCGCCATAAG ATGAGTATTA TGCCCTCGCT GGATGCTTCC  | 1620 |
| 55 | CCGGAGAGCC ATATTCCCT CAGCCTGCAT TTTGCCGATG CCCACCAGGG GTTATTGCAC   | 1680 |
|    | GGGAAGTCGG AGCTTGAGGC ACAATCTGTC GCGATCAGCC ATGGGCGACT GGTGTGGCC   | 1740 |
| 60 | GATAGCGAAG GCAAGCTGTT TAGCGCCGCC ATTCCGAAGC AAGGGGATGG AAACGAACTG  | 1800 |
|    | AAAATGAAAG CCATGCCTCA GCATGCGCTC GATGAACATT TTGGTCATGA CCACCAGATT  | 1860 |
|    | TCTGGATTTT TCCATGACGA CCACGGCCAG CTTAATGCGC TGGTGAAAAA TAACTTCAGG  | 1920 |
| 65 | CAGCAGCATG CCTGCCCGTT GGGTAACGAT CATCAGTTTC ACCCGGCTG GAACCTGACT   | 1980 |

- 15 -

|    |            |            |            |            |            |            |      |
|----|------------|------------|------------|------------|------------|------------|------|
|    | GATGCGCTGG | TTATCGACAA | TCAGCTGGGG | CTGCATCATA | CCAATCCTGA | ACCGCATGAG | 2040 |
| 5  | ATTCTTGATA | TGGGGCATT  | AGGCAGCCTG | GCGTTACAGG | AGGGCAAGCT | TCACTATTTT | 2100 |
|    | GACCAGCTGA | CCAAAGGGTG | GACTGGCGCG | GAGTCAGATT | GTAAGCAGCT | GAAAAAAGGC | 2160 |
|    | CTGGATGGAG | CAGCTTATCT | ACTGAAAGAC | GGTGAAGTGA | AACGCCTGAA | TATTAATCAG | 2220 |
| 10 | AGCACCTCCT | CTATCAAGCA | CGGAACGGAA | AACGTTTTTT | CGCTGCCGCA | TGTGCGCAAT | 2280 |
|    | AAACCGGAGC | CGGGAGATGC | CCTGCAAGGG | CTGAATAAAG | ACGATAAGGC | CCAGGCCATG | 2340 |
| 15 | GCGGTGATTG | GGGTAAATAA | ATACCTGGCG | CTGACGGAAA | AAGGGGACAT | TCGCTCCTTC | 2400 |
|    | CAGATAAAAC | CCGGCACCCA | GCAGTTGGAG | CGGCCGGCAC | AAACTCTCAG | CCGCGAAGGT | 2460 |
|    | ATCAGCGGCG | AACTGAAAGA | CATTCATGTC | GACCACAAGC | AGAACCTGTA | TGCCTTGACC | 2520 |
| 20 | CACGAGGGAG | AGGTGTTTCA | TCAGCCGCGT | GAAGCCTGGC | AGAATGGTGC | CGAAAGCAGC | 2580 |
|    | AGCTGGCACA | AACTGGCGTT | GCCACAGAGT | GAAAGTAAGC | TAAAAAGTCT | GGACATGAGC | 2640 |
| 25 | CATGAGCACA | AACCGATTGC | CACCTTTGAA | GACGGTAGCC | AGCATCAGCT | GAAGGCTGGC | 2700 |
|    | GGCTGGCAGC | CCTATGCGGC | ACCTGAACGC | GGGCCGCTGG | CGGTGGGTAC | CAGCGGTTCA | 2760 |
|    | CAAACCGTCT | TTAACCGACT | AATGCAGGGG | GTGAAAGGCA | AGGTGATCCC | AGGCAGCGGG | 2820 |
| 30 | TTGACGGTTA | AGCTCTCGGC | TCAGACGGGG | GGAATGACCG | GCGCCGAAGG | GCGCAAGGTC | 2880 |
|    | AGCAGTAAAT | TTCCGAAAG  | GATCCGCGCC | TATGCGTTCA | ACCCAACAAT | GTCCACGCCG | 2940 |
| 35 | CGACCGATTA | AAAATGCTGC | TTATGCCACA | CAGCACGGCT | GGCAGGGGCG | TGAGGGGTTG | 3000 |
|    | AAGCCGTTGT | ACGAGATGCA | GGGAGCGCTG | ATTAAACAAC | TGGATGCGCA | TAACGTTCTG | 3060 |
|    | CATAACCGCG | CACAGCCAGA | TTTGCAAGGC | AAACTGGAAA | CTCTGGATT  | AGGCCAACAT | 3120 |
| 40 | GGCGCAGAAT | TGCTTAACGA | CATGAAGCGC | TTCCGCGACG | AACTGGAGCA | GAGTGCAACC | 3180 |
|    | CGTTCGGTGA | CCGTTTTAGG | TCAACATCAG | GGAGTGCTAA | AAAGCAACGG | TGAAATCAAT | 3240 |
| 45 | AGCGAATTTA | AGCCATCGCC | CGGCAAGGCG | TTGGTCCAGA | GCTTTAACGT | CAATCGCTCT | 3300 |
|    | GGTCAGGATC | TAAGCAAGTC | ACTGCAACAG | GCAGTACATG | CCACGCCGCC | ATCCGCAGAG | 3360 |
|    | AGTAAACTGC | AATCCATGCT | GGGGCACTTT | GTCAGTGCCG | GGGTGGATAT | GAGTCATCAG | 3420 |
| 50 | AAGGGCGAGA | TCCCGCTGGG | CCGCCAGCGC | GATCCGAATG | ATAAAACCGC | ACTGACCAAA | 3480 |
|    | TCGCGTTTAA | TTTAGATAC  | CGTGACCATC | GGTGAAGTGC | ATGAACTGGC | CGATAAGGCG | 3540 |
| 55 | AAACTGGTAT | CTGACCATAA | ACCCGATGCC | GATCAGATAA | AACAGCTGCG | CCAGCAGTTC | 3600 |
|    | GATACGCTGC | GTGAAAAGCG | GTATGAGAGC | AATCCGGTGA | AGCATTACAC | CGATATGGGC | 3660 |
|    | TTCACCCATA | ATAAGGCGCT | GGAAGCAAAC | TATGATGCGG | TCAAAGCCTT | TATCAATGCC | 3720 |
| 60 | TTTAAGAAAG | AGCACCACGG | CGTCAATCTG | ACCACGCGTA | CCGTACTGGA | ATCACAGGGC | 3780 |
|    | AGTGCGGAGC | TGGCGAAGAA | GCTCAAGAAT | ACGCTGTTGT | CCCTGGACAG | TGGTGAAAGT | 3840 |
| 65 | ATGAGCTTCA | GCCGGTCATA | TGGCGGGGGC | GTCAGCACTG | TCTTTGTGCC | TACCCTTAGC | 3900 |

- 16 -

|    |  |      |
|----|--|------|
|    | AAGAAGGTGC CAGTTCCGGT GATCCCCGGA GCCGGCATCA CGCTGGATCG CGCCTATAAC  | 3960 |
|    | CTGAGCTTCA GTCGTACCAG CGGCGGATTG AACGTCAGTT TTGGCCGCGA CGGCGGGGTG  | 4020 |
| 5  | AGTGGTAACA TCATGGTCGC TACCGGCCAT GATGTGATGC CCTATATGAC CGGTAAGAAA  | 4080 |
|    | ACCACTGTCAG GTAACGCCAG TGAATGGTTG AGCGCAAAAC ATAAAATCAG CCCGGACTTG | 4140 |
| 10 | CGTATCGGCG CTGCTGTGAG TGGCACCTGT CAAGGAACGC TACAAAACAG CCTGAAGTTT  | 4200 |
|    | AAGCTGACAG AGGATGAGCT GCCTGGCTTT ATCCATGGCT TGACGCATGG CACGTTGACC  | 4260 |
|    | CCGGCAGAAC TGTGCAAAA GGGGATCGAA CATCAGATGA AGCAGGGCAG CAAACTGACG   | 4320 |
| 15 | TTTAGCGTCG ATACCTCGGC AAATCTGGAT CTGCGTGCCG GTATCAATCT GAACGAAGAC  | 4380 |
|    | GGCAGTAAAC CAAATGGTGT CACTGCCCCG GTTTCTGCCG GGCTAAGTGC ATCGGCAAAC  | 4440 |
| 20 | CTGGCCGCGG GCTCGCGTGA ACGCAGCACC ACCTCTGGCC AGTTTGGCAG CACGACTTCG  | 4500 |
|    | GCCAGCAATA ACCGCCAAC CTTCTCAAC GGGGTGCGCG CGGGTGCTAA CCTGACGGCT    | 4560 |
|    | GCTTTAGGGG TTGCCATTC ATCTACGCAT GAAGGGAAC CGGTCGGGAT CTTCCCGGCA    | 4620 |
| 25 | TTTACCTCGA CCAATGTTTC GGCAGCGCTG GCGCTGGATA ACCGTACCTC ACAGAGTATC  | 4680 |
|    | AGCCTGGAAT TGAAGCGCGC GGAGCCGGTG ACCAGCAACG ATATCAGCGA GTTGACCTCC  | 4740 |
| 30 | ACGCTGGGAA AACACTTTAA GGATAGCGCC ACAACGAAGA TGCTTGCCGC TCTCAAAGAG  | 4800 |
|    | TTAGATGACG CTAAGCCCGC TGAACAACCTG CATATTTTAC AGCAGCATTT CAGTGCAAAA | 4860 |
|    | GATGTCGTCG GTGATGAACG CTACGAGGCG GTGCGCAACC TGAAAAAAT GGTGATACGT   | 4920 |
| 35 | CAACAGGCTG CGGACAGCCA CAGCATGGAA TTAGGATCTG CCAGTCACAG CACGACCTAC  | 4980 |
|    | AATAATCTGT CGAGAATAAA TAATGACGGC ATTGTCGAGC TGCTACACAA ACATTTTCGAT | 5040 |
| 40 | GCGGCATTAC CAGCAAGCAG TGCCAAACGT CTTGGTGAAA TGATGAATAA CGATCCGGCA  | 5100 |
|    | CTGAAAGATA TTATTAAGCA GCTGCAAAGT ACGCCGTTCA GCAGCGCCAG CGTGTCGATG  | 5160 |
|    | GAGCTGAAAG ATGGTCTGCG TGAGCAGACG GAAAAAGCAA TACTGGACGG TAAGGTCGGT  | 5220 |
| 45 | CGTGAAGAAG TGGGAGTACT TTTCCAGGAT CGTAACAAC TCGTGTTAA ATCGGTCAGC    | 5280 |
|    | GTCAGTCAGT CCGTCAGCAA AAGCGAAGGC TTCAATACCC CAGCGCTGTT ACTGGGGACG  | 5340 |
| 50 | AGCAACAGCG CTGCTATGAG CATGGAGCGC AACATCGGAA CCATTAATTT TAAATACGGC  | 5400 |
|    | CAGGATCAGA ACACCCACG GCGATTACCT CTGGAGGGTG GAATAGCTCA GGCTAATCCG   | 5460 |
|    | CAGGTCGCAT CTGCGCTTAC TGATTGAAG AAGGAAGGGC TGGAAATGAA GAGCTAA      | 5517 |

55

This DNA molecule is known as the dspE gene for *Erwinia amylovora*. This isolated DNA molecule of the present invention encodes a protein or polypeptide which elicits a plant pathogen's hypersensitive response having an amino acid sequence of SEQ.

ID. No. 28 as follows:

60

- 17 -

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Met | Glu | Leu | Lys | Ser | Leu | Gly | Thr | Glu | His | Lys | Ala | Ala | Val | His | Thr |  |
|    | 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |  |
| 5  | Ala | Ala | His | Asn | Pro | Val | Gly | His | Gly | Val | Ala | Leu | Gln | Gln | Gly | Ser |  |
|    |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |  |
|    | Ser | Ser | Ser | Ser | Pro | Gln | Asn | Ala | Ala | Ala | Ser | Leu | Ala | Ala | Glu | Gly |  |
|    |     |     |     | 35  |     |     |     | 40  |     |     |     |     | 45  |     |     |     |  |
| 10 | Lys | Asn | Arg | Gly | Lys | Met | Pro | Arg | Ile | His | Gln | Pro | Ser | Thr | Ala | Ala |  |
|    |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |  |
|    | Asp | Gly | Ile | Ser | Ala | Ala | His | Gln | Gln | Lys | Lys | Ser | Phe | Ser | Leu | Arg |  |
| 15 | 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |  |
|    | Gly | Cys | Leu | Gly | Thr | Lys | Lys | Phe | Ser | Arg | Ser | Ala | Pro | Gln | Gly | Gln |  |
|    |     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |  |
| 20 | Pro | Gly | Thr | Thr | His | Ser | Lys | Gly | Ala | Thr | Leu | Arg | Asp | Leu | Leu | Ala |  |
|    |     |     |     |     | 100 |     |     |     | 105 |     |     |     |     | 110 |     |     |  |
|    | Arg | Asp | Asp | Gly | Glu | Thr | Gln | His | Glu | Ala | Ala | Ala | Pro | Asp | Ala | Ala |  |
|    |     |     |     | 115 |     |     |     | 120 |     |     |     |     | 125 |     |     |     |  |
| 25 | Arg | Leu | Thr | Arg | Ser | Gly | Gly | Val | Lys | Arg | Arg | Asn | Met | Asp | Asp | Met |  |
|    |     | 130 |     |     |     |     | 135 |     |     |     |     |     | 140 |     |     |     |  |
|    | Ala | Gly | Arg | Pro | Met | Val | Lys | Gly | Gly | Ser | Gly | Glu | Asp | Lys | Val | Pro |  |
| 30 | 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |  |
|    | Thr | Gln | Gln | Lys | Arg | His | Gln | Leu | Asn | Asn | Phe | Gly | Gln | Met | Arg | Gln |  |
|    |     |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     | 175 |     |  |
| 35 | Thr | Met | Leu | Ser | Lys | Met | Ala | His | Pro | Ala | Ser | Ala | Asn | Ala | Gly | Asp |  |
|    |     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |  |
|    | Arg | Leu | Gln | His | Ser | Pro | Pro | His | Ile | Pro | Gly | Ser | His | His | Glu | Ile |  |
|    |     |     | 195 |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |  |
| 40 | Lys | Glu | Glu | Pro | Val | Gly | Ser | Thr | Ser | Lys | Ala | Thr | Thr | Ala | His | Ala |  |
|    |     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |  |
|    | Asp | Arg | Val | Glu | Ile | Ala | Gln | Glu | Asp | Asp | Asp | Ser | Glu | Phe | Gln | Gln |  |
| 45 | 225 |     |     |     |     | 230 |     |     |     | 235 |     |     |     |     |     | 240 |  |
|    | Leu | His | Gln | Gln | Arg | Leu | Ala | Arg | Glu | Arg | Glu | Asn | Pro | Pro | Gln | Pro |  |
|    |     |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |     |  |
| 50 | Pro | Lys | Leu | Gly | Val | Ala | Thr | Pro | Ile | Ser | Ala | Arg | Phe | Gln | Pro | Lys |  |
|    |     |     | 260 |     |     |     |     | 265 |     |     |     |     |     | 270 |     |     |  |
|    | Leu | Thr | Ala | Val | Ala | Glu | Ser | Val | Leu | Glu | Gly | Thr | Asp | Thr | Thr | Gln |  |
|    |     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |     |     |     |  |
| 55 | Ser | Pro | Leu | Lys | Pro | Gln | Ser | Met | Leu | Lys | Gly | Ser | Gly | Ala | Gly | Val |  |
|    |     | 290 |     |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |  |
|    | Thr | Pro | Leu | Ala | Val | Thr | Leu | Asp | Lys | Gly | Lys | Leu | Gln | Leu | Ala | Pro |  |
| 60 | 305 |     |     |     |     | 310 |     |     |     |     | 315 |     |     |     |     | 320 |  |
|    | Asp | Asn | Pro | Pro | Ala | Leu | Asn | Thr | Leu | Leu | Lys | Gln | Thr | Leu | Gly | Lys |  |
|    |     |     |     |     | 325 |     |     |     |     | 330 |     |     |     |     | 335 |     |  |
| 65 | Asp | Thr | Gln | His | Tyr | Leu | Ala | His | His | Ala | Ser | Ser | Asp | Gly | Ser | Gln |  |
|    |     |     |     | 340 |     |     |     | 345 |     |     |     |     |     | 350 |     |     |  |

- 18 -

His Leu Leu Leu Asp Asn Lys Gly His Leu Phe Asp Ile Lys Ser Thr  
 355 360 365  
 5 Ala Thr Ser Tyr Ser Val Leu His Asn Ser His Pro Gly Glu Ile Lys  
 370 375 380  
 Gly Lys Leu Ala Gln Ala Gly Thr Gly Ser Val Ser Val Asp Gly Lys  
 385 390 395 400  
 10 Ser Gly Lys Ile Ser Leu Gly Ser Gly Thr Gln Ser His Asn Lys Thr  
 405 410 415  
 Met Leu Ser Gln Pro Gly Glu Ala His Arg Ser Leu Leu Thr Gly Ile  
 420 425 430  
 15 Trp Gln His Pro Ala Gly Ala Ala Arg Pro Gln Gly Glu Ser Ile Arg  
 435 440 445  
 20 Leu His Asp Asp Lys Ile His Ile Leu His Pro Glu Leu Gly Val Trp  
 450 455 460  
 Gln Ser Ala Asp Lys Asp Thr His Ser Gln Leu Ser Arg Gln Ala Asp  
 465 470 475 480  
 25 Gly Lys Leu Tyr Ala Leu Lys Asp Asn Arg Thr Leu Gln Asn Leu Ser  
 485 490 495  
 Asp Asn Lys Ser Ser Glu Lys Leu Val Asp Lys Ile Lys Ser Tyr Ser  
 500 505 510  
 30 Val Asp Gln Arg Gly Gln Val Ala Ile Leu Thr Asp Thr Pro Gly Arg  
 515 520 525  
 His Lys Met Ser Ile Met Pro Ser Leu Asp Ala Ser Pro Glu Ser His  
 530 535 540  
 Ile Ser Leu Ser Leu His Phe Ala Asp Ala His Gln Gly Leu Leu His  
 545 550 555 560  
 40 Gly Lys Ser Glu Leu Glu Ala Gln Ser Val Ala Ile Ser His Gly Arg  
 565 570 575  
 Leu Val Val Ala Asp Ser Glu Gly Lys Leu Phe Ser Ala Ala Ile Pro  
 580 585 590  
 Lys Gln Gly Asp Gly Asn Glu Leu Lys Met Lys Ala Met Pro Gln His  
 595 600 605  
 50 Ala Leu Asp Glu His Phe Gly His Asp His Gln Ile Ser Gly Phe Phe  
 610 615 620  
 His Asp Asp His Gly Gln Leu Asn Ala Leu Val Lys Asn Asn Phe Arg  
 625 630 635 640  
 55 Gln Gln His Ala Cys Pro Leu Gly Asn Asp His Gln Phe His Pro Gly  
 645 650 655  
 Trp Asn Leu Thr Asp Ala Leu Val Ile Asp Asn Gln Leu Gly Leu His  
 660 665 670  
 60 His Thr Asn Pro Glu Pro His Glu Ile Leu Asp Met Gly His Leu Gly  
 675 680 685



- 19 -

|    |     |      |     |     |      |      |     |      |     |     |      |      |      |     |     |      |  |
|----|-----|------|-----|-----|------|------|-----|------|-----|-----|------|------|------|-----|-----|------|--|
|    | Ser | Leu  | Ala | Leu | Gln  | Glu  | Gly | Lys  | Leu | His | Tyr  | Phe  | Asp  | Gln | Leu | Thr  |  |
|    | 690 |      |     |     |      |      | 695 |      |     |     |      | 700  |      |     |     |      |  |
| 5  | Lys | Gly  | Trp | Thr | Gly  | Ala  | Glu | Ser  | Asp | Cys | Lys  | Gln  | Leu  | Lys | Lys | Gly  |  |
|    | 705 |      |     |     |      | 710  |     |      |     |     | 715  |      |      |     |     | 720  |  |
|    | Leu | Asp  | Gly | Ala | Ala  | Tyr  | Leu | Leu  | Lys | Asp | Gly  | Glu  | Val  | Lys | Arg | Leu  |  |
|    |     |      |     |     | 725  |      |     |      |     | 730 |      |      |      |     | 735 |      |  |
| 10 | Asn | Ile  | Asn | Gln | Ser  | Thr  | Ser | Ser  | Ile | Lys | His  | Gly  | Thr  | Glu | Asn | Val  |  |
|    |     |      |     | 740 |      |      |     |      | 745 |     |      |      |      | 750 |     |      |  |
|    | Phe | Ser  | Leu | Pro | His  | Val  | Arg | Asn  | Lys | Pro | Glu  | Pro  | Gly  | Asp | Ala | Leu  |  |
|    |     |      | 755 |     |      |      |     | 760  |     |     |      |      | 765  |     |     |      |  |
| 15 | Gln | Gly  | Leu | Asn | Lys  | Asp  | Asp | Lys  | Ala | Gln | Ala  | Met  | Ala  | Val | Ile | Gly  |  |
|    |     | 770  |     |     |      |      | 775 |      |     |     |      | 780  |      |     |     |      |  |
|    | Val | Asn  | Lys | Tyr | Leu  | Ala  | Leu | Thr  | Glu | Lys | Gly  | Asp  | Ile  | Arg | Ser | Phe  |  |
| 20 |     | 785  |     |     |      | 790  |     |      |     |     | 795  |      |      |     |     | 800  |  |
|    | Gln | Ile  | Lys | Pro | Gly  | Thr  | Gln | Gln  | Leu | Glu | Arg  | Pro  | Ala  | Gln | Thr | Leu  |  |
|    |     |      |     |     | 805  |      |     |      |     | 810 |      |      |      |     | 815 |      |  |
| 25 | Ser | Arg  | Glu | Gly | Ile  | Ser  | Gly | Glu  | Leu | Lys | Asp  | Ile  | His  | Val | Asp | His  |  |
|    |     |      |     | 820 |      |      |     |      | 825 |     |      |      |      | 830 |     |      |  |
|    | Lys | Gln  | Asn | Leu | Tyr  | Ala  | Leu | Thr  | His | Glu | Gly  | Glu  | Val  | Phe | His | Gln  |  |
|    |     |      | 835 |     |      |      |     | 840  |     |     |      |      | 845  |     |     |      |  |
| 30 | Pro | Arg  | Glu | Ala | Trp  | Gln  | Asn | Gly  | Ala | Glu | Ser  | Ser  | Ser  | Trp | His | Lys  |  |
|    |     | 850  |     |     |      |      | 855 |      |     |     |      | 860  |      |     |     |      |  |
|    | Leu | Ala  | Leu | Pro | Gln  | Ser  | Glu | Ser  | Lys | Leu | Lys  | Ser  | Leu  | Asp | Met | Ser  |  |
| 35 |     | 865  |     |     |      | 870  |     |      |     |     | 875  |      |      |     |     | 880  |  |
|    | His | Glu  | His | Lys | Pro  | Ile  | Ala | Thr  | Phe | Glu | Asp  | Gly  | Ser  | Gln | His | Gln  |  |
|    |     |      |     |     | 885  |      |     |      |     | 890 |      |      |      |     | 895 |      |  |
| 40 | Leu | Lys  | Ala | Gly | Gly  | Trp  | His | Ala  | Tyr | Ala | Ala  | Pro  | Glu  | Arg | Gly | Pro  |  |
|    |     |      |     | 900 |      |      |     |      | 905 |     |      |      |      | 910 |     |      |  |
|    | Leu | Ala  | Val | Gly | Thr  | Ser  | Gly | Ser  | Gln | Thr | Val  | Phe  | Asn  | Arg | Leu | Met  |  |
|    |     |      | 915 |     |      |      |     | 920  |     |     |      |      | 925  |     |     |      |  |
| 45 | Gln | Gly  | Val | Lys | Gly  | Lys  | Val | Ile  | Pro | Gly | Ser  | Gly  | Leu  | Thr | Val | Lys  |  |
|    |     | 930  |     |     |      |      | 935 |      |     |     |      | 940  |      |     |     |      |  |
|    | Leu | Ser  | Ala | Gln | Thr  | Gly  | Gly | Met  | Thr | Gly | Ala  | Glu  | Gly  | Arg | Lys | Val  |  |
| 50 |     | 945  |     |     |      | 950  |     |      |     |     | 955  |      |      |     |     | 960  |  |
|    | Ser | Ser  | Lys | Phe | Ser  | Glu  | Arg | Ile  | Arg | Ala | Tyr  | Ala  | Phe  | Asn | Pro | Thr  |  |
|    |     |      |     |     | 965  |      |     |      |     | 970 |      |      |      |     | 975 |      |  |
| 55 | Met | Ser  | Thr | Pro | Arg  | Pro  | Ile | Lys  | Asn | Ala | Ala  | Tyr  | Ala  | Thr | Gln | His  |  |
|    |     |      |     | 980 |      |      |     |      | 985 |     |      |      |      | 990 |     |      |  |
|    | Gly | Trp  | Gln | Gly | Arg  | Glu  | Gly | Leu  | Lys | Pro | Leu  | Tyr  | Glu  | Met | Gln | Gly  |  |
|    |     |      | 995 |     |      |      |     | 1000 |     |     |      |      | 1005 |     |     |      |  |
| 60 | Ala | Leu  | Ile | Lys | Gln  | Leu  | Asp | Ala  | His | Asn | Val  | Arg  | His  | Asn | Ala | Pro  |  |
|    |     |      |     |     | 1010 |      |     | 1015 |     |     |      | 1020 |      |     |     |      |  |
|    | Gln | Pro  | Asp | Leu | Gln  | Ser  | Lys | Leu  | Glu | Thr | Leu  | Asp  | Leu  | Gly | Glu | His  |  |
| 65 |     | 1025 |     |     |      | 1030 |     |      |     |     | 1035 |      |      |     |     | 1040 |  |

- 20 -

Gly Ala Glu Leu Leu Asn Asp Met Lys Arg Phe Arg Asp Glu Leu Glu  
 1045 1050 1055  
 5 Gln Ser Ala Thr Arg Ser Val Thr Val Leu Gly Gln His Gln Gly Val  
 1060 1065 1070  
 Leu Lys Ser Asn Gly Glu Ile Asn Ser Glu Phe Lys Pro Ser Pro Gly  
 1075 1080 1085  
 10 Lys Ala Leu Val Gln Ser Phe Asn Val Asn Arg Ser Gly Gln Asp Leu  
 1090 1095 1100  
 Ser Lys Ser Leu Gln Gln Ala Val His Ala Thr Pro Pro Ser Ala Glu  
 1105 1110 1115 1120  
 Ser Lys Leu Gln Ser Met Leu Gly His Phe Val Ser Ala Gly Val Asp  
 1125 1130 1135  
 20 Met Ser His Gln Lys Gly Glu Ile Pro Leu Gly Arg Gln Arg Asp Pro  
 1140 1145 1150  
 Asn Asp Lys Thr Ala Leu Thr Lys Ser Arg Leu Ile Leu Asp Thr Val  
 1155 1160 1165  
 25 Thr Ile Gly Glu Leu His Glu Leu Ala Asp Lys Ala Lys Leu Val Ser  
 1170 1175 1180  
 Asp His Lys Pro Asp Ala Asp Gln Ile Lys Gln Leu Arg Gln Gln Phe  
 1185 1190 1195 1200  
 Asp Thr Leu Arg Glu Lys Arg Tyr Glu Ser Asn Pro Val Lys His Tyr  
 1205 1210 1215  
 35 Thr Asp Met Gly Phe Thr His Asn Lys Ala Leu Glu Ala Asn Tyr Asp  
 1220 1225 1230  
 Ala Val Lys Ala Phe Ile Asn Ala Phe Lys Lys Glu His His Gly Val  
 1235 1240 1245  
 40 Asn Leu Thr Thr Arg Thr Val Leu Glu Ser Gln Gly Ser Ala Glu Leu  
 1250 1255 1260  
 Ala Lys Lys Leu Lys Asn Thr Leu Leu Ser Leu Asp Ser Gly Glu Ser  
 1265 1270 1275 1280  
 Met Ser Phe Ser Arg Ser Tyr Gly Gly Gly Val Ser Thr Val Phe Val  
 1285 1290 1295  
 50 Pro Thr Leu Ser Lys Lys Val Pro Val Pro Val Ile Pro Gly Ala Gly  
 1300 1305 1310  
 Ile Thr Leu Asp Arg Ala Tyr Asn Leu Ser Phe Ser Arg Thr Ser Gly  
 1315 1320 1325  
 55 Gly Leu Asn Val Ser Phe Gly Arg Asp Gly Gly Val Ser Gly Asn Ile  
 1330 1335 1340  
 Met Val Ala Thr Gly His Asp Val Met Pro Tyr Met Thr Gly Lys Lys  
 1345 1350 1355 1360  
 Thr Ser Ala Gly Asn Ala Ser Asp Trp Leu Ser Ala Lys His Lys Ile  
 1365 1370 1375

- 21 -

|    |   |                |
|----|---|----------------|
|    | Ser Pro Asp Leu Arg Ile Gly Ala Ala Val Ser Gly Thr Leu Gln Gly |                |
|    | 1380  | 1385 1390      |
| 5  | Thr Leu Gln Asn Ser Leu Lys Phe Lys Leu Thr Glu Asp Glu Leu Pro |                |
|    | 1395  | 1400 1405      |
|    | Gly Phe Ile His Gly Leu Thr His Gly Thr Leu Thr Pro Ala Glu Leu |                |
|    | 1410  | 1415 1420      |
| 10 | Leu Gln Lys Gly Ile Glu His Gln Met Lys Gln Gly Ser Lys Leu Thr |                |
|    | 1425  | 1430 1435 1440 |
|    | Phe Ser Val Asp Thr Ser Ala Asn Leu Asp Leu Arg Ala Gly Ile Asn |                |
|    | 1445  | 1450 1455      |
| 15 | Leu Asn Glu Asp Gly Ser Lys Pro Asn Gly Val Thr Ala Arg Val Ser |                |
|    | 1460  | 1465 1470      |
| 20 | Ala Gly Leu Ser Ala Ser Ala Asn Leu Ala Ala Gly Ser Arg Glu Arg |                |
|    | 1475  | 1480 1485      |
|    | Ser Thr Thr Ser Gly Gln Phe Gly Ser Thr Thr Ser Ala Ser Asn Asn |                |
|    | 1490  | 1495 1500      |
| 25 | Arg Pro Thr Phe Leu Asn Gly Val Gly Ala Gly Ala Asn Leu Thr Ala |                |
|    | 1505  | 1510 1515 1520 |
|    | Ala Leu Gly Val Ala His Ser Ser Thr His Glu Gly Lys Pro Val Gly |                |
|    | 1525  | 1530 1535      |
| 30 | Ile Phe Pro Ala Phe Thr Ser Thr Asn Val Ser Ala Ala Leu Ala Leu |                |
|    | 1540  | 1545 1550      |
| 35 | Asp Asn Arg Thr Ser Gln Ser Ile Ser Leu Glu Leu Lys Arg Ala Glu |                |
|    | 1555  | 1560 1565      |
|    | Pro Val Thr Ser Asn Asp Ile Ser Glu Leu Thr Ser Thr Leu Gly Lys |                |
|    | 1570  | 1575 1580      |
| 40 | His Phe Lys Asp Ser Ala Thr Thr Lys Met Leu Ala Ala Leu Lys Glu |                |
|    | 1585  | 1590 1595 1600 |
|    | Leu Asp Asp Ala Lys Pro Ala Glu Gln Leu His Ile Leu Gln Gln His |                |
|    | 1605  | 1610 1615      |
| 45 | Phe Ser Ala Lys Asp Val Val Gly Asp Glu Arg Tyr Glu Ala Val Arg |                |
|    | 1620  | 1625 1630      |
| 50 | Asn Leu Lys Lys Leu Val Ile Arg Gln Gln Ala Ala Asp Ser His Ser |                |
|    | 1635  | 1640 1645      |
|    | Met Glu Leu Gly Ser Ala Ser His Ser Thr Thr Tyr Asn Asn Leu Ser |                |
|    | 1650  | 1655 1660      |
| 55 | Arg Ile Asn Asn Asp Gly Ile Val Glu Leu Leu His Lys His Phe Asp |                |
|    | 1665  | 1670 1675 1680 |
|    | Ala Ala Leu Pro Ala Ser Ser Ala Lys Arg Leu Gly Glu Met Met Asn |                |
|    | 1685  | 1690 1695      |
| 60 | Asn Asp Pro Ala Leu Lys Asp Ile Ile Lys Gln Leu Gln Ser Thr Pro |                |
|    | 1700  | 1705 1710      |
| 65 | Phe Ser Ser Ala Ser Val Ser Met Glu Leu Lys Asp Gly Leu Arg Glu |                |
|    | 1715  | 1720 1725      |

- 22 -

Gln Thr Glu Lys Ala Ile Leu Asp Gly Lys Val Gly Arg Glu Glu Val  
 1730 1735 1740  
 5 Gly Val Leu Phe Gln Asp Arg Asn Asn Leu Arg Val Lys Ser Val Ser  
 1745 1750 1755 1760  
 Val Ser Gln Ser Val Ser Lys Ser Glu Gly Phe Asn Thr Pro Ala Leu  
 1765 1770 1775  
 10 Leu Leu Gly Thr Ser Asn Ser Ala Ala Met Ser Met Glu Arg Asn Ile  
 1780 1785 1790  
 Gly Thr Ile Asn Phe Lys Tyr Gly Gln Asp Gln Asn Thr Pro Arg Arg  
 1795 1800 1805  
 15 Phe Thr Leu Glu Gly Gly Ile Ala Gln Ala Asn Pro Gln Val Ala Ser  
 1810 1815 1820  
 20 Ala Leu Thr Asp Leu Lys Lys Glu Gly Leu Glu Met Lys Ser  
 1825 1830 1835

This protein or polypeptide is about 198 kDa and has a pI of 8.98.

25 The present invention relates to an isolated DNA molecule having a nucleotide sequence of SEQ. ID. No. 29 as follows:

ATGACATCGT CACAGCAGCG GGTGAAAGG TTTTACAGT ATTTCTCCGC CGGGTGTAAG 60  
 30 ACGCCCATAC ATCTGAAAGA CGGGGTGTGC GCCCTGTATA ACGAACAAGA TGAGGAGGCG 120  
 GCGGTGCTGG AAGTACCGCA ACACAGCGAC AGCCTGTAC TACTGTCCG AATCATTGAG 180  
 GCTGACCCAC AAACCTCAAT AACCTGTAT TCGATGCTAT TACAGCTGAA TTTTGAAATG 240  
 35 GCGGCCATGC GCGGCTGTTG GCTGGCGCTG GATGAAGTGC ACAACGTGCG TTTATGTTTT 300  
 CAGCAGTCGC TGGAGCATCT GGATGAAGCA AGTTTTAGCG ATATCGTTAG CGGCTTCATC 360  
 40 GAACATGCGG CAGAAGTGCG TGAGTATATA GCGCAATTAG ACGAGAGTAG CGCGGCATAA 420

This is known as the dspF gene. This isolated DNA molecule of the present invention  
 encodes a hypersensitive response elicitor protein or polypeptide having an amino  
 45 acid sequence of SEQ. ID. No. 30 as follows:

Met Thr Ser Ser Gln Gln Arg Val Glu Arg Phe Leu Gln Tyr Phe Ser  
 1 5 10 15  
 50 Ala Gly Cys Lys Thr Pro Ile His Leu Lys Asp Gly Val Cys Ala Leu  
 20 25 30  
 Tyr Asn Glu Gln Asp Glu Glu Ala Ala Val Leu Glu Val Pro Gln His  
 35 40 45  
 55 Ser Asp Ser Leu Leu Leu His Cys Arg Ile Ile Glu Ala Asp Pro Gln  
 50 55 60

- 23 -

Thr Ser Ile Thr Leu Tyr Ser Met Leu Leu Gln Leu Asn Phe Glu Met  
 65 70 75 80  
 5 Ala Ala Met Arg Gly Cys Trp Leu Ala Leu Asp Glu Leu His Asn Val  
 85 90 95  
 Arg Leu Cys Phe Gln Gln Ser Leu Glu His Leu Asp Glu Ala Ser Phe  
 100 105 110  
 10 Ser Asp Ile Val Ser Gly Phe Ile Glu His Ala Ala Glu Val Arg Glu  
 115 120 125  
 Tyr Ile Ala Gln Leu Asp Glu Ser Ser Ala Ala  
 130 135  
 15

This protein or polypeptide is about 16 kDa and has a pI of 4.45.

The hypersensitive response elicitor polypeptide or protein derived from *Pseudomonas syringae* has an amino acid sequence corresponding to SEQ. ID.

20 No. 31 as follows:

Met Gln Ser Leu Ser Leu Asn Ser Ser Ser Leu Gln Thr Pro Ala Met  
 1 5 10 15  
 Ala Leu Val Leu Val Arg Pro Glu Ala Glu Thr Thr Gly Ser Thr Ser  
 20 25 30  
 25 Ser Lys Ala Leu Gln Glu Val Val Val Lys Leu Ala Glu Glu Leu Met  
 35 40 45  
 Arg Asn Gly Gln Leu Asp Asp Ser Ser Pro Leu Gly Lys Leu Leu Ala  
 50 55 60  
 30 Lys Ser Met Ala Ala Asp Gly Lys Ala Gly Gly Gly Ile Glu Asp Val  
 65 70 75 80  
 Ile Ala Ala Leu Asp Lys Leu Ile His Glu Lys Leu Gly Asp Asn Phe  
 85 90 95  
 Gly Ala Ser Ala Asp Ser Ala Ser Gly Thr Gly Gln Gln Asp Leu Met  
 100 105 110  
 35 Thr Gln Val Leu Asn Gly Leu Ala Lys Ser Met Leu Asp Asp Leu Leu  
 115 120 125  
 Thr Lys Gln Asp Gly Gly Thr Ser Phe Ser Glu Asp Asp Met Pro Met  
 130 135 140  
 40 Leu Asn Lys Ile Ala Gln Phe Met Asp Asp Asn Pro Ala Gln Phe Pro  
 145 150 155 160  
 Lys Pro Asp Ser Gly Ser Trp Val Asn Glu Leu Lys Glu Asp Asn Phe  
 165 170 175  
 Leu Asp Gly Asp Glu Thr Ala Ala Phe Arg Ser Ala Leu Asp Ile Ile  
 180 185 190

- 24 -

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Gly | Gln | Gln | Leu | Gly | Asn | Gln | Gln | Ser | Asp | Ala | Gly | Ser | Leu | Ala | Gly |  |
|    |     |     | 195 |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |  |
|    | Thr | Gly | Gly | Gly | Leu | Gly | Thr | Pro | Ser | Ser | Phe | Ser | Asn | Asn | Ser | Ser |  |
|    |     | 210 |     |     |     |     | 215 |     |     |     |     |     | 220 |     |     |     |  |
| 5  | Val | Met | Gly | Asp | Pro | Leu | Ile | Asp | Ala | Asn | Thr | Gly | Pro | Gly | Asp | Ser |  |
|    |     | 225 |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |  |
|    | Gly | Asn | Thr | Arg | Gly | Glu | Ala | Gly | Gln | Leu | Ile | Gly | Glu | Leu | Ile | Asp |  |
|    |     |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     | 255 |     |  |
| 10 | Arg | Gly | Leu | Gln | Ser | Val | Leu | Ala | Gly | Gly | Gly | Leu | Gly | Thr | Pro | Val |  |
|    |     |     |     | 260 |     |     |     |     | 265 |     |     |     |     |     | 270 |     |  |
|    | Asn | Thr | Pro | Gln | Thr | Gly | Thr | Ser | Ala | Asn | Gly | Gly | Gln | Ser | Ala | Gln |  |
|    |     |     | 275 |     |     |     |     | 280 |     |     |     |     | 285 |     |     |     |  |
|    | Asp | Leu | Asp | Gln | Leu | Leu | Gly | Gly | Leu | Leu | Leu | Lys | Gly | Leu | Glu | Ala |  |
|    |     | 290 |     |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |  |
| 15 | Thr | Leu | Lys | Asp | Ala | Gly | Gln | Thr | Gly | Thr | Asp | Val | Gln | Ser | Ser | Ala |  |
|    |     | 305 |     |     |     | 310 |     |     |     |     | 315 |     |     |     |     | 320 |  |
|    | Ala | Gln | Ile | Ala | Thr | Leu | Leu | Val | Ser | Thr | Leu | Leu | Gln | Gly | Thr | Arg |  |
|    |     |     |     |     | 325 |     |     |     |     | 330 |     |     |     |     | 335 |     |  |
| 20 | Asn | Gln | Ala | Ala | Ala |     |     |     |     |     |     |     |     |     |     |     |  |
|    |     |     |     |     | 340 |     |     |     |     |     |     |     |     |     |     |     |  |

This hypersensitive response elicitor polypeptide or protein has a molecular weight of 34-35 kDa. It is rich in glycine (about 13.5%) and lacks cysteine and tyrosine.

- 25 Further information about the hypersensitive response elicitor derived from *Pseudomonas syringae* is found in He, S. Y., H. C. Huang, and A. Collmer, "Pseudomonas syringae pv. syringae Harpin<sub>PS</sub>: a Protein that is Secreted via the Hrp Pathway and Elicits the Hypersensitive Response in Plants," Cell 73:1255-1266 (1993), which is hereby incorporated by reference. The DNA molecule encoding the
- 30 hypersensitive response elicitor from *Pseudomonas syringae* has a nucleotide sequence corresponding to SEQ. ID. No. 32 as follows:

|    |  |     |
|----|--|-----|
|    | ATGCAGAGTC TCAGTCTTAA CAGCAGCTCG CTGCAAACCC CGGCAATGGC CCTTGTCTCTG | 60  |
|    | GTACGTCCTG AAGCCGAGAC GACTGGCAGT ACGTCGAGCA AGGCGCTTCA GGAAGTTGTC  | 120 |
| 35 | GTGAAGCTGG CCGAGGAACT GATGCGCAAT GGTCAACTCG ACGACAGCTC GCCATTGGGA  | 180 |
|    | AAACTGTTGG CCAAGTCGAT GGCCGAGAT GGCAAGGCGG GCGGCGGTAT TGAGGATGTC   | 240 |
|    | ATCGCTGCGC TGGACAAGCT GATCCATGAA AAGCTCGGTG ACAACTTCGG CGCGTCTGCG  | 300 |

- 25 -

GACAGCGCCT CGGGTACCGG ACAGCAGGAC CTGATGACTC AGGTGCTCAA TGGCCTGGCC 360  
 AAGTCGATGC TCGATGATCT TCTGACCAAG CAGGATGGCG GGACAAGCTT CTCCGAAGAC 420  
 GATATGCCGA TGCTGAACAA GATCGCGCAG TTCATGGATG ACAATCCCGC ACAGTTTCCC 480  
 AAGCCGGACT CGGGCTCCTG GGTGAACGAA CTCAAGGAAG ACAACTTCCT TGATGGCGAC 540  
 5 GAAACGGCTG CGTTCCGTTC GGCCTCGAC ATCATTGGCC AGCAACTGGG TAATCAGCAG 600  
 AGTGACGCTG GCAGTCTGGC AGGGACGGGT GGAGGTCTGG GCACTCCGAG CAGTTTTTCC 660  
 AACAACTCGT CCGTGATGGG TGATCCGCTG ATCGACGCCA ATACCGGTCC CGGTGACAGC 720  
 GGCAATACCC GTGGTGAAGC GGGGCAACTG ATCGGCGAGC TTATCGACCG TGGCCTGCAA 780  
 TCGGTATTGG CCGGTGGTGG ACTGGGCACA CCCGTAAACA CCCCAGAGAC CGGTACGTCG 840  
 10 GCGAATGGCG GACAGTCCGC TCAGGATCTT GATCAGTTGC TGGGCGGCTT GCTGCTCAAG 900  
 GGCCTGGAGG CAACGCTCAA GGATGCCGGG CAAACAGGCA CCGACGTGCA GTCGAGCGCT 960  
 GCGCAAATCG CCACCTTGCT GGTCAGTACG CTGCTGCAAG GCACCCGCAA TCAGGCTGCA 1020  
 GCCTGA 1026

15 Another potentially suitable hypersensitive response elicitor from  
*Pseudomonas syringae* is disclosed in U.S. Patent Application Serial No. 09/120,817,  
 which is hereby incorporated by reference. The protein has a nucleotide sequence of  
 SEQ. ID. No. 33 as follows:

20 TCCACTTCGC TGATTTTGAA ATTGGCAGAT TCATAGAAAC GTTCAGGTGT GGAAATCAGG 60  
 CTGAGTGC GC AGATTTTCGTT GATAAGGGTG TGGTACTGGT CATTGTTGGT CATTTC AAGG 120  
 CCTCTGAGTG CGGTGCGGAG CAATACCACT CTTCTGCTG GCGTGTGCAC ACTGAGTGC 180  
 25 AGGCATAGGC ATTTTCAGTTC CTTGCGTTGG TTGGGCATAT AAAAAAAGGA ACTTTTAAAA 240  
 ACAGTGCAAT GAGATGCCGG CAAAACGGGA ACCGGTCGCT GCGCTTTGCC ACTCACTTCG 300  
 30 AGCAAGCTCA ACCCCAAACA TCCACATCCC TATCGAACGG ACAGCGATAC GGCCACTTGC 360  
 TCTGGTAAAC CCTGGAGCTG GCGTCGGTCC AATTGCCAC TTAGCGAGGT AACGCAGCAT 420  
 GAGCATCGGC ATCACACCCC GGCCGCAACA GACCACCAG CCACTCGATT TTTCCGGCGT 480  
 35 AAGCGGCAAG AGTCCTCAAC CAAACACGTT CGGCGAGCAG AACACTCAGC AAGCGATCGA 540  
 CCCGAGTGCA CTGTTGTTTCG GCAGCGACAC ACAGAAAGAC GTCAACTTCG GCACGCCCGA 600  
 40 CAGCACCGTC CAGAATCCGC AGGACGCCAG CAAGCCCAAC GACAGCCAGT CCAACATCGC 660  
 TAAATTGATC AGTGCAATTGA TCATGTCGTT GCTGCAGATG CTCACCAACT CCAATAAAAA 720  
 GCAGGACACC AATCAGGAAC AGCCTGATAG CCAGGCTCCT TTCCAGAACA ACGGCGGGCT 780

- 26 -

CGGTACACCG TCGGCCGATA GCGGGGGCGG CGGTACACCG GATGCGACAG GTGGCGGCGG 840  
 5 CGGTGATACG CCAAGCGCAA CAGGCGGTGG CGGCGGTGAT ACTCCGACCG CAACAGGCGG 900  
 TGGCGGCAGC GGTGGCGGCG GCACACCCAC TGCAACAGGT GGCGGCAGCG GTGGCACACC 960  
 CACTGCAACA GGCGGTGGCG AGGGTGGCGT AACACCGCAA ATCACTCCGC AGTTGGCCAA 1020  
 10 CCCTAACCGT ACCTCAGGTA CTGGCTCGGT GTCGGACACC GCAGGTTCTA CCGAGCAAGC 1080  
 CGGCAAGATC AATGTGGTGA AAGACACCAT CAAGGTCGGC GCTGGCGAAG TCTTTGACGG 1140  
 CCACGGCGCA ACCTTCACTG CCGACAAATC TATGGGTAAC GGAGACCAGG GCGAAAATCA 1200  
 15 GAAGCCCATG TTCGAGCTGG CTGAAGGCGC TACGTTGAAG AATGTGAACC TGGGTGAGAA 1260  
 CGAGGTCGAT GGCATCCACG TGAAAGCCAA AAACGCTCAG GAAGTCACCA TTGACAACGT 1320  
 20 GCATGCCCAG AACGTCGGTG AAGACCTGAT TACGGTCAAA GCGAGGGAG GCGCAGCGGT 1380  
 CACTAATCTG AACATCAAGA ACAGCAGTGC CAAAGGTGCA GACGACAAGG TTGTCCAGCT 1440  
 CAACGCCAAC ACTCACTTGA AAATCGACAA CTTCAAGGCC GACGATTTG GCACGATGGT 1500  
 25 TCGCACCAAC GGTGGCAAGC AGTTTGATGA CATGAGCATC GAGCTGAACG GCATCGAAGC 1560  
 TAACCACGGC AAGTTCGCCC TGGTGAAAAG CGACAGTGAC GATCTGAAGC TGGCAACGGG 1620  
 30 CAACATCGCC ATGACCGACG TCAAACACGC CTACGATAAA ACCCAGGCAT CGACCCAACA 1680  
 CACCGAGCTT TGAATCCAGA CAAGTAGCTT GAAAAAAGGG GGTGGACTC 1729

35 This DNA molecule is known as the dspE gene for *Pseudomonas syringae*. This isolated DNA molecule of the present invention encodes a protein or polypeptide which elicits a plant pathogen's hypersensitive response having an amino acid sequence of SEQ. ID. No. 34 as follows:

40 Met Ser Ile Gly Ile Thr Pro Arg Pro Gln Gln Thr Thr Thr Pro Leu  
     1                    5                    10                    15  
 Asp Phe Ser Ala Leu Ser Gly Lys Ser Pro Gln Pro Asn Thr Phe Gly  
                     20                    25                    30  
 45 Glu Gln Asn Thr Gln Gln Ala Ile Asp Pro Ser Ala Leu Leu Phe Gly  
                     35                    40                    45  
 Ser Asp Thr Gln Lys Asp Val Asn Phe Gly Thr Pro Asp Ser Thr Val  
 50                    50                    55                    60  
 Gln Asn Pro Gln Asp Ala Ser Lys Pro Asn Asp Ser Gln Ser Asn Ile  
     65                    70                    75                    80  
 55 Ala Lys Leu Ile Ser Ala Leu Ile Met Ser Leu Leu Gln Met Leu Thr  
                     85                    90                    95



- 27 -

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Asn | Ser | Asn | Lys | Lys | Gln | Asp | Thr | Asn | Gln | Glu | Gln | Pro | Asp | Ser | Gln |  |
|    |     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |  |
| 5  | Ala | Pro | Phe | Gln | Asn | Asn | Gly | Gly | Leu | Gly | Thr | Pro | Ser | Ala | Asp | Ser |  |
|    |     |     | 115 |     |     |     | 120 |     |     |     |     |     | 125 |     |     |     |  |
|    | Gly | Gly | Gly | Gly | Thr | Pro | Asp | Ala | Thr | Gly | Gly | Gly | Gly | Gly | Asp | Thr |  |
|    |     |     | 130 |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |  |
| 10 | Pro | Ser | Ala | Thr | Gly | Gly | Gly | Gly | Gly | Asp | Thr | Pro | Thr | Ala | Thr | Gly |  |
|    |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     |     | 160 |  |
|    | Gly | Gly | Gly | Ser | Gly | Gly | Gly | Gly | Thr | Pro | Thr | Ala | Thr | Gly | Gly | Gly |  |
|    |     |     |     | 165 |     |     |     |     | 170 |     |     |     |     |     | 175 |     |  |
| 15 | Ser | Gly | Gly | Thr | Pro | Thr | Ala | Thr | Gly | Gly | Gly | Glu | Gly | Gly | Val | Thr |  |
|    |     |     |     | 180 |     |     |     |     | 185 |     |     |     |     |     | 190 |     |  |
| 20 | Pro | Gln | Ile | Thr | Pro | Gln | Leu | Ala | Asn | Pro | Asn | Arg | Thr | Ser | Gly | Thr |  |
|    |     |     | 195 |     |     |     | 200 |     |     |     |     |     | 205 |     |     |     |  |
|    | Gly | Ser | Val | Ser | Asp | Thr | Ala | Gly | Ser | Thr | Glu | Gln | Ala | Gly | Lys | Ile |  |
|    |     |     | 210 |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |  |
| 25 | Asn | Val | Val | Lys | Asp | Thr | Ile | Lys | Val | Gly | Ala | Gly | Glu | Val | Phe | Asp |  |
|    |     |     |     |     | 230 |     |     |     |     |     | 235 |     |     |     |     | 240 |  |
|    | Gly | His | Gly | Ala | Thr | Phe | Thr | Ala | Asp | Lys | Ser | Met | Gly | Asn | Gly | Asp |  |
|    |     |     |     | 245 |     |     |     |     | 250 |     |     |     |     |     | 255 |     |  |
| 30 | Gln | Gly | Glu | Asn | Gln | Lys | Pro | Met | Phe | Glu | Leu | Ala | Glu | Gly | Ala | Thr |  |
|    |     |     |     | 260 |     |     |     |     | 265 |     |     |     |     | 270 |     |     |  |
| 35 | Leu | Lys | Asn | Val | Asn | Leu | Gly | Glu | Asn | Glu | Val | Asp | Gly | Ile | His | Val |  |
|    |     |     | 275 |     |     |     | 280 |     |     |     |     |     | 285 |     |     |     |  |
|    | Lys | Ala | Lys | Asn | Ala | Gln | Glu | Val | Thr | Ile | Asp | Asn | Val | His | Ala | Gln |  |
|    |     |     | 290 |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |  |
| 40 | Asn | Val | Gly | Glu | Asp | Leu | Ile | Thr | Val | Lys | Gly | Glu | Gly | Gly | Ala | Ala |  |
|    |     |     |     |     | 310 |     |     |     |     |     | 315 |     |     |     |     | 320 |  |
|    | Val | Thr | Asn | Leu | Asn | Ile | Lys | Asn | Ser | Ser | Ala | Lys | Gly | Ala | Asp | Asp |  |
|    |     |     |     | 325 |     |     |     |     | 330 |     |     |     |     |     | 335 |     |  |
| 45 | Lys | Val | Val | Gln | Leu | Asn | Ala | Asn | Thr | His | Leu | Lys | Ile | Asp | Asn | Phe |  |
|    |     |     |     | 340 |     |     |     |     | 345 |     |     |     |     | 350 |     |     |  |
| 50 | Lys | Ala | Asp | Asp | Phe | Gly | Thr | Met | Val | Arg | Thr | Asn | Gly | Gly | Lys | Gln |  |
|    |     |     | 355 |     |     |     |     | 360 |     |     |     |     | 365 |     |     |     |  |
|    | Phe | Asp | Asp | Met | Ser | Ile | Glu | Leu | Asn | Gly | Ile | Glu | Ala | Asn | His | Gly |  |
|    |     |     | 370 |     |     |     | 375 |     |     |     |     | 380 |     |     |     |     |  |
| 55 | Lys | Phe | Ala | Leu | Val | Lys | Ser | Asp | Ser | Asp | Asp | Leu | Lys | Leu | Ala | Thr |  |
|    |     |     |     |     | 390 |     |     |     |     |     | 395 |     |     |     |     | 400 |  |
|    | Gly | Asn | Ile | Ala | Met | Thr | Asp | Val | Lys | His | Ala | Tyr | Asp | Lys | Thr | Gln |  |
|    |     |     |     | 405 |     |     |     |     |     | 410 |     |     |     |     |     | 415 |  |

- 28 -

Ala Ser Thr Gln His Thr Glu Leu  
420

5

This protein or polypeptide is about 42.9 kDa.

The hypersensitive response elicitor polypeptide or protein derived from *Pseudomonas solanacearum* has an amino acid sequence corresponding to SEQ.

10 ID. No. 35 as follows:

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
|    | Met | Ser | Val | Gly | Asn | Ile | Gln | Ser | Pro | Ser | Asn | Leu | Pro | Gly | Leu | Gln |  |
|    | 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |  |
| 15 | Asn | Leu | Asn | Leu | Asn | Thr | Asn | Thr | Asn | Ser | Gln | Gln | Ser | Gly | Gln | Ser |  |
|    |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |  |
|    | Val | Gln | Asp | Leu | Ile | Lys | Gln | Val | Glu | Lys | Asp | Ile | Leu | Asn | Ile | Ile |  |
|    |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |  |
|    | Ala | Ala | Leu | Val | Gln | Lys | Ala | Ala | Gln | Ser | Ala | Gly | Gly | Asn | Thr | Gly |  |
|    |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |  |
| 20 | Asn | Thr | Gly | Asn | Ala | Pro | Ala | Lys | Asp | Gly | Asn | Ala | Asn | Ala | Gly | Ala |  |
|    | 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |  |
|    | Asn | Asp | Pro | Ser | Lys | Asn | Asp | Pro | Ser | Lys | Ser | Gln | Ala | Pro | Gln | Ser |  |
|    |     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |  |
| 25 | Ala | Asn | Lys | Thr | Gly | Asn | Val | Asp | Asp | Ala | Asn | Asn | Gln | Asp | Pro | Met |  |
|    |     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |  |
|    | Gln | Ala | Leu | Met | Gln | Leu | Leu | Glu | Asp | Leu | Val | Lys | Leu | Leu | Lys | Ala |  |
|    |     |     | 115 |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |  |
|    | Ala | Leu | His | Met | Gln | Gln | Pro | Gly | Gly | Asn | Asp | Lys | Gly | Asn | Gly | Val |  |
|    |     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |  |
| 30 | Gly | Gly | Ala | Asn | Gly | Ala | Lys | Gly | Ala | Gly | Gly | Gln | Gly | Gly | Leu | Ala |  |
|    | 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     |     | 160 |  |
|    | Glu | Ala | Leu | Gln | Glu | Ile | Glu | Gln | Ile | Leu | Ala | Gln | Leu | Gly | Gly | Gly |  |
|    |     |     |     | 165 |     |     |     |     |     | 170 |     |     |     |     | 175 |     |  |
| 35 | Gly | Ala | Gly | Ala | Gly | Gly | Ala | Gly | Gly | Gly | Val | Gly | Gly | Ala | Gly | Gly |  |
|    |     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |  |
|    | Ala | Asp | Gly | Gly | Ser | Gly | Ala | Gly | Gly | Ala | Gly | Gly | Ala | Asn | Gly | Ala |  |
|    |     |     | 195 |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |  |
|    | Asp | Gly | Gly | Asn | Gly | Val | Asn | Gly | Asn | Gln | Ala | Asn | Gly | Pro | Gln | Asn |  |
|    |     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |  |

- 29 -

|    |   |             |
|----|---|-------------|
|    | Ala Gly Asp Val Asn Gly Ala Asn Gly Ala Asp Asp Gly Ser Glu Asp |             |
|    | 225   | 230 235 240 |
|    | Gln Gly Gly Leu Thr Gly Val Leu Gln Lys Leu Met Lys Ile Leu Asn |             |
|    |   | 245 250 255 |
| 5  | Ala Leu Val Gln Met Met Gln Gln Gly Gly Leu Gly Gly Gly Asn Gln |             |
|    |   | 260 265 270 |
|    | Ala Gln Gly Gly Ser Lys Gly Ala Gly Asn Ala Ser Pro Ala Ser Gly |             |
|    |   | 275 280 285 |
| 10 | Ala Asn Pro Gly Ala Asn Gln Pro Gly Ser Ala Asp Asp Gln Ser Ser |             |
|    |   | 290 295 300 |
|    | Gly Gln Asn Asn Leu Gln Ser Gln Ile Met Asp Val Val Lys Glu Val |             |
|    | 305   | 310 315 320 |
|    | Val Gln Ile Leu Gln Gln Met Leu Ala Ala Gln Asn Gly Gly Ser Gln |             |
|    |   | 325 330 335 |
| 15 | Gln Ser Thr Ser Thr Gln Pro Met                                 |             |
|    |   | 340         |

It is encoded by a DNA molecule having a nucleotide sequence corresponding SEQ.

ID. No. 36 as follows:

|    |   |     |
|----|---|-----|
|    | ATGTCAGTCG GAAACATCCA GAGCCCGTCG AACCTCCCGG GTCTGCAGAA CCTGAACCTC | 60  |
| 20 | AACACCAACA CCAACAGCCA GCAATCGGGC CAGTCCGTGC AAGACCTGAT CAAGCAGGTC | 120 |
|    | GAGAAGGACA TCCTCAACAT CATCGCAGCC CTCGTGCAGA AGGCCGCACA GTCGGCGGGC | 180 |
|    | GGCAACACCG GTAACACCGG CAACGCGCCG GCGAAGGACG GCAATGCCAA CGCGGGCGCC | 240 |
|    | AACGACCCGA GCAAGAACGA CCGAGCAAG AGCCAGGCTC CGCAGTCGGC CAACAAGACC  | 300 |
|    | GGCAACGTCG ACGACGCCAA CAACCAGGAT CCGATGCAAG CGCTGATGCA GCTGCTGGAA | 360 |
| 25 | GACCTGGTGA AGCTGCTGAA GGCGGCCCTG CACATGCAGC AGCCCGGCGG CAATGACAAG | 420 |
|    | GGCAACGGCG TGGGCGGTGC CAACGGCGCC AAGGGTGCCG GCGGCCAGGG CGGCCTGGCC | 480 |
|    | GAAGCGCTGC AGGAGATCGA GCAGATCCTC GCCAGCTCG GCGGCGGCGG TGCTGGCGCC  | 540 |
|    | GGCGGCGCGG GTGGCGGTGT CGGCGGTGCT GGTGGCGCGG ATGGCGGCTC CGGTGCGGGT | 600 |
|    | GGCGCAGGCG GTGCGAACGG CGCCGACGGC GGCAATGGCG TGAACGGCAA CCAGGCGAAC | 660 |
| 30 | GGCCCGCAGA ACGCAGGCGA TGTCAACGGT GCCAACGGCG CGGATGACGG CAGCGAAGAC | 720 |
|    | CAGGGCGGCC TCACCGGCGT GCTGCAAAAG CTGATGAAGA TCCTGAACGC GCTGGTGCAG | 780 |
|    | ATGATGCAGC AAGGCGGCCT CGGCGGCGGC AACCAGGCGC AGGGCGGCTC GAAGGGTGCC | 840 |
|    | GGCAACGCCT CGCCGGCTTC CGGCGCGAAC CCGGGCGCGA ACCAGCCCGG TTCGGCGGAT | 900 |

- 30 -

GATCAATCGT CCGGCCAGAA CAATCTGCAA TCCCAGATCA TGGATGTGGT GAAGGAGGTC 960  
 GTCCAGATCC TGCAGCAGAT GCTGGCGGCG CAGAACGGCG GCAGCCAGCA GTCCACCTCG 1020  
 ACGCAGCCGA TGTA 1035

5 Further information regarding the hypersensitive response elicitor polypeptide or protein derived from *Pseudomonas solanacearum* is set forth in Arlat, M., F. Van Gijsegem, J. C. Huet, J. C. Pemollet, and C. A. Boucher, "PopA1, a Protein which Induces a Hypersensitive-like Response in Specific Petunia Genotypes, is Secreted  
 10 via the Hrp Pathway of *Pseudomonas solanacearum*," EMBO J. 13:543-533 (1994), which is hereby incorporated by reference.

The hypersensitive response elicitor polypeptide or protein from *Xanthomonas campestris* pv. glycines has an amino acid sequence corresponding to SEQ. ID. No. 37 as follows:

15 Thr Leu Ile Glu Leu Met Ile Val Val Ala Ile Ile Ala Ile Leu Ala  
 1 5 10 15  
 Ala Ile Ala Leu Pro Ala Tyr Gln Asp Tyr  
 20 25

20 This sequence is an amino terminal sequence having only 26 residues from the hypersensitive response elicitor polypeptide or protein of *Xanthomonas campestris* pv. glycines. It matches with fimbrial subunit proteins determined in other  
 25 *Xanthomonas campestris* pathovars.

The hypersensitive response elicitor polypeptide or protein from *Xanthomonas campestris* pv. *pelargonii* is heat stable, protease sensitive, and has a molecular weight of 20 kDa. It includes an amino acid sequence corresponding to SEQ. ID. No. 38 as follows:

30 Ser Ser Gln Gln Ser Pro Ser Ala Gly Ser Glu Gln Gln Leu Asp Gln  
 1 5 10 15  
 Leu Leu Ala Met  
 20

35 Isolation of *Erwinia carotovora* hypersensitive response elicitor protein or polypeptide is described in Cui et al., "The RsmA Mutants of *Erwinia carotovora*

- 31 -

subsp. *carotovora* Strain Ecc71 Overexpress *hrp* N<sub>Ecc</sub> and Elicit a Hypersensitive Reaction-like Response in Tobacco Leaves," MPMI, 9(7):565-73 (1996), which is hereby incorporated by reference. The hypersensitive response elicitor protein or polypeptide of *Erwinia stewartii* is set forth in Ahmad et al., "Harpin is Not  
 5 Necessary for the Pathogenicity of *Erwinia stewartii* on Maize," 8th Int'l. Cong. Molec. Plant-Microbe Interact., July 14-19, 1996 and Ahmad, et al., "Harpin is Not Necessary for the Pathogenicity of *Erwinia stewartii* on Maize," Ann. Mtg. Am. Phytopath. Soc., July 27-31, 1996, which are hereby incorporated by reference.

Hypersensitive response elicitor proteins or polypeptides from  
 10 *Phytophthora parasitica*, *Phytophthora cryptogea*, *Phytophthora cinnamoni*, *Phytophthora capsici*, *Phytophthora megasperma*, and *Phytophthora citrophthora* are described in Kaman, et al., "Extracellular Protein Elicitors from Phytophthora: Most Specificity and Induction of Resistance to Bacterial and Fungal Phytopathogens," Molec. Plant-Microbe Interact., 6(1):15-25 (1993), Ricci et al., "Structure and  
 15 Activity of Proteins from Pathogenic Fungi Phytophthora Eliciting Necrosis and Acquired Resistance in Tobacco," Eur. J. Biochem., 183:555-63 (1989), Ricci et al., "Differential Production of Parasiticein, and Elicitor of Necrosis and Resistance in Tobacco, by Isolates of *Phytophthora parasitica*," Plant Path. 41:298-307 (1992), Baillreul et al., "A New Elicitor of the Hypersensitive Response in Tobacco: A  
 20 Fungal Glycoprotein Elicits Cell Death, Expression of Defence Genes, Production of Salicylic Acid, and Induction of Systemic Acquired Resistance," Plant J., 8(4):551-60 (1995), and Bonnet et al., "Acquired Resistance Triggered by Elicitors in Tobacco and Other Plants," Eur. J. Plant Path., 102:181-92 (1996), which are hereby incorporated by reference.

25 Another hypersensitive response elicitor in accordance with the present invention is from *Clavibacter michiganensis* subsp. *sepedonicus* which is fully described in U.S. Patent Application Serial No. 09/136,625, which is hereby incorporated by reference.

The above elicitors are exemplary. Other elicitors can be identified by  
 30 growing fungi or bacteria that elicit a hypersensitive response under conditions which genes encoding an elicitor are expressed. Cell-free preparations from culture

supernatants can be tested for elicitor activity (i.e. local necrosis) by using them to infiltrate appropriate plant tissues.

Fragments of the above hypersensitive response elicitor polypeptides or proteins as well as fragments of full length elicitors from other pathogens are encompassed by the present invention.

Suitable fragments can be produced by several means. In the first, subclones of the gene encoding a known elicitor protein are produced by conventional molecular genetic manipulation by subcloning gene fragments. The subclones then are expressed *in vitro* or *in vivo* in bacterial cells to yield a smaller protein or peptide that can be tested for elicitor activity according to the procedure described below.

As an alternative, fragments of an elicitor protein can be produced by digestion of a full-length elicitor protein with proteolytic enzymes like chymotrypsin or *Staphylococcus* proteinase A, or trypsin. Different proteolytic enzymes are likely to cleave elicitor proteins at different sites based on the amino acid sequence of the elicitor protein. Some of the fragments that result from proteolysis may be active elicitors of resistance.

In another approach, based on knowledge of the primary structure of the protein, fragments of the elicitor protein gene may be synthesized by using the PCR technique together with specific sets of primers chosen to represent particular portions of the protein. These then would be cloned into an appropriate vector for expression of a truncated peptide or protein.

Chemical synthesis can also be used to make suitable fragments. Such a synthesis is carried out using known amino acid sequences for the elicitor being produced. Alternatively, subjecting a full length elicitor to high temperatures and pressures will produce fragments. These fragments can then be separated by conventional procedures (e.g., chromatography, SDS-PAGE).

An example of suitable fragments of a hypersensitive response elicitor which do not elicit a hypersensitive response include fragments of the *Erwinia amylovora* hypersensitive response elicitor. Suitable fragments include a C-terminal fragment of the amino acid sequence of SEQ. ID. No. 23, an N-terminal fragment of the amino acid sequence of SEQ. ID. No. 23, or an internal fragment of the amino acid sequence of SEQ. ID. No. 23. The C-terminal fragment of the amino acid

- 33 -

sequence of SEQ. ID. No. 23 can span the following amino acids of SEQ. ID. No. 23: 169 and 403, 210 and 403, 267 and 403, or 343 and 403. The internal fragment of the amino acid sequence of SEQ. ID. No. 23 can span the following amino acids of SEQ. ID. No. 23: 105 and 179, 137 and 166, 121 and 150, or 137 and 156. Other suitable  
5 fragments can be identified in accordance with the present invention.

Another example of a useful fragment of a hypersensitive response elicitor which fragment does not itself elicit a hypersensitive response is the protein fragment containing amino acids 190 to 294 of the amino acid sequence (SEQ. ID. No. 31) for the *Pseudomonas syringae* pv. *syringae* hypersensitive response elicitor.  
10 This fragment is useful in imparting disease resistance and enhancing plant growth.

Yet another example of a useful fragment of a hypersensitive response elicitor is the peptide having an amino acid sequence corresponding to SEQ. ID. No. 39. This peptide is derived from the hypersensitive response eliciting glycoprotein of *Phytophthora megasperma* and enhances plant growth.

15 Variants may be made by, for example, the deletion or addition of amino acids that have minimal influence on the properties, secondary structure, and hydrophobic nature of the polypeptide. For example, a polypeptide may be conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide  
20 may also be conjugated to a linker or other sequence for ease of synthesis, purification, or identification of the polypeptide.

The fragment of the present invention is preferably in isolated form (i.e. separated from its host organism) and more preferably produced in purified form (preferably at least about 60%, more preferably 80%, pure) by conventional  
25 techniques. Typically, the fragment of the present invention is produced but not secreted into the growth medium of recombinant host cells. Alternatively, the protein or polypeptide of the present invention is secreted into growth medium. In the case of unsecreted protein, to isolate the protein fragment, the host cell (e.g., *E. coli*) carrying a recombinant plasmid is propagated, lysed by sonication, heat, or chemical treatment,  
30 and the homogenate is centrifuged to remove bacterial debris. The supernatant is then subjected to heat treatment and the fragment is separated by centrifugation. The supernatant fraction containing the fragment is subjected to gel filtration in an

- 34 -

appropriately sized dextran or polyacrylamide column to separate the fragment. If necessary, the protein fraction may be further purified by ion exchange or HPLC.

The DNA molecule encoding the fragment of the hypersensitive response elicitor polypeptide or protein can be incorporated in cells using  
5 conventional recombinant DNA technology. Generally, this involves inserting the DNA molecule into an expression system to which the DNA molecule is heterologous (i.e. not normally present). The heterologous DNA molecule is inserted into the expression system or vector in proper sense orientation and correct reading frame. The vector contains the necessary elements for the transcription and translation of the  
10 inserted protein-coding sequences.

U.S. Patent No. 4,237,224 to Cohen and Boyer, which is hereby incorporated by reference, describes the production of expression systems in the form of recombinant plasmids using restriction enzyme cleavage and ligation with DNA ligase. These recombinant plasmids are then introduced by means of transformation  
15 and replicated in unicellular cultures including procaryotic organisms and eucaryotic cells grown in tissue culture.

Recombinant genes may also be introduced into viruses, such as vaccina virus. Recombinant viruses can be generated by transfection of plasmids into cells infected with virus.

20 Suitable vectors include, but are not limited to, the following viral vectors such as lambda vector system gt11, gt WES.tB, Charon 4, and plasmid vectors such as pBR322, pBR325, pACYC177, pACYC1084, pUC8, pUC9, pUC18, pUC19, pLG339, pR290, pKC37, pKC101, SV 40, pBluescript II SK +/- or KS +/- (see "Stratagene Cloning Systems" Catalog (1993) from Stratagene, La Jolla, Calif, which  
25 is hereby incorporated by reference), pQE, pIH821, pGEX, pET series (see F.W. Studier et. al., "Use of T7 RNA Polymerase to Direct Expression of Cloned Genes," Gene Expression Technology vol. 185 (1990), which is hereby incorporated by reference), and any derivatives thereof. Recombinant molecules can be introduced into cells via transformation, particularly transduction, conjugation, mobilization, or  
30 electroporation. The DNA sequences are cloned into the vector using standard cloning procedures in the art, as described by Sambrook et al., Molecular Cloning: A



- 35 -

Laboratory Manual, Cold Springs Laboratory, Cold Springs Harbor, New York (1989), which is hereby incorporated by reference.

A variety of host-vector systems may be utilized to express the protein-encoding sequence(s). Primarily, the vector system must be compatible with the host cell used. Host-vector systems include but are not limited to the following: bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA; microorganisms such as yeast containing yeast vectors; mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); and plant cells infected by bacteria. The expression elements of these vectors vary in their strength and specificities. Depending upon the host-vector system utilized, any one of a number of suitable transcription and translation elements can be used.

Different genetic signals and processing events control many levels of gene expression (e.g., DNA transcription and messenger RNA (mRNA) translation).

Transcription of DNA is dependent upon the presence of a promotor which is a DNA sequence that directs the binding of RNA polymerase and thereby promotes mRNA synthesis. The DNA sequences of eucaryotic promotors differ from those of procaryotic promotors. Furthermore, eucaryotic promotors and accompanying genetic signals may not be recognized in or may not function in a procaryotic system, and, further, procaryotic promotors are not recognized and do not function in eucaryotic cells.

Similarly, translation of mRNA in procaryotes depends upon the presence of the proper procaryotic signals which differ from those of eucaryotes. Efficient translation of mRNA in procaryotes requires a ribosome binding site called the Shine-Dalgarno ("SD") sequence on the mRNA. This sequence is a short nucleotide sequence of mRNA that is located before the start codon, usually AUG, which encodes the amino-terminal methionine of the protein. The SD sequences are complementary to the 3'-end of the 16S rRNA (ribosomal RNA) and probably promote binding of mRNA to ribosomes by duplexing with the rRNA to allow correct positioning of the ribosome. For a review on maximizing gene expression, see Roberts and Lauer, Methods in Enzymology, 68:473 (1979), which is hereby incorporated by reference.

- 36 -

Promoters vary in their "strength" (i.e. their ability to promote transcription). For the purposes of expressing a cloned gene, it is desirable to use strong promoters in order to obtain a high level of transcription and, hence, expression of the gene. Depending upon the host cell system utilized, any one of a number of suitable promoters may be used. For instance, when cloning in *E. coli*, its bacteriophages, or plasmids, promoters such as the T7 phage promoter, *lac* promoter, *trp* promoter, *recA* promoter, ribosomal RNA promoter, the  $P_R$  and  $P_L$  promoters of coliphage lambda and others, including but not limited, to *lacUV5*, *ompF*, *bla*, *lpp*, and the like, may be used to direct high levels of transcription of adjacent DNA segments. Additionally, a hybrid *trp-lacUV5 (tac)* promoter or other *E. coli* promoters produced by recombinant DNA or other synthetic DNA techniques may be used to provide for transcription of the inserted gene.

Bacterial host cell strains and expression vectors may be chosen which inhibit the action of the promoter unless specifically induced. In certain operations, the addition of specific inducers is necessary for efficient transcription of the inserted DNA. For example, the *lac* operon is induced by the addition of lactose or IPTG (isopropylthio-beta-D-galactoside). A variety of other operons, such as *trp*, *pro*, etc., are under different controls.

Specific initiation signals are also required for efficient gene transcription and translation in procaryotic cells. These transcription and translation initiation signals may vary in "strength" as measured by the quantity of gene specific messenger RNA and protein synthesized, respectively. The DNA expression vector, which contains a promoter, may also contain any combination of various "strong" transcription and/or translation initiation signals. For instance, efficient translation in *E. coli* requires an SD sequence about 7-9 bases 5' to the initiation codon ("ATG") to provide a ribosome binding site. Thus, any SD-ATG combination that can be utilized by host cell ribosomes may be employed. Such combinations include but are not limited to the SD-ATG combination from the *cro* gene or the *N* gene of coliphage lambda, or from the *E. coli* tryptophan E, D, C, B or A genes. Additionally, any SD-ATG combination produced by recombinant DNA or other techniques involving incorporation of synthetic nucleotides may be used.

- 37 -

Once the isolated DNA molecule encoding the fragment of a hypersensitive response elicitor polypeptide or protein has been cloned into an expression system, it is ready to be incorporated into a host cell. Such incorporation can be carried out by the various forms of transformation noted above, depending upon the vector/host cell system. Suitable host cells include, but are not limited to, bacteria, virus, yeast, mammalian cells, insect, plant, and the like.

The present invention further relates to methods of imparting disease resistance to plants, enhancing plant growth, and/or effecting insect control for plants. These methods involve applying the fragment of a hypersensitive response elicitor polypeptide or protein which does not elicit a hypersensitive response in a non-infectious form to all or part of a plant or a plant seed under conditions effective for the fragment to impart disease resistance, enhance growth, and/or control insects. Alternatively, these fragments of a hypersensitive response elicitor protein or polypeptide can be applied to plants such that seeds recovered from such plants themselves are able to impart disease resistance in plants, to enhance plant growth, and/or to effect insect control.

As an alternative to applying a fragment of a hypersensitive response elicitor polypeptide or protein to plants or plant seeds in order to impart disease resistance in plants, to effect plant growth, and/or to control insects on the plants or plants grown from the seeds, transgenic plants or plant seeds can be utilized. When utilizing transgenic plants, this involves providing a transgenic plant transformed with a DNA molecule encoding a fragment of a hypersensitive response elicitor polypeptide or protein, which fragment does not elicit a hypersensitive response, and growing the plant under conditions effective to permit that DNA molecule to impart disease resistance to plants, to enhance plant growth, and/or to control insects. Alternatively, a transgenic plant seed transformed with a DNA molecule encoding a fragment of a hypersensitive response elicitor polypeptide or protein which fragment does not elicit a hypersensitive response can be provided and planted in soil. A plant is then propagated from the planted seed under conditions effective to permit that DNA molecule to impart disease resistance to plants, to enhance plant growth, and/or to control insects.

- 38 -

The embodiment of the present invention where the hypersensitive response elicitor polypeptide or protein is applied to the plant or plant seed can be carried out in a number of ways, including: 1) application of an isolated fragment or 2) application of bacteria which do not cause disease and are transformed with a gene encoding the fragment. In the latter embodiment, the fragment can be applied to plants or plant seeds by applying bacteria containing the DNA molecule encoding the fragment of the hypersensitive response elicitor polypeptide or protein which fragment does not elicit a hypersensitive response. Such bacteria must be capable of secreting or exporting the fragment so that the fragment can contact plant or plant seed cells. In these embodiments, the fragment is produced by the bacteria *in planta* or on seeds or just prior to introduction of the bacteria to the plants or plant seeds.

The methods of the present invention can be utilized to treat a wide variety of plants or their seeds to impart disease resistance, enhance growth, and/or control insects. Suitable plants include dicots and monocots. More particularly, useful crop plants can include: alfalfa, rice, wheat, barley, rye, cotton, sunflower, peanut, corn, potato, sweet potato, bean, pea, chicory, lettuce, endive, cabbage, brussel sprout, beet, parsnip, turnip, cauliflower, broccoli, radish, spinach, onion, garlic, eggplant, pepper, celery, carrot, squash, pumpkin, zucchini, cucumber, apple, pear, melon, citrus, strawberry, grape, raspberry, pineapple, soybean, tobacco, tomato, sorghum, and sugarcane. Examples of suitable ornamental plants are: *Arabidopsis thaliana*, *Saintpaulia*, petunia, pelargonium, poinsettia, chrysanthemum, carnation, and zinnia.

With regard to the use of the fragments of the hypersensitive response elicitor protein or polypeptide of the present invention in imparting disease resistance, absolute immunity against infection may not be conferred, but the severity of the disease is reduced and symptom development is delayed. Lesion number, lesion size, and extent of sporulation of fungal pathogens are all decreased. This method of imparting disease resistance has the potential for treating previously untreatable diseases, treating diseases systemically which might not be treated separately due to cost, and avoiding the use of infectious agents or environmentally harmful materials.

The method of imparting pathogen resistance to plants in accordance with the present invention is useful in imparting resistance to a wide variety of

- 39 -

pathogens including viruses, bacteria, and fungi. Resistance, *inter alia*, to the following viruses can be achieved by the method of the present invention: *Tobacco mosaic virus* and *Tomato mosaic virus*. Resistance, *inter alia*, to the following bacteria can also be imparted to plants in accordance with present invention:

- 5    *Pseudomonas solanacearum*, *Pseudomonas syringae* pv. *tabaci*, and *Xanthomonas campestris* pv. *pelargonii*. Plants can be made resistant, *inter alia*, to the following fungi by use of the method of the present invention: *Fusarium oxysporum* and *Phytophthora infestans*.

- With regard to the use of the fragments of the hypersensitive response
- 10    elicitor protein or polypeptide of the present invention to enhance plant growth, various forms of plant growth enhancement or promotion can be achieved. This can occur as early as when plant growth begins from seeds or later in the life of a plant. For example, plant growth according to the present invention encompasses greater yield, increased quantity of seeds produced, increased percentage of seeds
- 15    germinated, increased plant size, greater biomass, more and bigger fruit, earlier fruit coloration, and earlier fruit and plant maturation. As a result, the present invention provides significant economic benefit to growers. For example, early germination and early maturation permit crops to be grown in areas where short growing seasons would otherwise preclude their growth in that locale. Increased percentage of seed
- 20    germination results in improved crop stands and more efficient seed use. Greater yield, increased size, and enhanced biomass production allow greater revenue generation from a given plot of land.

- Another aspect of the present invention is directed to effecting any form of insect control for plants. For example, insect control according to the present
- 25    invention encompasses preventing insects from contacting plants to which the hypersensitive response elicitor has been applied, preventing direct insect damage to plants by feeding injury, causing insects to depart from such plants, killing insects proximate to such plants, interfering with insect larval feeding on such plants, preventing insects from colonizing host plants, preventing colonizing insects from
- 30    releasing phytotoxins, etc. The present invention also prevents subsequent disease damage to plants resulting from insect infection.

- 40 -

The present invention is effective against a wide variety of insects. European corn borer is a major pest of corn (dent and sweet corn) but also feeds on over 200 plant species including green, wax, and lima beans and edible soybeans, peppers, potato, and tomato plus many weed species. Additional insect larval feeding  
5 pests which damage a wide variety of vegetable crops include the following: beet armyworm, cabbage looper, corn ear worm, fall armyworm, diamondback moth, cabbage root maggot, onion maggot, seed corn maggot, pickleworm (melonworm), pepper maggot, tomato pinworm, and maggots. Collectively, this group of insect  
10 pests represents the most economically important group of pests for vegetable production worldwide.

The method of the present invention involving application of the fragment of a hypersensitive response elicitor polypeptide or protein, which fragment does not elicit a hypersensitive response, can be carried out through a variety of procedures when all or part of the plant is treated, including leaves, stems, roots,  
15 propagules (e.g., cuttings), etc. This may (but need not) involve infiltration of the fragment of the hypersensitive response elicitor polypeptide or protein into the plant. Suitable application methods include high or low pressure spraying, injection, and leaf abrasion proximate to when elicitor application takes place. When treating plant seeds or propagules (e.g., cuttings), in accordance with the application embodiment of  
20 the present invention, the fragment of the hypersensitive response elicitor protein or polypeptide, in accordance with present invention, can be applied by low or high pressure spraying, coating, immersion, or injection. Other suitable application procedures can be envisioned by those skilled in the art provided they are able to effect contact of the fragment with cells of the plant or plant seed. Once treated with  
25 the fragment of the hypersensitive response elicitor of the present invention, the seeds can be planted in natural or artificial soil and cultivated using conventional procedures to produce plants. After plants have been propagated from seeds treated in accordance with the present invention, the plants may be treated with one or more applications of the fragment of the hypersensitive response elicitor protein or  
30 polypeptide or whole elicitors to impart disease resistance to plants, to enhance plant growth, and/or to control insects on the plants.

- 41 -

The fragment of the hypersensitive response elicitor polypeptide or protein, in accordance with the present invention, can be applied to plants or plant seeds alone or in a mixture with other materials. Alternatively, the fragment can be applied separately to plants with other materials being applied at different times.

5           A composition suitable for treating plants or plant seeds in accordance with the application embodiment of the present invention contains a fragment of a hypersensitive response elicitor polypeptide or protein which fragment does not elicit a hypersensitive response in a carrier. Suitable carriers include water, aqueous solutions, slurries, or dry powders. In this embodiment, the composition contains  
10 greater than 500 nM of the fragment.

Although not required, this composition may contain additional additives including fertilizer, insecticide, fungicide, nematocide, and mixtures thereof. Suitable fertilizers include  $(\text{NH}_4)_2\text{NO}_3$ . An example of a suitable insecticide is Malathion. Useful fungicides include Captan.

15           Other suitable additives include buffering agents, wetting agents, coating agents, and abrading agents. These materials can be used to facilitate the process of the present invention. In addition, the hypersensitive response eliciting fragment can be applied to plant seeds with other conventional seed formulation and treatment materials, including clays and polysaccharides.

20           In the alternative embodiment of the present invention involving the use of transgenic plants and transgenic seeds, a fragment of a hypersensitive response elicitor need not be applied topically to the plants or seeds. Instead, transgenic plants transformed with a DNA molecule encoding such a fragment are produced according to procedures well known in the art.

25           The vector described above can be microinjected directly into plant cells by use of micropipettes to transfer mechanically the recombinant DNA. Crossway, Mol. Gen. Genetics, 202:179-85 (1985), which is hereby incorporated by reference. The genetic material may also be transferred into the plant cell using polyethylene glycol. Krens, et al., Nature, 296:72-74 (1982), which is hereby  
30 incorporated by reference.

Another approach to transforming plant cells with a gene which imparts resistance to pathogens is particle bombardment (also known as biolistic

- 42 -

transformation) of the host cell. This can be accomplished in one of several ways. The first involves propelling inert or biologically active particles at cells. This technique is disclosed in U.S. Patent Nos. 4,945,050, 5,036,006, and 5,100,792, all to Sanford et al., which are hereby incorporated by reference. Generally, this procedure involves propelling inert or biologically active particles at the cells under conditions effective to penetrate the outer surface of the cell and to be incorporated within the interior thereof. When inert particles are utilized, the vector can be introduced into the cell by coating the particles with the vector containing the heterologous DNA. Alternatively, the target cell can be surrounded by the vector so that the vector is carried into the cell by the wake of the particle. Biologically active particles (e.g., dried bacterial cells containing the vector and heterologous DNA) can also be propelled into plant cells.

Yet another method of introduction is fusion of protoplasts with other entities, either minicells, cells, lysosomes, or other fusible lipid-surfaced bodies. Fraley, et al., Proc. Natl. Acad. Sci. USA, 79:1859-63 (1982), which is hereby incorporated by reference.

The DNA molecule may also be introduced into the plant cells by electroporation. Fromm et al., Proc. Natl. Acad. Sci. USA, 82:5824 (1985), which is hereby incorporated by reference. In this technique, plant protoplasts are electroporated in the presence of plasmids containing the expression cassette. Electrical impulses of high field strength reversibly permeabilize biomembranes allowing the introduction of the plasmids. Electroporated plant protoplasts reform the cell wall, divide, and regenerate.

Another method of introducing the DNA molecule into plant cells is to infect a plant cell with *Agrobacterium tumefaciens* or *A. rhizogenes* previously transformed with the gene. Under appropriate conditions known in the art, the transformed plant cells are grown to form shoots or roots, and develop further into plants. Generally, this procedure involves inoculating the plant tissue with a suspension of bacteria and incubating the tissue for 48 to 72 hours on regeneration medium without antibiotics at 25-28°C.

*Agrobacterium* is a representative genus of the Gram-negative family Rhizobiaceae. Its species are responsible for crown gall (*A. tumefaciens*) and hairy



- 43 -

root disease (*A. rhizogenes*). The plant cells in crown gall tumors and hairy roots are induced to produce amino acid derivatives known as opines, which are catabolized only by the bacteria. The bacterial genes responsible for expression of opines are a convenient source of control elements for chimeric expression cassettes. In addition, assaying for the presence of opines can be used to identify transformed tissue.

Heterologous genetic sequences can be introduced into appropriate plant cells, by means of the Ti plasmid of *A. tumefaciens* or the Ri plasmid of *A. rhizogenes*. The Ti or Ri plasmid is transmitted to plant cells on infection by *Agrobacterium* and is stably integrated into the plant genome. J. Schell, Science, 10 237:1176-83 (1987), which is hereby incorporated by reference.

After transformation, the transformed plant cells must be regenerated.

Plant regeneration from cultured protoplasts is described in Evans et al., Handbook of Plant Cell Cultures, Vol. 1: (MacMillan Publishing Co., New York, 1983); and Vasil I.R. (ed.), Cell Culture and Somatic Cell Genetics of Plants, Acad. 15 Press, Orlando, Vol. I, 1984, and Vol. III (1986), which are hereby incorporated by reference.

It is known that practically all plants can be regenerated from cultured cells or tissues, including but not limited to, all major species of sugarcane, sugar beets, cotton, fruit trees, and legumes.

Means for regeneration vary from species to species of plants, but generally a suspension of transformed protoplasts or a petri plate containing transformed explants is first provided. Callus tissue is formed and shoots may be induced from callus and subsequently rooted. Alternatively, embryo formation can be induced in the callus tissue. These embryos germinate as natural embryos to form 25 plants. The culture media will generally contain various amino acids and hormones, such as auxin and cytokinins. It is also advantageous to add glutamic acid and proline to the medium, especially for such species as corn and alfalfa. Efficient regeneration will depend on the medium, on the genotype, and on the history of the culture. If these three variables are controlled, then regeneration is usually reproducible and 30 repeatable.

- 44 -

After the expression cassette is stably incorporated in transgenic plants, it can be transferred to other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.

Once transgenic plants of this type are produced, the plants themselves  
5 can be cultivated in accordance with conventional procedure with the presence of the gene encoding the fragment of the hypersensitive response elicitor resulting in disease resistance, enhanced plant growth, and/or control of insects on the plant. Alternatively, transgenic seeds or propagules (e.g., cuttings) are recovered from the transgenic plants. The seeds can then be planted in the soil and cultivated using  
10 conventional procedures to produce transgenic plants. The transgenic plants are propagated from the planted transgenic seeds under conditions effective to impart disease resistance to plants, to enhance plant growth, and/or to control insects. While not wishing to be bound by theory, such disease resistance, growth enhancement, and/or insect control may be RNA mediated or may result from expression of the  
15 polypeptide or protein fragment.

When transgenic plants and plant seeds are used in accordance with the present invention, they additionally can be treated with the same materials as are used to treat the plants and seeds to which a fragment of a hypersensitive response elicitor in accordance with the present invention is applied. These other materials, including  
20 a fragment of a hypersensitive response elicitor in accordance with the present invention, can be applied to the transgenic plants and plant seeds by the above-noted procedures, including high or low pressure spraying, injection, coating, and immersion. Similarly, after plants have been propagated from the transgenic plant seeds, the plants may be treated with one or more applications of the fragment of a  
25 hypersensitive response elicitor in accordance with the present invention to impart disease resistance, enhance growth, and/or control insects. Such plants may also be treated with conventional plant treatment agents (e.g., insecticides, fertilizers, etc.).

## EXAMPLES

30

### Example 1 - Bacterial Strains and Plasmids

*Escherichia coli* strains used in the following examples include DH5 $\alpha$  and BL21(DE3) purchased from Gibco BRL (Grand Island, N.Y.) and Stratagene

- 45 -

(La Jolla, CA), respectively. The pET28(b) vector was purchased from Novagen (Madison, WI). Eco DH5 $\alpha$ /2139 contained the complete *hrpN* gene. The 2139 construct was produced by D. Bauer at Cornell University. The *hrpN* gene was cleaved from the 2139 plasmid by restriction enzyme digestion with HindIII, then  
5 purified from an agarose gel to serve as the DNA template for PCR synthesis of truncated *hrpN* clones. These clones were subsequently inserted into the (His)<sub>6</sub> vector pET28(b) which contained a Kan<sup>r</sup> gene for selection of transformants.

### Example 2 - DNA Manipulation

10 Restriction enzymes were obtained from Boehringer Mannheim (Indianapolis, IN) or Gibco BRL. T4 DNA ligase, Calf Intestinal Alkaline Phosphatase (CIAP), and PCR Supermix<sup>TM</sup> were obtained from Gibco BRL. The QIAprep Spin Miniprep Kit, the Qiagen Plasmid Mini Kit, and the QIAquick PCR  
15 Purification Kit were purchased from Qiagen (Hilden, Germany). The PCR primers were synthesized by Lofstrand Labs Limited (Gaithersburg, MD). The oligopeptides were synthesized by Bio-Synthesis, Inc. (Lewisville, TX). All DNA manipulations such as plasmid isolation, restriction enzyme digestion, DNA ligation, and PCR were performed according to standard techniques (Sambrook, et al., Laboratory Manual,  
20 Second Edition, Cold Spring Harbor Laboratory Press (1989)) or protocols provided by the manufacturer.

### Example 3 - Fragmentation of *hrpN* Gene

25 A series of N-terminal and C-terminal truncated *hrpN* genes and internal fragments were generated via PCR (Fig. 1). The full length *hrpN* gene was used as the DNA template and 3' and 5' primers were designed for each truncated clone (Fig. 2). The 3' primers contained an NdeI enzyme cutting site which contained the start codon ATG (methionine) and the 5' primers contained the stop codon TAA  
30 and a HindIII enzyme cutting site for ligation into the pET28(b) vector. PCR was carried out in 0.5 ml tubes in a GeneAmp<sup>TM</sup> 9700 (Perkin-Elmer, Foster City, CA). 45  $\mu$ l of Supermix<sup>TM</sup> (Life Technology, Gaithersburg, MD) were mixed with 20 pmoles of each pair of DNA primers, 10 ng of full length harpin DNA, and deionized

- 46 -

H<sub>2</sub>O to a final volume of 50 µl. After heating the mixture at 95°C for 2 min, the PCR was performed for 30 cycles at 94°C for 1 min, 58°C for 1 min and 72°C for 1.5 min. The PCR products were verified on a 6% TBE gel (Novex, San Diego, CA). Amplified DNA was purified with the QIAquick PCR purification kit, digested with

5 Nde I and Hind III at 37°C for 5 hours, extracted once with phenol:chloroform:isoamylalcohol (25:25:1) and precipitated with ethanol. 5 µg of pET28(b) vector DNA were digested with 15 units of Nde I and 20 units of Hind III at 37°C for 3 hours followed with CIAP treatment to reduce the background resulting from incomplete single enzyme digestion. Digested vector DNA was purified with

10 the QIAquick PCR purification kit and directly used for ligation. Ligation was carried out at 14-16°C for 5-12 hours in a 15 µl mixture containing ca. 200 ng of digested pET28(b), 30 ng of targeted PCR fragment, and 1 unit T4 DNA ligase. 5 - 7.5 µl of ligation solution were added to 100 µl of DH5α competent cells in a 15 ml Falcon tube and incubated on ice for 30 min. After a heat shock at 42°C for 45 seconds, 0.9

15 ml SOC solution or 0.45 ml LB media were added to each tube and incubated at 37°C for 1 hour. 20, 100, and 200 µl of transformed cells were placed onto LB agar with 30 µg/ml of kanamycin and incubated at 37°C overnight. Single colonies were transferred to 3 ml LB-media and incubated overnight at 37°C. Plasmid DNA was prepared from 2 ml of culture with the QIAprep Miniprep kit (QIAGEN, Hilden,

20 Germany). The DNA from the transformed cells was analyzed by restriction enzyme digestion or partial sequencing to verify the success of the transformations. Plasmids with the desired DNA sequence were transferred into the BL21 strain using the standard chemical transformation method as indicated above. A clone containing the full length harpin protein in the pET28(b) vector was generated as a positive control,

25 and a clone with only the pET28(b) vector was generated as a negative control.

#### **Example 4 - Expression of Hypersensitive Response Elicitor Truncated Proteins**

*Escherichia coli* BL21(DE3) strains containing the hrpN clones were

30 grown in Luria broth medium (5g/L Difco Yeast extract, 10 g/L Difco Tryptone, 5 g/L NaCl, and 1 mM NaOH) containing 30 µg/ml of kanamycin at 37°C overnight. The bacteria were then inoculated into 100 volumes of the same medium and grown at

- 47 -

37°C to an OD<sub>620</sub> of 0.6-0.8. The bacteria were then inoculated into 250 volumes of the same medium and grown at 37°C to an OD<sub>620</sub> of ca. 0.3 or 0.6-0.8. One millimolar IPTG was then added and the cultures grown at 19°C overnight (ca. 18 hours). Not all of the clones were successfully expressed using this strategy. Several of the clones had to be grown in Terrific broth (12 g/L Bacto Tryptone, 24 g/L Bacto yeast, 0.4% glycerol, 0.17 M KH<sub>2</sub>PO<sub>4</sub>, and 0.72 K<sub>2</sub>HPO<sub>4</sub>), and/or grown at 37°C after IPTG induction, and/or harvested earlier than overnight (Table 1).

Table 1: Expression of hypersensitive response elicitor truncated proteins

| Fragment         | amino acids (SEQ. ID. No. 23) | Growth medium | Induction O.D.     | Expression temp. | Harvest time     |
|------------------|-------------------------------|---------------|--------------------|------------------|------------------|
| 1<br>(+ control) | 1-403                         | LB            | ca. 0.3 or 0.6-0.8 | 19°C or 25°C     | 16-18 hr         |
| 2<br>(+ control) | -                             | LB and TB     | ca. 0.3 or 0.6-0.8 | 19 C and 37 C    | 16-18 hr         |
| 3                | 105-403                       | LB            | 0.6-0.8            | 19°C             | 16-18 hr         |
| 4                | 169-403                       | TB            | ca. 0.3            | 19°C             | 16-18 hr         |
| 5                | 210-403                       | LB or M9ZB    | 0.6-0.8            | 19°C             | 16-18 hr         |
| 6                | 257-403                       | LB or M9ZB    | 0.6-0.8            | 19°C             | 16-18 hr         |
| 7                | 343-403                       | LB            | ca. 0.3            | 19°C             | 5 hr             |
| 8                | 1-75                          | TB            | ca. 0.3            | 37°C             | 16-18 hr         |
| 9                | 1-104                         | TB            | ca. 0.3            | 37°C             | 16-18 hr         |
| 10               | 1-168                         | TB            | ca. 0.3            | 37°C             | 16-18 hr         |
| 11               | 1-266                         | LB            | ca. 0.3            | 37°C             | 4 hr             |
| 12               | 1-342                         | LB            | 0.6-0.8            | 19°C             | 16-18 hr         |
| 13               | 76-209                        | LB            | ca. 0.3            | 37°C             | 5 hr             |
| 14               | 76-168                        | TB or LB      | ca. 0.3            | 37°C             | 3 hr or 16-18 hr |
| 15               | 105-209                       | M9ZB          | ca. 0.3            | 37°C             | 3 hr             |
| 16               | 169-209                       | no expression |                    |                  |                  |
| 17               | 105-168                       | LB            | ca. 0.3            | 37°C             | 3-5 hr           |
| 18               | 99-209                        | LB            | ca. 0.3            | 37°C             | 3 hr             |
| 19               | 137-204                       | LB            | ca. 0.3            | 37°C             | 3 hr             |
| 20               | 137-180                       | LB            | ca. 0.3            | 37°C             | 16-18 hr.        |
| 21               | 105-180                       | LB            | ca. 0.3            | 37°C             | 3 hr             |
| 22               | 150-209                       | no expression |                    |                  |                  |
| 23               | 150-180                       | no expression |                    |                  |                  |

#### Example 5 - Small Scale Purification of Hypersensitive Response Elicitor Truncated Proteins (Verification of Expression)

A 50 ml culture of a hrpN clone was grown as above to induce expression of the truncated protein. Upon harvesting of the culture, 1.5 ml of the cell

- 48 -

suspension were centrifuged at 14,000 rpm for 5 minutes, re-suspended in urea lysis buffer (8 M urea, 0.1 M Na<sub>2</sub>HPO<sub>4</sub>, and 0.01 M Tris -- pH 8.0), incubated at room temperature for 10 minutes, then centrifuged again at 14,000 rpm for 10 minutes, and the supernatant saved. A 50 µl aliquot of a 50% slurry of an equilibrated (His)<sub>6</sub>-  
5 binding nickel agarose resin was added to the supernatant and mixed at 4°C for one hour. The nickel agarose was then washed three times with urea washing buffer (8 M urea, 0.1 M Na<sub>2</sub>HPO<sub>4</sub>, and 0.01 M Tris -- pH 6.3), centrifuging at 5,000 rpm for five minutes between washings. The protein was eluted from the resin with 50 µl of urea elution buffer (8 M urea, 0.1 M Na<sub>2</sub>HPO<sub>4</sub>, 0.01 M Tris, and 0.1 M EDTA -- pH 6.3).  
10 The eluate was run on a 4-20%, a 16%, or a 10-20% Tris-Glycine pre-cast gel depending upon the size of the truncated protein to verify the expression.

#### **Example 6 - Induction of HR in Tobacco**

A 1.5 ml aliquot from the 50 ml cultures grown for small scale  
15 purification of the truncated proteins was centrifuged at 14,000 rpm for four minutes and re-suspended in an equal volume of 5 mM potassium phosphate buffer, pH 6.8. The cell suspension was sonicated for ca. 30 seconds then diluted 1:2 and 1:10 with phosphate buffer. Both dilutions plus the neat cell lysate were infiltrated into the fourth to ninth leaves of 10-15 leaf tobacco plants by making a hole in single leaf  
20 panes and infiltrating the bacterial lysate into the intercellular leaf space using a syringe without a needle. The HR response was recorded 24-48 hr post infiltration. Tobacco (*Nicotiana tabacum* v. Xanthi) seedlings were grown in an environmental chamber at 20-25°C with a photoperiod of 12-h light /12-h dark and ca. 40% RH. Cell lysate was used for the initial HR assays (in order to screen the truncated proteins  
25 for HR activity) as the small scale urea purification yielded very little protein which was denatured due to the purification process.

#### **Example 7 - Large Scale Native Purification of Hypersensitive Response Elicitor Truncated Proteins for Comprehensive Biological Activity Assays**

30

Six 500 ml cultures of a hrpN clone were grown as described earlier to induce expression of the truncated protein. Upon harvesting of the culture, the cells were centrifuged at 7,000 rpm for 5 minutes, re-suspended in imidazole lysis buffer (5

- 49 -

mM imidazole, 0.5 M NaCl, 20 mM Tris) plus Triton X-100 at 0.05% and lysozyme at 0.1 mg/ml, incubated at 30°C for 15 minutes, sonicated for two minutes, centrifuged again at 15,000 rpm for 20 minutes, and the supernatant was saved. A 4 ml aliquot of a 50% slurry of an equilibrated (His)<sub>6</sub>-binding nickel agarose resin was added to the supernatant and mixed at 4°C for ca. four hours. The nickel agarose was then washed three times with imidazole washing buffer (20 mM imidazole, 0.5 M NaCl, and 20 mM Tris), centrifuging at 5,000 rpm for five minutes between washings, then placed in a disposable chromatography column. The column was centrifuged at 1100 rpm for one minute to remove any residual wash buffer and then the protein was eluted from the resin with 4 ml of imidazole elution buffer (1 M imidazole, 0.5 M NaCl, and 20 mM Tris) by incubating the column with the elution buffer for ten minutes at room temperature and then centrifuging the column at 1100 rpm for one minute. The eluate was run on a 4-20%, a 16%, or a 10-20% Tris-Glycine pre-cast gel depending upon the size of the truncated protein to verify the expression. The concentration of the proteins was determined by comparison of the protein bands with a standard protein in the Mark 12 molecular weight marker.

**Example 8 - Large Scale Urea Purification of Hypersensitive Response Elicitor Truncated Proteins For Comprehensive Biological Activity Assay**

The procedure was the same as the large scale native purification except that urea lysis buffer, washing buffer, and elution buffer were used, and the cells were not sonicated as in the native purification. After purification, the protein was renatured by dialyzing against lower and lower concentrations of urea over an eight hour period, then dialyzing overnight against 10 mM Tris/20 mM NaCl. The renaturing process caused the N-terminal proteins to precipitate. The precipitated 1-168 protein was solubilized by the addition of 100 mM Tris-HCl at pH 10.4 then heating the protein at 30°C for ca. one hour. The concentration of the protein was determined by comparison of the protein bands with a standard protein in the Mark 12 molecular weight marker. The 1-75 and 1-104 protein fragments were not successfully solubilized using this strategy so they were sonicated in 100 mM Tris-HCl at pH 10.4 to solubilize as much of the protein as possible and expose the active sites of the protein for the biological activity assays.

- 50 -

**Example 9 – Induction of Growth Enhancement (GE)**

Sixty tomato (*Lycopersicon spp.* cv. Marglobe) seeds were soaked  
5 overnight in 10 and 20 µg/ml of the truncated protein diluted with 5mM potassium  
phosphate buffer, pH 6.8. The next morning, the sixty seeds were sewn in three pots  
and 12-15 days later and again 18-20 days later the heights of the 10 tallest tomato  
plants per pot were measured and compared with the heights of the control plants  
treated only with phosphate buffer. Analyses were done on the heights to determine if  
10 there was a significant difference in the height of the plants treated with the truncated  
proteins compared with the buffer control, and thereby determine whether the proteins  
induced growth enhancement.

**Example 10 – Induction of Systemic Acquired Resistance (SAR)**

15 Three tobacco (*Nicotiana tabacum* cv. Xanthi) plants with 8-12 leaves  
(ca. 75 day old plants) were used in the assay. One leaf of the tobacco plants was  
covered up and the rest of the leaves were sprayed with ca. 50 ml of a 20 µg/ml  
solution of the truncated proteins diluted with 5mM potassium phosphate buffer. Five  
20 to seven days later two leaves (the unsprayed leaf and the sprayed leaf opposite and  
just above the unsprayed leaf) were inoculated with 20 µl of a 1.8 µg/ml solution of  
TMV along with a pinch of diatomaceous earth by rubbing the mixture along the top  
surface of the leaves. The TMV entered the plants through tiny lesions made by the  
diatomaceous earth. Ca. 3-4 days post TMV inoculation, the number of TMV lesions  
25 was counted on both leaves compared with the number of lesions on the negative  
control buffer treated leaves. Analyses were done to determine the efficacy of  
reducing the number of TMV lesions by the protein fragments compared to the buffer  
control. Percentage of efficacy was calculated as: Reduction in TMV lesions (%  
efficacy) =  $100 \times (1 - \text{mean \# of lesions on treated leaves} / \text{mean \# of lesions on buffer}$   
30  $\text{control leaves})$ .



**Example 11 - Expression of Hypersensitive Response Elicitor Truncated Proteins**

The small scale expression and purification of the fragment proteins was done to screen for expression and HR activity (Table 2).

5

Table 2

Expression and HR activity of hypersensitive response elicitor truncated proteins (small scale screening)

| Fragment #   | Amino Acids<br>(SEQ. ID. No. 23) | Expression              | HR activity |
|--------------|----------------------------------|-------------------------|-------------|
| 1(+control)  | 1-403                            | +                       | +           |
| 2(- control) | -                                | background protein only | -           |
| 3            | 105-403                          | +                       | +           |
| 4            | 169-403                          | +                       | -           |
| 5            | 210-403                          | +                       | -           |
| 6            | 267-403                          | +                       | -           |
| 7            | 343-403                          | +/-                     | -           |
| 8            | 1-75                             | +                       | -           |
| 9            | 1-104                            | +                       | +/-         |
| 10           | 1-168                            | +                       | +           |
| 11           | 1-266                            | +                       | +           |
| 12           | 1-342                            | +                       | +           |
| 13           | 76-209                           | +                       | +           |
| 14           | 76-168                           | +                       | -           |
| 15           | 105-209                          | +                       | +           |
| 16           | 169-209                          | -                       | -           |
| 17           | 105-168                          | +                       | -           |
| 18           | 99-209                           | +                       | +           |
| 19           | 137-204                          | +                       | +           |
| 20           | 137-180                          | +                       | +           |
| 21           | 105-180                          | +                       | +           |
| 22           | 150-209                          | -                       | -           |
| 23           | 150-180                          | -                       | -           |

10

All of the cloned fragment proteins were expressed at varying levels except for three small fragments (amino acids 169-209, 150-209, and 150-180). Fragments 210-403 and 267-403 were expressed very well, yielding a high concentration of protein from a small scale purification, resulting in a substantial protein band on SDS gel

15

electrophoresis. Other fragments (such as a.a. 1-168 and 1-104) produced much less protein, resulting in faint protein bands upon electrophoresis. It was difficult to determine whether fragment 343-403, the smallest C-terminal protein, was expressed, as there were several background proteins apparent on the gel, in addition to the suspected 343-403 protein. The positive and negative control proteins, consisting of

- 52 -

the full length hypersensitive response elicitor protein and only background proteins, respectively, were tested for expression and HR activity as well.

The large scale expression and purification of the fragment proteins was done to determine the level of expression and titer of the HR activity (Table 3).

5

Table 3

Expression level and HR titer of hypersensitive response elicitor truncated proteins (large scale purification)

10

| Fragment #    | Amino acids<br>(SEQ. ID. No. 23) | Expression | HR titer                |
|---------------|----------------------------------|------------|-------------------------|
| 1 (+ control) | 1-403                            | 3.7 mg/ml  | 5-7 µg/ml               |
| 2 (- control) | -                                | -          | 1:2 dilution            |
| 4             | 169-403                          | 2 mg/ml    | -                       |
| 5             | 210-403                          | 5 mg/ml    | -                       |
| 6             | 267-403                          | 4 mg/ml    | -                       |
| 7             | 343-402                          | 200µg/ml   | -                       |
| 8             | 1-75                             | 50µg/ml    | -                       |
| 9             | 1-104                            | 50µg/ml    | 3 µg/ml (1:16 dilution) |
| 10            | 1-168                            | 1 mg/ml    | 1 µg/ml                 |
| 13            | 76-209                           | 2.5 mg/ml  | 5 µg/ml                 |
| 14            | 76-168                           | 2 mg/ml    | -                       |
| 15            | 105-209                          | 5 mg/ml    | 5-10µg/ml               |
| 17            | 105-168                          | 250µg/ml   | -                       |
| 19            | 137-204                          | 3.6 mg/ml  | 3.5 µg/ml               |
| 20            | 137-180                          | 250 µg/ml  | 16 µg/ml                |

The truncated proteins deemed to be the most important in characterizing the hypersensitive response elicitor were chosen for large scale expression. The positive control (full length hypersensitive response elicitor) was expressed at a relatively high level at 3.7 mg/ml. All of the C-terminal proteins were expressed at relatively high levels from 2-5 mg/ml, except for fragment 343-403 as discussed earlier. The N-terminal fragments were expressed very well also; however, during the purification process, the protein precipitated and very little was resolubilized. The concentrations in Table 3 reflect only the solubilized protein. The internal fragments were expressed in the range of 2-3.6 mg/ml. It was extremely difficult to determine the concentration of fragment 105-168 (it was suspected that the concentration was much higher than indicated), as the protein bands on the SDS gel were large, but poorly stained. The

- 53 -

negative control contained several background proteins as expected, but no obviously induced dominant protein.

### **Example 12 - Induction of HR in Tobacco**

5                   The full length positive control protein elicited HR down to only 5-7µg/ml. The negative control (pET 28) imidazole purified "protein" - which contained only background proteins - elicited an HR response down to the 1:2 dilution, which lowered the sensitivity of the assay as the 1:1 and 1:2 dilutions could  
10 not be used. This false HR was likely due to an affinity of the imidazole used in the purification process to bind to one or several of the background proteins, thereby not completely dialyzing out. Imidazole at a concentration of ca. 60 mM did elicit a false HR response.

                  One definitive domain encompassing a small internal region of the  
15 protein from a.a. 137-180 (SEQ. ID. No. 23), a mere 44 a.a, is identified as the smallest HR domain. The other potential HR domain is thought to be located in the N-terminus of the protein from a.a. 1-104 (possibly a.a. 1-75) (SEQ. ID. No. 23). It was difficult to confirm or narrow down the N-terminus HR domain due to the difficulties encountered in purifying these fragment proteins. The N-terminus  
20 fragment proteins had to be purified with urea as no protein was recovered when the native purification process was used. Consequently, these proteins precipitated during the renaturing process and were difficult or nearly impossible to get back into solution, thereby making it hard to run the proteins through the HR assay, as only soluble protein is able to elicit HR. Difficulty narrowing the N-terminus HR domain  
25 was only compounded by the fact that the negative control elicited false HR at the low dilution levels thereby reducing the sensitivity of the assay.

                  Surprisingly, when the internal HR domain was cleaved between a.a. 168 and 169 (fragments 76-168 and 105-168) (SEQ. ID. No. 23) the fragment lost its HR activity. This suggests that the HR activity of fragment 1-168 (SEQ. ID. No. 23)  
30 should not be attributed to the internal HR domain, but rather to some other domain, leading to the assumption that there was likely a second HR domain to be found in the N-terminal region of the protein. However, as discussed earlier it was difficult to confirm this assumption.

- 54 -

The hypersensitive response elicitor C-terminus (a.a. 210-403 (SEQ. ID. No. 23)) did not contain an HR domain. It did not elicit HR at a detectable level using the current HR assay. Even the large C-terminal fragment from a.a. 169-403 (SEQ. ID. No. 23) did not elicit HR even though it contained part of the internal HR domain. As stated above, cleaving the protein between amino acids 168 and 169 (SEQ. ID. No. 23) causes a loss of HR activity.

Because some of the small cloned proteins with 61 a.a. or less were not expressed, several oligopeptides were synthesized with 30 a.a. to narrow down the functional region of the internal HR domain. The oligopeptides were synthesized within the range of a.a. 121-179 (SEQ. ID. No. 23). However, these oligos did not elicit HR. It was not expected that there would be an HR from oligos 137-166, 121-150, and 137-156 (SEQ. ID. No. 23) as these fragments did not contain the imperative amino acids 168 and 169 (SEQ. ID. No. 23). It was expected that the oligo 150-179 (SEQ. ID. No. 23) would elicit an HR. It is possible that 30 a.a. is too small for the protein to elicit any activity due to a lack of folding and, therefore, a lack of binding or that during the synthesis of the peptides important amino acids were missed (either in the process, or simply by the choice of which 30 amino acids to synthesize) and, therefore, the fragments would not be able to elicit HR.

#### 20 Example 13 - Induction of Plant Growth Enhancement (PGE)

The C-terminal fragments enhanced the growth of tomato by 9% to 21%. The N-terminal fragments enhanced the growth of tomato by 4% to 13%. The internal fragments enhanced growth by 9% to 20%. The 76-209 fragment enhanced growth by 18% at a concentration of 60 µg/ml, but not at the typical 20 µg/ml. This was attributed to the inaccuracy of the quantification process (Table 4).

- 55 -

Table 4

| Fragment #    | Amino acids | PGE ht>buffer<br>@ 10 µg/ml | PGE ht>buffer<br>@ 20 µg/ml           |
|---------------|-------------|-----------------------------|---------------------------------------|
| 1 (+ control) | 1-403       | 12%                         | 11%                                   |
| 2 (- control) | -           | -3%                         | -2%                                   |
| 4             | 169-403     | 9%                          | 12%                                   |
| 5             | 210-403     | 13%                         | 14%                                   |
| 6             | 267-403     | 21%                         | 16% @ 40µg/ml<br>21%<br>23% @ 40µg/ml |
| 7             | 343-403     | 7%                          | 7%                                    |
| 9             | 1-104       | 4%                          | 8%                                    |
| 10            | 1-168       | 13%                         | 5%                                    |
| 13            | 76-209      | 7%                          | 4%                                    |
| 14            | 76-168      | 18%                         | 18% @ 60µg/ml<br>20%                  |
| 15            | 105-209     | 14%                         | 19%                                   |
| 17            | 105-168     | 19%                         | 16%                                   |
| 19            | 137-204     | 11%                         | 13%                                   |
| 20            | 137-180     | --                          | 9%                                    |

\*A height greater than 10% above the buffer control was necessary to pass the PGE assay.

The oligopeptides enhanced growth from 7.4% to 17.3% (Table 5).

Table 5

| Fragment | Amino acids | Expression | HR titer | TMV efficacy | PGE ht>buffer |
|----------|-------------|------------|----------|--------------|---------------|
| oligo    | 150-179     | NA         | -        | 72.9%        | 10.1%         |
| oligo    | 137-166     | NA         | -        | 61.2%        | 12.0%         |
| oligo    | 121-150     | NA         | -        | 60.0%        | 17.3%         |
| oligo    | 137-156     | NA         | -        | -87.7%       | 7.4%          |

The data suggests that there is more than one PGE domain, although the C-terminal and internal domains appear to be dominant over the N-terminal domain, as the N-terminal fragments enhanced growth the least amount.

#### **Example 14 – Induction of Systemic Acquired Resistance (SAR)**

All of the hypersensitive response elicitor fragments tested to date appear to have 60% efficacy or greater, except for the oligopeptide 137-156 (Tables 5 and 6).

- 56 -

Table 6

| Fragment #    | Amino acids | Efficacy of TMV control |
|---------------|-------------|-------------------------|
| 1 (+ control) | 1-403       | 84% & 72%               |
| 2 (- control) | -           | 40% & 31%               |
| 4             | 169-403     | 64% & 79%               |
| 5             | 210-403     | 77% and 78%             |
| 6             | 267-403     | 70% and 72%             |
| 9             | 1-104       | 82%                     |
| 10            | 1-168       | 69%                     |
| 13            | 76-209      | 44% and 84%             |
| 14            | 76-168      | 83% & 87%               |
| 15            | 105-209     | 57% and 67%             |
| 17            | 105-168     | 89%                     |
| 19            | 137-204     | 89% & 77%               |
| 20            | 137-180     | 64% & 58%               |

5

These data suggest that there are multiple SAR domains within the protein.

#### **Example 15 – Relationship Between HR, PGE, and SAR**

10

It is clear that the hypersensitive response activity is separable from the plant growth enhancement activity. The C-terminal fragments clearly enhance the growth of tomato by ca. 20% at a concentration of only 20 µg/ml, but these same fragments were not able to elicit HR in tobacco, even at higher concentrations than 200 µg/ml. The SAR activity also appears to be separable from the HR activity. This finding is highly significant for future work on transgenic applications of the hypersensitive response elicitor technology. The fragments that induce PGE and/or SAR but do not elicit HR will be imperative for this technology, as constitutive expression of even low levels of an HR elicitor might kill a plant.

20

#### **Example 16 - Non-HR Eliciting Fragments Derived from the Hypersensitive Response Elicitor from *Pseudomonas syringae* pv. *syringae* Induce Resistance in Tobacco to TMV and Promote the Growth of Tomato**

25

To test whether non-HR eliciting fragments derived from HrpZ, the hypersensitive response elicitor from *Pseudomonas syringae* pv. *syringae*, is able to induce disease resistance, several fragment constructs were made and the expressed

- 57 -

fragment proteins were tested for HR elicitation and disease resistance induction in tobacco and growth promotion in tomato.

The following segments of *hrpZ*, the gene encoding the hypersensitive response elicitor from *Pseudomonas syringae* pv. *syringae*, were amplified by PCR using Pfu Turbo (Stratagene): Regions coding for amino acids 152-190, aa 152-294, aa 190-294, aa 301-341, and full length HrpZ (aa 1-341). The DNA fragments were cloned into pCAL-n (Stratagene) to create C-terminal fusion proteins to the calmodulin-binding peptide. pCAL-n was chosen, because the fusion protein could be easily and gently purified on calmodulin resin. The DNA was transformed into *E. coli* DH5 $\alpha$ , and the correct clones were identified. The clones were then transferred to *E. coli* BLR DE3 for protein expression. The bacteria were grown in Terrific Broth to an OD<sub>620</sub> of 0.8-1.0. Protein expression was then induced with IPTG and the bacteria were incubated for an additional 3 h. All of the HrpZ fragments were able to be expressed this way.

Amino acid fragments 152-294 and 190-294 were chosen for further analysis and characterization. It was expected that the fragment 152-294 contained a domain that elicited the HR, while fragment 190-294 contained no domain that elicited the HR. The cultures were spun down, and the bacteria resuspended in 40 ml of 10 mM Tris pH 8.0. Twenty  $\mu$ l of antifoam and 40  $\mu$ l of 200 mM PMSF were added, and the bacteria was sonicated to break open the cells. The bacterial debris was removed by centrifugation, and the supernatant was placed in a boiling water bath for 10 min. The precipitate was removed by centrifugation and the supernatant, a crude protein preparation, was retained for tests.

Fifteen  $\mu$ l of each supernatant was run on a gel and stained to determine if the protein was present. It was estimated that about five times as much of the 152-294 fragment was present as the 190-294 fragment. Several dilutions of each preparation were infiltrated into tobacco leaves on two plants for HR tests (Table 7). As shown in Table 7, the 152-294 fragment elicited an HR, but the 190-294 fragment did not.

- 58 -

Table 7

HR test results of HrpZ fragments

| HrpZ Fragment | Dilution of Fragment Preparation <sup>a</sup> |     |      |       |
|---------------|---|-----|------|-------|
|               | 1:2   | 1:5 | 1:25 | 1:125 |
| 152-294       | +,+ <sup>b</sup>                              | +,+ | +,+  | -, -  |
| 190-294       | -,-   | -,- | -,-  | -,-   |

<sup>a</sup> The preparations were diluted with MilliQ water.<sup>b</sup> The results are indicated for each of two plants. +, HR; -, no HR.

10

The fragment preparations were then tested for inducing resistance to TMV and for growth enhancement. Due to the difference in concentration of the HrpZ fragments, the 152-294 preparation was diluted 40-fold and the 190-294 preparation was diluted 8-fold. The results showed that the 190-294 aa fragment reduced the number of TMV lesions by 85% in comparison to buffer controls (Table 8). In contrast, the 152-294 aa fragment reduced the number of TMV lesions by only 55%. As also shown in Table 8, plants treated with the 152-294 aa fragment grew 4.64% more than buffer treated plants, while plants treated with the 190-294 aa fragment grew 2.62% more than the buffer treated plants.

20

Table 8

HR test, TMV, and PGE test results

| HrpZ Fragment | HR elicitation <sup>a</sup> | TMV (% efficacy) <sup>b</sup> | PGE(% > buffer ht) <sup>c</sup> |
|---------------|-----------------------------|-------------------------------|---------------------------------|
| 152-294       | +                           | 54.64                         | 4.64                            |
| 190-294       | -                           | 85.25                         | 2.62                            |

<sup>a</sup> +, elicits HR in tobacco leaves; -, no HR in tobacco leaves.<sup>b</sup> % reduction in TMV lesions in unsprayed leaf of tobacco.<sup>c</sup> % greater height than buffer sprayed plants.

30

The results of these tests show that amino acids 152-190 appear to be involved in HR elicitation, because their removal eliminated the ability to elicit the HR. Both fragment preparations achieved disease control and growth enhancement. Thus, the ability to elicit the HR is not the determining factor for reduction in TMV infection and growth enhancement.

35



- 59 -

**Example 17 - Use of 13 Amino Acid Peptide Derived from *Phytophthora megasperma* Stimulates Tomato Seedling Growth**

Parsley leaves develop a typical resistance reaction against the soybean pathogen *Phytophthora megasperma* comprising hypersensitive cell death, defense related gene activation, and phytoalexin formulation. Several years ago, a 42 kDa glycoprotein elicitor was purified from the fungal culture filtrate of *Phytophthora megasperma* (Parker et al., "An Extracellular Glycoprotein from *Phytophthora megasperma* f.sp. glycinea Elicits Phytoalexin Synthesis in Cultured Parsley Cells and Protoplasts," Mol. Plant Microbe Interact. 4:19-27 (1991), which is hereby incorporated by reference). Then, an oligopeptide of 13 amino acid was identified within the 42 kDa glycoprotein. The 13 amino acids peptide appeared to have similar biological activity as that of the full length glycoprotein (42 kDa). It is sufficient to elicit a complex defense response in parsley cells including H<sup>+</sup>/Ca<sup>2+</sup> influxes, K<sup>+</sup>/Cl<sup>-</sup> effluxes, active oxygen production, SAR gene induction, and phytoalexin compound accumulation (Nurnberger et al., "High Affinity Binding of a Fungal Oligopeptide Elicitor to Parsley Plasma Membranes Triggers Multiple Defense Response," Cell 78:449-460 (1994), which is hereby incorporated by reference).

To test if the 13 amino acid peptide derived from the 42 kDa protein also enhanced plant growth, 20 mg of the oligopeptide was synthesized from Biosynthesis Corp. The synthesized sequence of the peptide is NH<sub>2</sub>-Val-Trp-Asn-Gln-Pro-Val-Arg-Gly-Phe-Lys-Val-Tyr-Glu-COOH (SEQ. ID. No. 39). The synthesized peptide was resuspended in 10 ml of 5 mM potassium phosphate buffer and, then, diluted to 1 and 100 ng/ml with the same buffer. About 100 tomato seeds (variety, Marglobe) were submerged in 20 ml of peptide solution overnight. The soaked seeds were planted in an 8 inch pot with artificial soil. Seeds soaked in the buffer without the peptide were used as a control. After seedlings emerged and the first two true leaves fully expanded, the height of the tomato seedlings was recorded. The peptide was not able to elicit the HR in tobacco and other tested plants. However, it had a profound effect on plant growth promotion. Table 9 shows that tomato seedlings treated with the peptide increased 12.6 % in height, indicating that the fungal peptide derived from the 42 kDa glycoprotein can promote tomato seedling growth. Extended studies showed that the peptide also had similar growth

- 60 -

effect in other crops including tobacco. Similar growth promotion effects were achieved by plants sprayed with the peptide solution.

Table 9

|    |                             |                          |     |     |     |     |                       |      |
|----|-----------------------------|--------------------------|-----|-----|-----|-----|-----------------------|------|
| 5  | Treatment                   | Height of seedlings (cm) |     |     |     |     | Average (cm) % Change |      |
|    | Buffer                      | 6.0                      | 6.0 | 6.0 | 5.5 | 5.5 | 5.55                  | -    |
| 10 |                             | 5.5                      | 5.5 | 5.0 | 5.0 | 5.5 |                       |      |
|    | Peptide Solution (100ng/ml) | 6.5                      | 6.0 | 6.5 | 6.5 | 6.5 | 6.25                  | 12.6 |
|    |                             | 6.0                      | 6.0 | 6.0 | 6.0 | 6.5 |                       |      |

15                    Although the invention has been described in detail for the purpose of illustration, it is understood that such detail is solely for that purpose, and variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention which is defined by the following claims.

- 61 -

**WHAT IS CLAIMED:**

1. An isolated fragment of a hypersensitive response elicitor protein or polypeptide, wherein said fragment does not elicit a hypersensitive response but has other activity in plants.  
5
2. An isolated fragment according to claim 1, wherein the hypersensitive response elicitor protein or polypeptide is derived from an *Erwinia Pseudomonas*, *Xanthomonas*, or *Phytophthora*.  
10
3. An isolated fragment according to claim 2, wherein the hypersensitive response elicitor protein or polypeptide is derived from *Erwinia amylovora*.  
15
4. An isolated fragment according to claim 3, wherein the fragment is selected from the group consisting of a C-terminal fragment of the amino acid sequence of SEQ. ID. No. 23, an N-terminal fragment of the amino acid sequence of SEQ. ID. No. 23, and an internal fragment of the amino acid sequence of SEQ. ID. No. 23.  
20
5. An isolated fragment according to claim 4, wherein the fragment is a C-terminal fragment of the amino acid sequence of SEQ. ID. No. 23 spanning the following amino acids of SEQ. ID. No. 23: 169 and 403, 210 and 403, 267 and 403, or 343 and 403.  
25
6. An isolated fragment according to claim 4, wherein the fragment is an N-terminal fragment of the amino acid sequence of SEQ. ID. No. 23.  
30
7. An isolated fragment according to claim 4, wherein the fragment is an internal fragment of the amino acid sequence of SEQ. ID. No. 23 spanning the following amino acids of SEQ. ID. No. 23: 105 and 179, 137 and 166, 121 and 150, or 137 and 156.

- 62 -

8. An isolated fragment according to claim 2, wherein the hypersensitive response elicitor is derived from *Pseudomonas syringae*.

9. An isolated fragment according to claim 8, wherein the  
5 fragment contains amino acids 190 to 294 of SEQ. ID. No. 31.

10. An isolated DNA molecule encoding a fragment according to claim 1.

10 11. An isolated DNA molecule according to claim 10, wherein the hypersensitive response elicitor protein or polypeptide is derived from an *Erwinia Pseudomonas, Xanthomonas, or Phytophthora*.

12. An isolated DNA molecule according to claim 11, wherein the  
15 hypersensitive response elicitor protein or polypeptide is derived from *Erwinia amylovora*.

13. An isolated DNA molecule according to claim 12, wherein the fragment is selected from the group consisting of a C-terminal fragment of the amino  
20 acid sequence of SEQ. ID. No. 23, an N-terminal fragment of the amino acid sequence of SEQ. ID. No. 23, and an internal fragment of the amino acid sequence of SEQ. ID. No. 23.

14. An isolated DNA molecule according to claim 12, wherein the  
25 fragment is a C-terminal fragment of the amino acid sequence of SEQ. ID. No. 23 spanning the following amino acids of SEQ. ID. No. 23: 169 and 403, 210 and 403, 267 and 403, or 343 and 403.

15. An isolated DNA molecule according to claim 12, wherein the  
30 fragment is an N-terminal fragment of the amino acid sequence of SEQ. ID. No. 23.

- 63 -

16. An isolated DNA molecule according to claim 12, wherein the fragment is an internal fragment of the amino acid sequence of SEQ. ID. No. 23 spanning the following amino acids of SEQ. ID. No. 23: 105 and 179, 137 and 166, 121 and 150, or 137 and 156.

5

17. An isolated DNA molecule according to claim 11, wherein the hypersensitive response elicitor is derived from *Pseudomonas syringae*.

18. An isolated DNA molecule according to claim 18, wherein the  
10 fragment contains amino acids 190 to 294 of SEQ. ID. No. 31.

19. An expression system transformed with a DNA molecule according to claim 10.

20. An expression system according to claim 19, wherein said  
15 DNA molecule is in proper sense orientation and correct reading frame.

21. A host cell transformed with a DNA molecule according to  
claim 10.

20

22. A host cell according to claim 21, wherein the host cell is selected from the group consisting of a plant cell and a bacterial cell.

23. A host cell according to claim 21, wherein the DNA molecule  
25 is transformed with an expression system.

24. A transgenic plant transformed with the DNA molecule of  
claim 10.

25. A transgenic plant according to claim 24, wherein the plant is  
30 selected from the group consisting of alfalfa, rice, wheat, barley, rye, cotton, sunflower, peanut, corn, potato, sweet potato, bean, pea, chicory, lettuce, endive,

- 64 -

cabbage, brussel sprout, beet, parsnip, turnip, cauliflower, broccoli, radish, spinach, onion, garlic, eggplant, pepper, celery, carrot, squash, pumpkin, zucchini, cucumber, apple, pear, melon, citrus, strawberry, grape, raspberry, pineapple, soybean, tobacco, tomato, sorghum, and sugarcane.

5

26. A transgenic plant according to claim 24, wherein the plant is selected from the group consisting of *Arabidopsis thaliana*, *Saintpaulia*, petunia, pelargonium, poinsettia, chrysanthemum, carnation, and zinnia.

10

27. A transgenic plant seed transformed with the DNA molecule of claim 10.

15

28. A transgenic plant seed according to claim 27, wherein the plant seed is selected from the group consisting of alfalfa, rice, wheat, barley, rye, cotton, sunflower, peanut, corn, potato, sweet potato, bean, pea, chicory, lettuce, endive, cabbage, brussel sprout, beet, parsnip, turnip, cauliflower, broccoli, radish, spinach, onion, garlic, eggplant, pepper, celery, carrot, squash, pumpkin, zucchini, cucumber, apple, pear, melon, citrus, strawberry, grape, raspberry, pineapple, soybean, tobacco, tomato, sorghum, and sugarcane.

20

29. A transgenic plant seed according to claim 27, wherein the plant seed is selected from the group consisting of *Arabidopsis thaliana*, *Saintpaulia*, petunia, pelargonium, poinsettia, chrysanthemum, carnation, and zinnia.

25

30. A method of imparting disease resistance to plants comprising: applying a fragment of a hypersensitive response elicitor protein or polypeptide, which fragment does not elicit a hypersensitive response, in a non-infectious form to a plant or plant seed under conditions effective to impart disease resistance.

30

31. A method according to claim 30, wherein plants are treated during said applying.

- 65 -

32. A method according to claim 30 wherein plant seeds are treated during said applying, said method further comprising:

planting the seeds treated with the fragment of the  
5 hypersensitive response elicitor in natural or artificial soil and  
propagating plants from the seeds planted in the soil.

33. A method of enhancing plant growth comprising:

applying a fragment of a hypersensitive response elicitor  
10 protein or polypeptide, which fragment does not elicit a hypersensitive response, in a  
non-infectious form to a plant or plant seed under conditions effective to enhance  
plant growth.

34. A method according to claim 33, wherein plants are treated  
15 during said applying.

35. A method according to claim 33, wherein plant seeds are treated during said applying, said method further comprising:

planting the seeds treated with the fragment of the  
20 hypersensitive response elicitor in natural or artificial soil and  
propagating plants from the seeds planted in the soil.

36. A method of insect control for plants comprising:

applying a fragment of a hypersensitive response elicitor protein or  
25 polypeptide, which fragment does not elicit a hypersensitive response, in a non-  
infectious form to a plant or plant seed under conditions effective to control insects.

37. A method according to claim 36, wherein plants are treated during said applying.

30

38. A method according to claim 36, wherein plant seeds are treated during said applying, said method further comprising:

- 66 -

planting the seeds treated with the fragment of the  
hypersensitive response elicitor in natural or artificial soil and  
propagating plants from the seeds planted in the soil.

5                   39.    A method of imparting disease resistance to plants comprising:  
                      providing a transgenic plant or plant seed transformed with a  
DNA molecule which encodes a fragment of a hypersensitive response elicitor protein  
or polypeptide, which fragment does not elicit a hypersensitive response, and  
                      growing the transgenic plant or transgenic plants produced  
10   from the transgenic plant seeds under conditions effective to impart disease resistance.

                  40.    A method according to claim 39, wherein a transgenic plant is  
provided.

15                  41.    A method according to claim 39, wherein a transgenic plant  
seed is provided.

                  42.    A method of enhancing plant growth comprising:  
                      providing a transgenic plant or a plant seed transformed with a  
20   DNA molecule which encodes a fragment of a hypersensitive response elicitor protein  
or polypeptide, which fragment does not elicit a hypersensitive response, and  
                      growing the transgenic plant or transgenic plants produced  
from the transgenic plant seeds under conditions effective to enhance plant growth.

25                  43.    A method according to claim 42, wherein a transgenic plant is  
provided.

                  44.    A method according to claim 42, wherein a transgenic plant  
seed is provided.

30

                  45.    A method of insect control for plants comprising:



- 67 -

providing a transgenic plant or plant seed transformed with a  
DNA molecule which encodes a fragment of a hypersensitive response elicitor protein  
or polypeptide, which fragment does not elicit a hypersensitive response, and  
growing the transgenic plant or transgenic plants produced  
5 from the transgenic plant seeds under conditions effective to control insects.

46. A method according to claim 45, wherein a transgenic plant is  
provided.

10 47. A method according to claim 45, wherein a transgenic plant  
seed is provided.

**THIS PAGE BLANK (USPTO)**

1/2

|     |                           |         |
|-----|---------------------------|---------|
| #1  | HARPIN                    |         |
|     | 1                         | 403     |
| #3  | C-TERMINAL FRAGMENTS      |         |
| #4  | 105                       | 403     |
| #5  | 169                       | 403     |
| #6  | 210                       | 403     |
| #7  | 267                       | 403     |
|     | 343                       | 403     |
| #8  | N-TERMINAL FRAGMENTS      |         |
| #9  | 1 75                      |         |
| #10 | 1 104                     |         |
| #11 | 1 168                     |         |
| #12 | 1 266                     |         |
|     | 1 342                     |         |
| #13 | INTERNAL FRAGMENTS        |         |
| #14 | 76 209                    |         |
| #15 | 76 168                    |         |
| #16 | 105 209                   |         |
| #17 | 169 209                   |         |
|     | 105 168                   |         |
| #18 | SYNTHESIZED OLIGOPEPTIDES |         |
| #19 | 99 209                    |         |
| #20 | 137 204                   | 150 179 |
| #21 | 137 180                   | 137 166 |
| #22 | 105 180                   | 121 150 |
| #23 | 150 209                   | 137 156 |
|     | 150 180                   |         |

HARPIN FRAGMENTS DERIVED FROM HrpN OF ERWINIA AMYLOVORA

**FIG. 1****SUBSTITUTE SHEET (RULE 26)**

**THIS PAGE BLANK (USPTO)**

2/2

N1; 5'-GGGAATTCATATGAGTCTGAATACAAGTGGG-3'  
N76; 5'-GGGAATTCATATGGGCGGTGGCTTAGGCGGT-3'  
N99; 5'-GGCATATGTCTGAACGCGCTGAACGATATG-3'  
N105; 5'-GGGAATTCATATGTTAGGCGGTTCGCTGAAC-3'  
N110; 5'-GGCATATGCTGAACACGCTGGGCTCGAAA-3'  
N137; 5'-GGCATATGTCAACGTCCCAAACGACGAT-3'  
N150; 5'-GGCATATGTCCACCTCAGACTCCAGCG-3'  
N169; 5'-GGGAATTCATATGCAAAGCCTGTTTGGTGATGGG-3'  
N210; 5'-GGGAATTCATATGGGTAAATGGTCTGAGCAAG-3'  
N267; 5'-GGGAATTCATATGAAAGCGGGCATTCAGGCG-3'  
N343; 5'-GGGAATTCATATGACACCAGCCAGTATGGAGCAG-3'  
C75; 5'-GCAAGCTTAAACAGCCCACCACCGCCCATCAT-3'  
C104; 5'-GCAAGCTTAAATCGTTCAGCGCGTTCGACAG-3'  
C168; 5'-GCAAGCTTAAATATCTCGCTGAACATCTTCAGCAG-3'  
C180; 5'-GCAAGCTTAAAGGTGCCATCTTGCCCATCAC-3'  
C204; 5'-GCAAGCTTAAATCAGTGACTCCTTTTTTATAGGC-3'  
C209; 5'-GCAAGCTTAAACAGGCCCGACAGCGCATCAGT-3'  
C266; 5'-GCAAGCTTAAACCGATAACCGGTACCCACGGC-3'  
C342; 5'-GCAAGCTTAAATCCGTCGTCATCTGGCTTGCTCAG-3'  
C403; 5'-GCAAGCTTAAAGCCGCGCCCAGCTTG-3'

OLIGONUCLEOTIDE PRIMERS USED FOR THE CONSTRUCTION  
OF THE SUBCLONES OF ERWINIA AMYLOVORA HrpN

**FIG. 2**

**THIS PAGE BLANK (USPTO)**

## SEQUENCE LISTING

<110> Eden Bi science Corporation

<120> HYPERSENSITIVE RESPONSE ELICITOR FRAGMENTS WHICH ARE  
ACTIVE BUT DO NOT ELICIT A HYPERSENSITIVE RESPONSE

<130> 21829/32

<140>

<141>

<150> 60/103,050

<151> 1998-10-05

<160> 39

<170> PatentIn Ver. 2.0

<210> 1

<211> 31

<212> DNA

<213> Erwinia amylovora

<400> 1

gggaattcat atgagtctga atacaagtgg g

31

<210> 2

<211> 31

<212> DNA

<213> Erwinia amylovora

<400> 2

gggaattcat atgggcggtg gcttaggcgg t

31

<210> 3

<211> 29

<212> DNA

<213> Erwinia amylovora

<400> 3

ggcatatgtc gaacgcgctg aacgatatg

29

<210> 4

<211> 31

<212> DNA

<213> Erwinia amylovora

**THIS PAGE BLANK (USPTO)**



<400> 4  
gggaattcat atgttaggcg gttcgctgaa c 31

<210> 5  
<211> 29  
<212> DNA  
<213> Erwinia amylovora

<400> 5  
ggcatatgct gaacacgctg ggctcgaaa 29

<210> 6  
<211> 29  
<212> DNA  
<213> Erwinia amylovora

<400> 6  
ggcatatgct aacgtcccaa aacgacgat 29

<210> 7  
<211> 27  
<212> DNA  
<213> Erwinia amylovora

<400> 7  
ggcatatgct cacctcagac tccagcg 27

<210> 8  
<211> 34  
<212> DNA  
<213> Erwinia amylovora

<400> 8  
gggaattcat atgcaaagcc tgtttggtga tggg 34

<210> 9  
<211> 31  
<212> DNA  
<213> Erwinia amylovora

<400> 9  
gggaattcat atgggtaatg gtctgagcaa g 31

<210> 10  
<211> 31  
<212> DNA  
<213> Erwinia amylovora

**THIS PAGE BLANK (USPTO)**

<400> 10  
gggaattcat atgaaagcgg gcattcaggc g 31

<210> 11  
<211> 34  
<212> DNA  
<213> Erwinia amylovora

<400> 11  
gggaattcat atgacaccag ccagtatgga gcag 34

<210> 12  
<211> 31  
<212> DNA  
<213> Erwinia amylovora

<400> 12  
gcaagcttaa cagcccacca ccgcccata t 31

<210> 13  
<211> 31  
<212> DNA  
<213> Erwinia amylovora

<400> 13  
gcaagcttaa atcggttcagc gcgttcgaca g 31

<210> 14  
<211> 34  
<212> DNA  
<213> Erwinia amylovora

<400> 14  
gcaagcttaa tatctcgctg aacatcttca gcag 34

<210> 15  
<211> 30  
<212> DNA  
<213> Erwinia amylovora

<400> 15  
gcaagcttaa ggtgccatct tgcccatcac 30

<210> 16  
<211> 34  
<212> DNA  
<213> Erwinia amylovora

**THIS PAGE BLANK (USPTO)**

<400> 16  
gcaagcttaa atcagtgact ccttttttat aggc 34

<210> 17  
<211> 31  
<212> DNA  
<213> Erwinia amylovora

<400> 17  
gcaagcttaa caggcccgac agcgcatcag t 31

<210> 18  
<211> 31  
<212> DNA  
<213> Erwinia amylovora

<400> 18  
gcaagcttaa accgataccg gtacccacgg c 31

<210> 19  
<211> 34  
<212> DNA  
<213> Erwinia amylovora

<400> 19  
gcaagcttaa tccgtcgta tctggcttgc tcag 34

<210> 20  
<211> 25  
<212> DNA  
<213> Erwinia amylovora

<400> 20  
gcaagcttaa gccgcgccca gcttg 25

<210> 21  
<211> 338  
<212> PRT  
<213> Erwinia chrysanthemi

<400> 21  
Met Gln Ile Thr Ile Lys Ala His Ile Gly Gly Asp Leu Gly Val Ser  
1 5 10 15

Gly Leu Gly Ala Gln Gly Leu Lys Gly Leu Asn Ser Ala Ala Ser Ser  
20 25 30

Leu Gly Ser Ser Val Asp Lys Leu Ser Ser Thr Ile Asp Lys Leu Thr

**THIS PAGE BLANK (USPTO)**

|   |     |         |
|---|-----|---------|
| 35  | 40  | 45      |
| Ser Ala Leu Thr S r Met Met Phe Gly Gly Ala Leu Ala Gln Gly Leu |     |         |
| 50  | 55  | 60      |
| Gly Ala Ser Ser Lys Gly Leu Gly Met Ser Asn Gln Leu Gly Gln Ser |     |         |
| 65  | 70  | 75 80   |
| Phe Gly Asn Gly Ala Gln Gly Ala Ser Asn Leu Leu Ser Val Pro Lys |     |         |
| 85  | 90  | 95      |
| Ser Gly Gly Asp Ala Leu Ser Lys Met Phe Asp Lys Ala Leu Asp Asp |     |         |
| 100   | 105 | 110     |
| Leu Leu Gly His Asp Thr Val Thr Lys Leu Thr Asn Gln Ser Asn Gln |     |         |
| 115   | 120 | 125     |
| Leu Ala Asn Ser Met Leu Asn Ala Ser Gln Met Thr Gln Gly Asn Met |     |         |
| 130   | 135 | 140     |
| Asn Ala Phe Gly Ser Gly Val Asn Asn Ala Leu Ser Ser Ile Leu Gly |     |         |
| 145   | 150 | 155 160 |
| Asn Gly Leu Gly Gln Ser Met Ser Gly Phe Ser Gln Pro Ser Leu Gly |     |         |
| 165   | 170 | 175     |
| Ala Gly Gly Leu Gln Gly Leu Ser Gly Ala Gly Ala Phe Asn Gln Leu |     |         |
| 180   | 185 | 190     |
| Gly Asn Ala Ile Gly Met Gly Val Gly Gln Asn Ala Ala Leu Ser Ala |     |         |
| 195   | 200 | 205     |
| Leu Ser Asn Val Ser Thr His Val Asp Gly Asn Asn Arg His Phe Val |     |         |
| 210   | 215 | 220     |
| Asp Lys Glu Asp Arg Gly Met Ala Lys Glu Ile Gly Gln Phe Met Asp |     |         |
| 225   | 230 | 235 240 |
| Gln Tyr Pro Glu Ile Phe Gly Lys Pro Glu Tyr Gln Lys Asp Gly Trp |     |         |
| 245   | 250 | 255     |
| Ser Ser Pro Lys Thr Asp Asp Lys Ser Trp Ala Lys Ala Leu Ser Lys |     |         |
| 260   | 265 | 270     |
| Pro Asp Asp Asp Gly Met Thr Gly Ala Ser Met Asp Lys Phe Arg Gln |     |         |
| 275   | 280 | 285     |
| Ala Met Gly Met Ile Lys Ser Ala Val Ala Gly Asp Thr Gly Asn Thr |     |         |

**THIS PAGE BLANK (USPTO)**



|   |     |     |     |
|---|-----|-----|-----|
| 290   | 295 | 300 |     |
| Asn Leu Asn Leu Arg Gly Ala Gly Gly Ala Ser Leu Gly Ile Asp Ala |     |     |     |
| 305   | 310 | 315 | 320 |
| Ala Val Val Gly Asp Lys Ile Ala Asn Met Ser Leu Gly Lys Leu Ala |     |     |     |
|   | 325 | 330 | 335 |
| Asn Ala   |     |     |     |

&lt;210&gt; 22

&lt;211&gt; 2141

&lt;212&gt; DNA

<213> *Erwinia chrysanthemi*

&lt;400&gt; 22

```

cgattttacc cgggtgaacg tgctatgacc gacagcatca cggatttcga caccgttacg 60
gcgtttatgg ccgcgatgaa cgggcatcag gcggcgcgct ggtecgccga atccggcgctc 120
gatctggtat ttcagtttgg ggacaccggg cgtgaactca tgatgcagat tcagccggggg 180
cagcaatata ccggcatgtt gcgcacgctg ctgcctcgtc gttatcagca ggccggcagag 240
tgcgatggct gccatctgtg cctgaacggc agcgatgtat tgatcctctg gtggccgctg 300
ccgtcggatc ccggcagtta tccgcagggtg atcgaacggt tgtttgaaact ggccgggaatg 360
acgttgccgt cgctatccat agcaccgacg gcgcgtccgc agacaggga cggacgcgcc 420
cgatcattaa gataaaggcg gcttttttta ttgcaaacg gtaacgggtga ggaaccgttt 480
caccgtcggc gtcactcagt aacaagtatc catcatgatg cctacatcgg gatccggctg 540
ggcatccgtt gcagataact ttgcgaacac ctgacatgaa tgaggaaacg aaattatgca 600
aattacgatc aaagcgca ca tcggcggtga tttggcgctc tccggctctg ggctgggtgc 660
tcagggaact aaaggactga attccggcgc ttcacgcgtg gggtccagcg tggataaact 720
gagcagcacc atcgataagt tgacctccgc gctgacttcg atgatgtttg gcggcgcgct 780
ggcgcgaggg ctgggcgcca gctcgaaggg gctggggatg agcaatcaac tgggccagtc 840
tttcggcaat ggcgcgcagg gtgcgagcaa cctgctatcc gtaccgaaat ccggcgggcga 900
tgcgttgtca aaaatgtttg ataaagcgct ggacgatctg ctgggtcatg acaccgtgac 960
caagctgact aaccagagca accaactggc taattcaatg ctgaacgcca gccagatgac 1020
ccagggtaat atgaatgcgt tcggcagcgg tgtgaacaac gcactgtcgt ccattctcgg 1080
caacggtctc ggccagtcga tgagtggctt ctctcagcct tctctggggg caggcggtct 1140
gcagggcctg agcggcgcgg gtgcattcaa ccagttgggt aatgccatcg gcattggcgt 1200
ggggcagaat gctgcgctga gtgcgttgag taacgtcagc acccacgtag acggtaacaa 1260
ccgccacttt gtagataaag aagatcgcgg catggcgaaa gagatcggcc agtttatgga 1320
tcagtatccg gaaatattcg gtaaacggga ataccagaaa gatggctgga gttcgccgaa 1380
gacggacgac aaatcctggg ctaaagcgct gagtaaacgg gatgatgacg gtatgaccgg 1440
cgccagcatg gacaaattcc gtcaggcgat gggatatgac aaaagcgcgg tggcggtgta 1500
taccggcaat accaacctga acctgcgtgg cgcgggcggt gcacgcgtgg gtatcgatgc 1560
ggctgtcgtc ggcgataaaa tagccaacat gtcgctgggt aagctggcca acgcctgata 1620
atctgtgctg gcctgataaa gcggaaacga aaaaagagac ggggaagcct gtctcttttc 1680
ttattatgcg gtttatgcgg ttacctggac cggttaatca tcgtcatcga tctggtacaa 1740
acgcacattt tcccgttcac tcgcgtcgtt acgcgccaca atcgcgatgg catcttcctc 1800

```

**THIS PAGE BLANK (USPTO)**

gtcgcctcaga ttgcgcgggt gatggggaac gccgggtgga atatagagaa actcgccggc 1860  
 cagatggaga cacgtctgcg ataaatctgt gccgtaacgt gtttctatcc gcccttttag 1920  
 cagatagatt gcggtttcgt aatcaacatg gtaatgcggt tccgcctgtg cgccggccgg 1980  
 gatcaccaca atattcatag aaagctgtct tgcacctacc gtatcgcggt agataccgac 2040  
 aaaatagggc agtttttgcg tggatatccgt ggggtgttcc ggctgacaa tcttgagttg 2100  
 gttcgtcatc atctttctcc atctgggcga cctgatcggt t 2141

<210> 23

<211> 403

<212> PRT

<213> *Erwinia amylovora*

<400> 23

Met Ser Leu Asn Thr Ser Gly Leu Gly Ala Ser Thr Met Gln Ile Ser  
 1 5 10 15

Ile Gly Gly Ala Gly Gly Asn Asn Gly Leu Leu Gly Thr Ser Arg Gln  
 20 25 30

Asn Ala Gly Leu Gly Gly Asn Ser Ala Leu Gly Leu Gly Gly Gly Asn  
 35 40 45

Gln Asn Asp Thr Val Asn Gln Leu Ala Gly Leu Leu Thr Gly Met Met  
 50 55 60

Met Met Met Ser Met Met Gly Gly Gly Gly Leu Met Gly Gly Gly Leu  
 65 70 75 80

Gly Gly Gly Leu Gly Asn Gly Leu Gly Gly Ser Gly Gly Leu Gly Glu  
 85 90 95

Gly Leu Ser Asn Ala Leu Asn Asp Met Leu Gly Gly Ser Leu Asn Thr  
 100 105 110

Leu Gly Ser Lys Gly Gly Asn Asn Thr Thr Ser Thr Thr Asn Ser Pro  
 115 120 125

Leu Asp Gln Ala Leu Gly Ile Asn Ser Thr Ser Gln Asn Asp Asp Ser  
 130 135 140

Thr Ser Gly Thr Asp Ser Thr Ser Asp Ser Ser Asp Pro Met Gln Gln  
 145 150 155 160

Leu Leu Lys Met Phe Ser Glu Ile Met Gln Ser Leu Phe Gly Asp Gly  
 165 170 175

Gln Asp Gly Thr Gln Gly Ser Ser Ser Gly Gly Lys Gln Pr Thr Glu  
 180 185 190

**THIS PAGE BLANK (USPTO)**

Gly Glu Gln Asn Ala Tyr Lys Lys Gly Val Thr Asp Ala Leu Ser Gly  
 195 200 205  
 Leu Met Gly Asn Gly Leu Ser Gln Leu Leu Gly Asn Gly Gly Leu Gly  
 210 215 220  
 Gly Gly Gln Gly Gly Asn Ala Gly Thr Gly Leu Asp Gly Ser Ser Leu  
 225 230 235 240  
 Gly Gly Lys Gly Leu Gln Asn Leu Ser Gly Pro Val Asp Tyr Gln Gln  
 245 250 255  
 Leu Gly Asn Ala Val Gly Thr Gly Ile Gly Met Lys Ala Gly Ile Gln  
 260 265 270  
 Ala Leu Asn Asp Ile Gly Thr His Arg His Ser Ser Thr Arg Ser Phe  
 275 280 285  
 Val Asn Lys Gly Asp Arg Ala Met Ala Lys Glu Ile Gly Gln Phe Met  
 290 295 300  
 Asp Gln Tyr Pro Glu Val Phe Gly Lys Pro Gln Tyr Gln Lys Gly Pro  
 305 310 315 320  
 Gly Gln Glu Val Lys Thr Asp Asp Lys Ser Trp Ala Lys Ala Leu Ser  
 325 330 335  
 Lys Pro Asp Asp Asp Gly Met Thr Pro Ala Ser Met Glu Gln Phe Asn  
 340 345 350  
 Lys Ala Lys Gly Met Ile Lys Arg Pro Met Ala Gly Asp Thr Gly Asn  
 355 360 365  
 Gly Asn Leu Gln Ala Arg Gly Ala Gly Gly Ser Ser Leu Gly Ile Asp  
 370 375 380  
 Ala Met Met Ala Gly Asp Ala Ile Asn Asn Met Ala Leu Gly Lys Leu  
 385 390 395 400  
 Gly Ala Ala

&lt;210&gt; 24

&lt;211&gt; 1288

&lt;212&gt; DNA

&lt;213&gt; Erwinia amylovora

**THIS PAGE BLANK (USPTO)**

&lt;400&gt; 24

```

aagcttcggc atggcacggt tgaccgttg gtcggcaggg tacgtttgaa ttattcataa 60
gaggaatacg ttatgagtct gaatacaagt gggctgggag cgtcaacgat gcaaatttct 120
atcggcgggt cgggcggaaa taacgggttg ctgggtacca gtcgccagaa tgctgggttg 180
ggtggcaatt ctgcactggg gctgggcggc ggtaatcaaa atgataccgt caatcagctg 240
gctggcttac tcaccggcat gatgatgat atgagcatga tgggcgggtg tgggctgatg 300
ggcggtggt taggcgggtg cttaggtaat ggcttgggtg gctcagggtg cctgggcgaa 360
ggactgtcga acgcgctgaa cgatatgtta ggcgggttcgc tgaacacgct gggctcgaaa 420
ggcggcaaca ataccacttc aacaacaaat tccccgctg accaggcgct gggattatac 480
tcaacgtccc aaaacgacga ttccacctcc ggcacagatt ccacctcaga ctccagcgac 540
ccgatgcagc agctgctgaa gatgttcagc gagataatgc aaagcctgtt tggatgaggg 600
caagatggca cccagggcag ttcctctggg ggcaagcagc cgaccgaagg cgagcagaac 660
gcctataaaa aaggagtcac tgatgcgctg tcgggcctga tgggtaatgg tctgagccag 720
ctccttggca acgggggact gggaggtggt cagggcggtg atgctggcac gggctctgac 780
ggttcgtcgc tgggcggcaa agggctgcaa aacctgagcg ggccggtgga ctaccagcag 840
ttaggtaacg ccgtgggtac cgggtatcgt atgaaagcgg gcattcaggc gctgaatgat 900
atcggtagcg acaggcacag ttcaaccgt tctttcgtca ataaaggcga tcgggcgatg 960
gcgaaggaaa tcggtcagtt catggaccag tatcctgagg tgtttggcaa gccgcagtac 1020
cagaaaggcc cgggtcagga ggtgaaaacc gatgacaaat catgggcaa agcactgagc 1080
aagccagatg acgacggaat gacaccagcc agtatggagc agttcaacaa agccaaggcc 1140
atgatcaaaa ggcccatggc ggggtgatac ggcaacggca acctgcaggc acgcgggtgc 1200
ggtggttctt cgctgggtat tgatgccatg atggccggtg atgccattaa caatatggca 1260
cttggcaagc tgggcgcggc ttaagctt 1288

```

&lt;210&gt; 25

&lt;211&gt; 1344

&lt;212&gt; DNA

<213> *Erwinia amylovora*

&lt;400&gt; 25

```

atgtcaattc ttacgcttaa caacaatacc tcgtcctcgc cgggtctgtt ccagtcgggg 60
ggggacaacg ggcttgggtg tcataatgca aattctcgtg tggggcaaca acccatcgat 120
cggcaaaacca ttgagcaaat ggctcaatta ttggcgggaa tggttaaagtc actgctatcg 180
ccacaatcag gtaatgcggc aaccggagcc ggtggcaatg accagactac aggagttggt 240
aacgctggcg gcctgaacgg acgaaaaggc acagcaggaa ccactccgca gtctgacagt 300
cagaacatgc tgagtgagat gggcaacaac gggctggatc aggccatcac gccgatggc 360
cagggcggcg ggcagatcgg cgataatcct ttactgaaag ccatgctgaa gcttattgca 420
cgcattgatg acggccaaag cgatcagttt ggccaacctg gtacgggcaa caacagtgcc 480
tcttcgggta cttcttcac tcggcggttc ctttttaacg atctatcagg ggggaaggcc 540
ccttcgggca actcccttc cggcaactac tctcccgta gtacctctc acccccatcc 600
acgccaacgt cccctacctc accgcttgat ttcccttctt ctcccacaa agcagccggg 660
ggcagcacgc cggtaaccga tcatcctgac cctgttggtg gcgcgggcat cggggccgga 720
aattcgggtg ccttcaccag cgccggcgct aatcagacgg tgctgcatga caccattacc 780
gtgaaagcgg gtcagggtgt tgatggcaaa ggacaaacct tcaccgcccg ttcagaatta 840
ggcgatggcg gccagtctga aaaccagaaa ccgctgttta tactggaaga cgggtgccagc 900
ctgaaaaacg tcaccatggg cgacgacggg gcggatggta ttcattctta cgggtgatgcc 960
aaaatagaca atctgcacgt caccaacgtg ggtgaggagc cgattaccgt taagccaaac 1020

```

**THIS PAGE BLANK (USPTO)**



agcgcgggca aaaaatccca cgttgaaatc actaacagtt ccttcgagca cgcctctgac 1080  
 aagatcctgc agctgaatgc cgataactaac ctgagcggtg acaacgtgaa ggccaaagac 1140  
 tttggtactt ttgtacgcac taacggcggc caacagggta actgggatct gaatctgagc 1200  
 catatcagcg cagaagacgg taagttctcg ttcgttaaaa gcgatagcga ggggctaaac 1260  
 gtcaatacca gtgatatctc actgggtgat gttgaaaacc actacaaagt gccgatgtcc 1320  
 gccaacctga aggtggctga atga 1344

<210> 26

<211> 447

<212> PRT

<213> *Erwinia amylovora*

<400> 26

Met Ser Ile Leu Thr Leu Asn Asn Asn Thr Ser Ser Ser Pro Gly Leu  
 1 5 10 15

Phe Gln Ser Gly Gly Asp Asn Gly Leu Gly Gly His Asn Ala Asn Ser  
 20 25 30

Ala Leu Gly Gln Gln Pro Ile Asp Arg Gln Thr Ile Glu Gln Met Ala  
 35 40 45

Gln Leu Leu Ala Glu Leu Leu Lys Ser Leu Leu Ser Pro Gln Ser Gly  
 50 55 60

Asn Ala Ala Thr Gly Ala Gly Gly Asn Asp Gln Thr Thr Gly Val Gly  
 65 70 75 80

Asn Ala Gly Gly Leu Asn Gly Arg Lys Gly Thr Ala Gly Thr Thr Pro  
 85 90 95

Gln Ser Asp Ser Gln Asn Met Leu Ser Glu Met Gly Asn Asn Gly Leu  
 100 105 110

Asp Gln Ala Ile Thr Pro Asp Gly Gln Gly Gly Gly Gln Ile Gly Asp  
 115 120 125

Asn Pro Leu Leu Lys Ala Met Leu Lys Leu Ile Ala Arg Met Met Asp  
 130 135 140

Gly Gln Ser Asp Gln Phe Gly Gln Pro Gly Thr Gly Asn Asn Ser Ala  
 145 150 155 160

Ser Ser Gly Thr Ser Ser Ser Gly Gly Ser Pro Phe Asn Asp Leu Ser  
 165 170 175

Gly Gly Lys Ala Pro Ser Gly Asn Ser Pro Ser Gly Asn Tyr Ser Pro  
 180 185 190

**THIS PAGE BLANK (USPTO)**

Val Ser Thr Phe Ser Pro Pr Ser Thr Pr Thr Ser Pro Thr Ser Pr  
 195 200 205

Leu Asp Phe Pro Ser Ser Pro Thr Lys Ala Ala Gly Gly Ser Thr Pro  
 210 215 220

Val Thr Asp His Pro Asp Pro Val Gly Ser Ala Gly Ile Gly Ala Gly  
 225 230 235 240

Asn Ser Val Ala Phe Thr Ser Ala Gly Ala Asn Gln Thr Val Leu His  
 245 250 255

Asp Thr Ile Thr Val Lys Ala Gly Gln Val Phe Asp Gly Lys Gly Gln  
 260 265 270

Thr Phe Thr Ala Gly Ser Glu Leu Gly Asp Gly Gly Gln Ser Glu Asn  
 275 280 285

Gln Lys Pro Leu Phe Ile Leu Glu Asp Gly Ala Ser Leu Lys Asn Val  
 290 295 300

Thr Met Gly Asp Asp Gly Ala Asp Gly Ile His Leu Tyr Gly Asp Ala  
 305 310 315 320

Lys Ile Asp Asn Leu His Val Thr Asn Val Gly Glu Asp Ala Ile Thr  
 325 330 335

Val Lys Pro Asn Ser Ala Gly Lys Lys Ser His Val Glu Ile Thr Asn  
 340 345 350

Ser Ser Phe Glu His Ala Ser Asp Lys Ile Leu Gln Leu Asn Ala Asp  
 355 360 365

Thr Asn Leu Ser Val Asp Asn Val Lys Ala Lys Asp Phe Gly Thr Phe  
 370 375 380

Val Arg Thr Asn Gly Gly Gln Gln Gly Asn Trp Asp Leu Asn Leu Ser  
 385 390 395 400

His Ile Ser Ala Glu Asp Gly Lys Phe Ser Phe Val Lys Ser Asp Ser  
 405 410 415

Glu Gly Leu Asn Val Asn Thr Ser Asp Ile Ser Leu Gly Asp Val Glu  
 420 425 430

Asn His Tyr Lys Val Pr Met Ser Ala Asn Leu Lys Val Ala Glu  
 435 440 445

**THIS PAGE BLANK (USPTO)**

&lt;210&gt; 27

&lt;211&gt; 5517

&lt;212&gt; DNA

<213> *Erwinia amylovora*

&lt;400&gt; 27

```

atggaattaa aatcactggg aactgaacac aaggcggcag tacacacagc ggcgcacaac 60
cctgtggggc atggtgttgc cttacagcag ggcagcagca gcagcagccc gcaaaatgcc 120
gctgcatcat tggcggcaga aggcaaaaat cgtgggaaaa tgccgagaat tcaccagcca 180
tctactgogg ctgatggtat cagcgctgct caccagcaaa agaaatcctt cagtctcagg 240
ggctgttttg ggacgaaaaa attttccaga tcggcaccgc agggccagcc aggtaccacc 300
cacagcaaaag gggcaacatt gcgcgatctg ctggcgcggg acgacggcga aacgcagcat 360
gaggcgggccg cgccagatgc ggcgcgtttg acccggttcgg gcggcgtaa acgccgaat 420
atggacgaca tggcggggcg gccaatggtg aaaggtggca gcggcgaa ga taaggtacca 480
acgcagcaaaa aacggcatca gctgaacaat tttggccaga tgcgccaaac gatgttgagc 540
aaaatggctc acccggttcc agccaacgcc ggcgatcgcc tgcagcattc accgcgcac 600
atccccgggtg gccaccacga aatcaaggaa gaaccggttg gctccaccag caaggcaaca 660
acggcccacg cagacagagt ggaaatcgct cagggaagatg acgacagcga attccagcaa 720
ctgcatcaac agcggctggc gcgcgaacgg gaaaatccac cgcagccgcc caaactcggc 780
gttgccacac cgattagcgc caggtttcag cccaaactga ctgcggttgc ggaaagcgtc 840
cttgaggggg cagataccac gcagtcaccc cttaaagccgc aatcaatgct gaaaggaagt 900
ggagccgggg taacgccgct ggcggtaacg ctggataaag gcaagttgca gctggcaccg 960
gataatccac ccgcgctcaa tacgttgttg aagcagacat tgggtaaa ga caccagcac 1020
tatctggcgc accatgccag cagcgacggg agccagcatc tgctgctgga caacaaaggc 1080
cacctgtttg atatcaaaaag caccgccacc agctatagcg tgctgcacaa cagccacccc 1140
ggtgagataa agggcaagct ggcgcaggcg ggtactggct ccgtcagcgt agacggtaaa 1200
agcggcaaga tctcgctggg gagcggtagc caaagtcaca acaaaacaat gctaagccaa 1260
ccgggggaag cgcaccgttc cttathtaacc ggcattttggc agcatcctgc tggcgagcgc 1320
cggccgcagg gcgagtcgat ccgcctgcat gacgacaaaa ttcataatcct gcatccggag 1380
ctgggcgtat ggcaatctgc ggataaagat acccacagcc agctgtctcg ccaggcagac 1440
ggtaagctct atgcgctgaa agacaaccgt accctgcaa acctctccga taataaatcc 1500
tcagaaaagc tggtcgataa aatcaaatcg tattccgttg atcagcgggg gcagggtggcg 1560
atcctgacgg atactcccgg ccgccataag atgagtatta tgccctcgct ggatgcttcc 1620
ccggagagcc atatttccct cagcctgcat tttgccgatg cccaccaggg gttattgcac 1680
gggaagtcgg agcttgaggc acaatctgtc gcgatcagcc atgggcgact ggttgtggcc 1740
gatagcgaag gcaagctgtt tagcgcggcc attccgaagc aaggggatgg aaacgaactg 1800
aaaatgaaag ccatgcctca gcatgcgctc gatgaacatt ttggtcatga ccaccagatt 1860
tctggatttt tccatgacga ccacggccag cttaatgcgc tgggtaaaaa taacttcagg 1920
cagcagcatg cctgcccgtt gggtaacgat catcagtttc accccggctg gaacctgact 1980
gatgcgctgg ttatcgacaa tcagctgggg ctgcatcata ccaatcctga accgcatgag 2040
attcttgata tggggcattt aggcagcctg gcgttacagg agggcaagct tcactatttt 2100
gaccagctga ccaaagggtg gactggcgcg gagtacagatt gtaagcagct gaaaaaggc 2160
ctggatggag cagcttatct actgaaagac ggtgaagtga aacgcctgaa tattaatcag 2220
agcacctcct ctatcaagca cggaacggaa aacgtttttt cgctgccgca tgtgcgcaat 2280
aaaccggagc cgggagatgc cctgcaaggg ctgaataaag acgataaggc ccaggccatg 2340
gcggtgattg gggtaataaa atacctggcg ctgacggaaa aaggggacat tcgctccttc 2400

```

**THIS PAGE BLANK (USPTO)**

cagataaaac ccggcaccga gcagttggag cggccggcac aaactctcag ccgcgaaggt 2460  
 atcagcggcg aactgaaaga cattcatgtc gaccacaagc agaaccctgta tgccttgacc 2520  
 caccgagggag aggtgtttca tcagccgctg gaagcctggc agaattggtgc cgaaagcagc 2580  
 agctggcaca aactggcggt gccacagagt gaaagtaagc taaaaagtct ggacatgagc 2640  
 catgagcaca aaccgattgc cacccttgaa gacggtagcc agcatcagct gaaggctggc 2700  
 ggctggcacg cctatgcggc acctgaacgc gggccgctgg cgggtgggtac cagcggttca 2760  
 caaaccgtct ttaaccgact aatgcagggg gtgaaaggca aggtgatccc aggcagcggg 2820  
 ttgacggtta agctctcggc tcagacgggg ggaatgaccg gcgccgaagg gcgcaagggtc 2880  
 agcagtaaat tttccgaaag gatccgcgcc tatgcgttca acccaacaat gtccacgcgc 2940  
 cgaccgatta aaaatgctgc ttatgccaca cagcacggct ggcagggggc tgagggggtg 3000  
 aagccgttgt acgagatgca gggagcgtg attaaacaac tggatgcgca taacgttcgt 3060  
 cataacgcgc cacagccaga tttgcagagc aaactggaaa ctctggattt aggcgaacat 3120  
 ggccgcagaat tgcttaacga catgaagcgc ttccgcgacg aactggagca gaggcaacc 3180  
 cgttcggtga ccgttttagg tcaacatcag ggagtgctaa aaagcaacgg tgaatcaat 3240  
 agcgaattta agccatcgcc cggcaaggcg ttggtccaga gctttaacgt caatcgctct 3300  
 ggtcaggatc taagcaagtc actgcaacag gcagtacatg ccacgccgcc atccgcagag 3360  
 agtaaaactgc aatccatgct ggggcacttt gtcagtgcgc ggggtggatat gagtcatcag 3420  
 aagggcgaga tcccgtggg cggccagcgc gatccgaatg ataaaaccgc actgaccaa 3480  
 tcgcgtttta ttttagatac cgtgaccatc ggtgaactgc atgaactggc cgataaggcg 3540  
 aaactggtat ctgaccataa acccgatgcc gatcagataa aacagctgcg ccagcagttc 3600  
 gatacgtgc gtgaaaagcg gtatgagagc aatccggtga agcattacac cgatatgggc 3660  
 ttcaccata ataaggcgct ggaagcaaac tatgatgcgg tcaaagcctt tatcaatgcc 3720  
 tttagaagag agcaccacgg cgtcaatctg accacgcgta ccgtactgga atcacagggc 3780  
 agtgcggagc tggcgaagaa gctcaagaat acgctgttgt ccctggacag tggtgaaagt 3840  
 atgagcttca gccggtcata tggcgggggc gtcagcactg tctttgtgcc tacccttagc 3900  
 aagaagggtc cagttccggg gatccccgga gccggcatca cgctggatcg cgcctataac 3960  
 ctgagcttca gtcgtaccag cggcgggattg aacgtcagtt ttggccgcga cggcgggggtg 4020  
 agtggtaaca tcatggtcgc taccggccat gatgtgatgc cctatatgac cggtaagaaa 4080  
 accagtgcag gtaacgccag tgactgggtg agcgcaaac ataaaatcag cccggacttg 4140  
 cgtatcggcg ctgctgtgag tggcaccctg caaggaaacg taaaaaacag cctgaagttt 4200  
 aagctgacag aggatgagct gcctggcttt atccatggct tgacgcagtg cacgttgacc 4260  
 ccggcagaac tggtgcaaaa ggggatcgaa catcagatga agcagggcag caaactgacg 4320  
 tttagcgtcg atacctcggc aaatctggat ctgctgccc gttatcaatct gaacgaagac 4380  
 ggcagtaaac caaatgggtg cactgcccgt gtttctgccc ggctaagtgc atcggcaaac 4440  
 ctggccgccg gctcgcgtga acgcagcacc acctctggcc agtttggcag cacgacttcg 4500  
 gccagcaata accgccaac ctccctcaac ggggtcggcg cgggtgctaa cctgacggct 4560  
 gctttagggg ttgccattc atctacgcat gaagggaaac cggtcgggat cttcccgga 4620  
 tttacctcga ccaatgtttc ggcagcgtg gcgctggata accgtacctc acagagtatc 4680  
 agcctggaat tgaagcgcgc ggagccggtg accagcaacg atatcagcga gttgacctcc 4740  
 acgctgggaa aacactttta ggatagcgcc acaacgaaga tgcttgccgc tctcaaagag 4800  
 ttagatgacg ctaagccgcg tgaacaactg catattttac agcagcattt cagtgcataa 4860  
 gatgtcgtcg gtgatgaacg ctacgagggc gtgcgcaacc tgaaaaaact ggtgatacgt 4920  
 caacaggctg cggacagcca cagcatggaa ttaggatctg ccagtcacag cacgacctac 4980  
 aataatctgt cgagaataaa taatgacggc attgtcgagc tgctacacaa acatttcgat 5040  
 gcggcattac cagcaagcag tgccaaacgt cttggtgaaa tgatgaataa cgatccggca 5100  
 ctgaaagata ttattaagca gctgcaaggt acgccgttca gcagcgccag cgtgtcgatg 5160  
 gagctgaaag atggtctgcg tgagcagacg gaaaaagcaa tactggacgg taaggtcggg 5220  
 cgtgaagaag tgggagtact tttccaggat cgtaacaact tgcgtgttaa atcggtcagc 5280

**THIS PAGE BLANK (USPTO)**



gtcagtcagt ccgtcagcaa aagcgaaggc ttcaataccc cagcgctggt actggggacg 5340  
 agcaacagcg ctgctatgag catggagcgc aacatcggaa ccattaattt taaatacggc 5400  
 caggatcaga acacccacg gcgatttacc ctggaggggtg gaatagctca ggctaataccg 5460  
 caggtcgcat ctgcgcttac tgatttgaag aaggaagggc tggaaatgaa gagctaa 5517

<210> 28

<211> 1838

<212> PRT

<213> *Erwinia amylovora*

<400> 28

Met Glu Leu Lys Ser Leu Gly Thr Glu His Lys Ala Ala Val His Thr  
 1 5 10 15

Ala Ala His Asn Pro Val Gly His Gly Val Ala Leu Gln Gln Gly Ser  
 20 25 30

Ser Ser Ser Ser Pro Gln Asn Ala Ala Ala Ser Leu Ala Ala Glu Gly  
 35 40 45

Lys Asn Arg Gly Lys Met Pro Arg Ile His Gln Pro Ser Thr Ala Ala  
 50 55 60

Asp Gly Ile Ser Ala Ala His Gln Gln Lys Lys Ser Phe Ser Leu Arg  
 65 70 75 80

Gly Cys Leu Gly Thr Lys Lys Phe Ser Arg Ser Ala Pro Gln Gly Gln  
 85 90 95

Pro Gly Thr Thr His Ser Lys Gly Ala Thr Leu Arg Asp Leu Leu Ala  
 100 105 110

Arg Asp Asp Gly Glu Thr Gln His Glu Ala Ala Ala Pro Asp Ala Ala  
 115 120 125

Arg Leu Thr Arg Ser Gly Gly Val Lys Arg Arg Asn Met Asp Asp Met  
 130 135 140

Ala Gly Arg Pro Met Val Lys Gly Gly Ser Gly Glu Asp Lys Val Pro  
 145 150 155 160

Thr Gln Gln Lys Arg His Gln Leu Asn Asn Phe Gly Gln Met Arg Gln  
 165 170 175

Thr Met Leu Ser Lys Met Ala His Pro Ala Ser Ala Asn Ala Gly Asp  
 180 185 190

Arg Leu Gln His Ser Pro Pro His Ile Pro Gly Ser His His Glu Ile

**THIS PAGE BLANK (USPTO)**

|   |     |             |
|---|-----|-------------|
| 195   | 200 | 205         |
| Lys Glu Glu Pro Val Gly Ser Thr Ser Lys Ala Thr Thr Ala His Ala |     |             |
| 210   | 215 | 220         |
| Asp Arg Val Glu Ile Ala Gln Glu Asp Asp Asp Ser Glu Phe Gln Gln |     |             |
| 225   | 230 | 235 240     |
| Leu His Gln Gln Arg Leu Ala Arg Glu Arg Glu Asn Pro Pro Gln Pro |     |             |
|   | 245 | 250 255     |
| Pro Lys Leu Gly Val Ala Thr Pro Ile Ser Ala Arg Phe Gln Pro Lys |     |             |
|   | 260 | 265 270     |
| Leu Thr Ala Val Ala Glu Ser Val Leu Glu Gly Thr Asp Thr Thr Gln |     |             |
|   | 275 | 280 285     |
| Ser Pro Leu Lys Pro Gln Ser Met Leu Lys Gly Ser Gly Ala Gly Val |     |             |
|   | 290 | 295 300     |
| Thr Pro Leu Ala Val Thr Leu Asp Lys Gly Lys Leu Gln Leu Ala Pro |     |             |
|   | 305 | 310 315 320 |
| Asp Asn Pro Pro Ala Leu Asn Thr Leu Leu Lys Gln Thr Leu Gly Lys |     |             |
|   | 325 | 330 335     |
| Asp Thr Gln His Tyr Leu Ala His His Ala Ser Ser Asp Gly Ser Gln |     |             |
|   | 340 | 345 350     |
| His Leu Leu Leu Asp Asn Lys Gly His Leu Phe Asp Ile Lys Ser Thr |     |             |
|   | 355 | 360 365     |
| Ala Thr Ser Tyr Ser Val Leu His Asn Ser His Pro Gly Glu Ile Lys |     |             |
|   | 370 | 375 380     |
| Gly Lys Leu Ala Gln Ala Gly Thr Gly Ser Val Ser Val Asp Gly Lys |     |             |
|   | 385 | 390 395 400 |
| Ser Gly Lys Ile Ser Leu Gly Ser Gly Thr Gln Ser His Asn Lys Thr |     |             |
|   | 405 | 410 415     |
| Met Leu Ser Gln Pro Gly Glu Ala His Arg Ser Leu Leu Thr Gly Ile |     |             |
|   | 420 | 425 430     |
| Trp Gln His Pro Ala Gly Ala Ala Arg Pro Gln Gly Glu Ser Ile Arg |     |             |
|   | 435 | 440 445     |
| Leu His Asp Asp Lys Ile His Ile Leu His Pro Glu Leu Gly Val Trp |     |             |

**THIS PAGE BLANK (USPTO)**

|   |     |             |
|---|-----|-------------|
| 450   | 455 | 460         |
| Gln Ser Ala Asp Lys Asp Thr His Ser Gln Leu Ser Arg Gln Ala Asp |     |             |
| 465   | 470 | 475 480     |
| Gly Lys Leu Tyr Ala Leu Lys Asp Asn Arg Thr Leu Gln Asn Leu Ser |     |             |
|   | 485 | 490 495     |
| Asp Asn Lys Ser Ser Glu Lys Leu Val Asp Lys Ile Lys Ser Tyr Ser |     |             |
|   | 500 | 505 510     |
| Val Asp Gln Arg Gly Gln Val Ala Ile Leu Thr Asp Thr Pro Gly Arg |     |             |
|   | 515 | 520 525     |
| His Lys Met Ser Ile Met Pro Ser Leu Asp Ala Ser Pro Glu Ser His |     |             |
|   | 530 | 535 540     |
| Ile Ser Leu Ser Leu His Phe Ala Asp Ala His Gln Gly Leu Leu His |     |             |
|   | 545 | 550 555 560 |
| Gly Lys Ser Glu Leu Glu Ala Gln Ser Val Ala Ile Ser His Gly Arg |     |             |
|   | 565 | 570 575     |
| Leu Val Val Ala Asp Ser Glu Gly Lys Leu Phe Ser Ala Ala Ile Pro |     |             |
|   | 580 | 585 590     |
| Lys Gln Gly Asp Gly Asn Glu Leu Lys Met Lys Ala Met Pro Gln His |     |             |
|   | 595 | 600 605     |
| Ala Leu Asp Glu His Phe Gly His Asp His Gln Ile Ser Gly Phe Phe |     |             |
|   | 610 | 615 620     |
| His Asp Asp His Gly Gln Leu Asn Ala Leu Val Lys Asn Asn Phe Arg |     |             |
|   | 625 | 630 635 640 |
| Gln Gln His Ala Cys Pro Leu Gly Asn Asp His Gln Phe His Pro Gly |     |             |
|   | 645 | 650 655     |
| Trp Asn Leu Thr Asp Ala Leu Val Ile Asp Asn Gln Leu Gly Leu His |     |             |
|   | 660 | 665 670     |
| His Thr Asn Pro Glu Pro His Glu Ile Leu Asp Met Gly His Leu Gly |     |             |
|   | 675 | 680 685     |
| Ser Leu Ala Leu Gln Glu Gly Lys Leu His Tyr Phe Asp Gln Leu Thr |     |             |
|   | 690 | 695 700     |
| Lys Gly Trp Thr Gly Ala Glu Ser Asp Cys Lys Gln Leu Lys Lys Gly |     |             |

**THIS PAGE BLANK (USPTO)**

|   |     |     |     |
|---|-----|-----|-----|
| 705   | 710 | 715 | 720 |
| Leu Asp Gly Ala Ala Tyr Leu Leu Lys Asp Gly Glu Val Lys Arg Leu | 725 | 730 | 735 |
| Asn Ile Asn Gln Ser Thr Ser Ser Ile Lys His Gly Thr Glu Asn Val | 740 | 745 | 750 |
| Phe Ser Leu Pro His Val Arg Asn Lys Pro Glu Pro Gly Asp Ala Leu | 755 | 760 | 765 |
| Gln Gly Leu Asn Lys Asp Asp Lys Ala Gln Ala Met Ala Val Ile Gly | 770 | 775 | 780 |
| Val Asn Lys Tyr Leu Ala Leu Thr Glu Lys Gly Asp Ile Arg Ser Phe | 785 | 790 | 795 |
| Gln Ile Lys Pro Gly Thr Gln Gln Leu Glu Arg Pro Ala Gln Thr Leu | 805 | 810 | 815 |
| Ser Arg Glu Gly Ile Ser Gly Glu Leu Lys Asp Ile His Val Asp His | 820 | 825 | 830 |
| Lys Gln Asn Leu Tyr Ala Leu Thr His Glu Gly Glu Val Phe His Gln | 835 | 840 | 845 |
| Pro Arg Glu Ala Trp Gln Asn Gly Ala Glu Ser Ser Ser Trp His Lys | 850 | 855 | 860 |
| Leu Ala Leu Pro Gln Ser Glu Ser Lys Leu Lys Ser Leu Asp Met Ser | 865 | 870 | 875 |
| His Glu His Lys Pro Ile Ala Thr Phe Glu Asp Gly Ser Gln His Gln | 885 | 890 | 895 |
| Leu Lys Ala Gly Gly Trp His Ala Tyr Ala Ala Pro Glu Arg Gly Pro | 900 | 905 | 910 |
| Leu Ala Val Gly Thr Ser Gly Ser Gln Thr Val Phe Asn Arg Leu Met | 915 | 920 | 925 |
| Gln Gly Val Lys Gly Lys Val Ile Pro Gly Ser Gly Leu Thr Val Lys | 930 | 935 | 940 |
| Leu Ser Ala Gln Thr Gly Gly Met Thr Gly Ala Glu Gly Arg Lys Val | 945 | 950 | 955 |
| Ser Ser Lys Phe Ser Glu Arg Ile Arg Ala Tyr Ala Phe Asn Pr Thr  |     |     |     |

**THIS PAGE BLANK (USPTO)**



|   |   |      |
|---|---|------|
| 965   | 970                                     | 975  |
| Met Ser Thr Pro Arg Pr  | Ile Lys Asn Ala Ala Tyr Ala Thr Gln His |      |
| 980   | 985                                     | 990  |
| Gly Trp Gln Gly Arg Glu Gly Leu Lys Pro Leu Tyr Glu Met Gln Gly |   |      |
| 995   | 1000                                    | 1005 |
| Ala Leu Ile Lys Gln Leu Asp Ala His Asn Val Arg His Asn Ala Pro |   |      |
| 1010  | 1015                                    | 1020 |
| Gln Pro Asp Leu Gln Ser Lys Leu Glu Thr Leu Asp Leu Gly Glu His |   |      |
| 1025  | 1030                                    | 1035 |
| 1040  |   |      |
| Gly Ala Glu Leu Leu Asn Asp Met Lys Arg Phe Arg Asp Glu Leu Glu |   |      |
| 1045  | 1050                                    | 1055 |
| Gln Ser Ala Thr Arg Ser Val Thr Val Leu Gly Gln His Gln Gly Val |   |      |
| 1060  | 1065                                    | 1070 |
| Leu Lys Ser Asn Gly Glu Ile Asn Ser Glu Phe Lys Pro Ser Pro Gly |   |      |
| 1075  | 1080                                    | 1085 |
| Lys Ala Leu Val Gln Ser Phe Asn Val Asn Arg Ser Gly Gln Asp Leu |   |      |
| 1090  | 1095                                    | 1100 |
| Ser Lys Ser Leu Gln Gln Ala Val His Ala Thr Pro Pro Ser Ala Glu |   |      |
| 1105  | 1110                                    | 1115 |
| 1120  |   |      |
| Ser Lys Leu Gln Ser Met Leu Gly His Phe Val Ser Ala Gly Val Asp |   |      |
| 1125  | 1130                                    | 1135 |
| Met Ser His Gln Lys Gly Glu Ile Pro Leu Gly Arg Gln Arg Asp Pro |   |      |
| 1140  | 1145                                    | 1150 |
| Asn Asp Lys Thr Ala Leu Thr Lys Ser Arg Leu Ile Leu Asp Thr Val |   |      |
| 1155  | 1160                                    | 1165 |
| Thr Ile Gly Glu Leu His Glu Leu Ala Asp Lys Ala Lys Leu Val Ser |   |      |
| 1170  | 1175                                    | 1180 |
| Asp His Lys Pro Asp Ala Asp Gln Ile Lys Gln Leu Arg Gln Gln Phe |   |      |
| 1185  | 1190                                    | 1195 |
| 1200  |   |      |
| Asp Thr Leu Arg Glu Lys Arg Tyr Glu Ser Asn Pro Val Lys His Tyr |   |      |
| 1205  | 1210                                    | 1215 |
| Thr Asp Met Gly Phe Thr His Asn Lys Ala L u Glu Ala Asn Tyr Asp |   |      |

**THIS PAGE BLANK (USPTO)**

|   |      |           |
|---|------|-----------|
| 1220  | 1225 | 1230      |
| Ala Val Lys Ala Phe Ile Asn Ala Phe Lys Lys Glu His His Gly Val |      |           |
| 1235  | 1240 | 1245      |
| Asn Leu Thr Thr Arg Thr Val Leu Glu Ser Gln Gly Ser Ala Glu Leu |      |           |
| 1250  | 1255 | 1260      |
| Ala Lys Lys Leu Lys Asn Thr Leu Leu Ser Leu Asp Ser Gly Glu Ser |      |           |
| 1265  | 1270 | 1275 1280 |
| Met Ser Phe Ser Arg Ser Tyr Gly Gly Gly Val Ser Thr Val Phe Val |      |           |
| 1285  | 1290 | 1295      |
| Pro Thr Leu Ser Lys Lys Val Pro Val Pro Val Ile Pro Gly Ala Gly |      |           |
| 1300  | 1305 | 1310      |
| Ile Thr Leu Asp Arg Ala Tyr Asn Leu Ser Phe Ser Arg Thr Ser Gly |      |           |
| 1315  | 1320 | 1325      |
| Gly Leu Asn Val Ser Phe Gly Arg Asp Gly Gly Val Ser Gly Asn Ile |      |           |
| 1330  | 1335 | 1340      |
| Met Val Ala Thr Gly His Asp Val Met Pro Tyr Met Thr Gly Lys Lys |      |           |
| 1345  | 1350 | 1355 1360 |
| Thr Ser Ala Gly Asn Ala Ser Asp Trp Leu Ser Ala Lys His Lys Ile |      |           |
| 1365  | 1370 | 1375      |
| Ser Pro Asp Leu Arg Ile Gly Ala Ala Val Ser Gly Thr Leu Gln Gly |      |           |
| 1380  | 1385 | 1390      |
| Thr Leu Gln Asn Ser Leu Lys Phe Lys Leu Thr Glu Asp Glu Leu Pro |      |           |
| 1395  | 1400 | 1405      |
| Gly Phe Ile His Gly Leu Thr His Gly Thr Leu Thr Pro Ala Glu Leu |      |           |
| 1410  | 1415 | 1420      |
| Leu Gln Lys Gly Ile Glu His Gln Met Lys Gln Gly Ser Lys Leu Thr |      |           |
| 1425  | 1430 | 1435 1440 |
| Phe Ser Val Asp Thr Ser Ala Asn Leu Asp Leu Arg Ala Gly Ile Asn |      |           |
| 1445  | 1450 | 1455      |
| Leu Asn Glu Asp Gly Ser Lys Pro Asn Gly Val Thr Ala Arg Val Ser |      |           |
| 1460  | 1465 | 1470      |
| Ala Gly Leu Ser Ala Ser Ala Asn Leu Ala Ala Gly Ser Arg Glu Arg |      |           |

**THIS PAGE BLANK (USPTO)**

|   |      |           |
|---|------|-----------|
| 1475  | 1480 | 1485      |
| Ser Thr Thr Ser Gly Gln Phe Gly Ser Thr Thr Ser Ala Ser Asn Asn |      |           |
| 1490  | 1495 | 1500      |
| Arg Pro Thr Phe Leu Asn Gly Val Gly Ala Gly Ala Asn Leu Thr Ala |      |           |
| 1505  | 1510 | 1515 1520 |
| Ala Leu Gly Val Ala His Ser Ser Thr His Glu Gly Lys Pro Val Gly |      |           |
| 1525  | 1530 | 1535      |
| Ile Phe Pro Ala Phe Thr Ser Thr Asn Val Ser Ala Ala Leu Ala Leu |      |           |
| 1540  | 1545 | 1550      |
| Asp Asn Arg Thr Ser Gln Ser Ile Ser Leu Glu Leu Lys Arg Ala Glu |      |           |
| 1555  | 1560 | 1565      |
| Pro Val Thr Ser Asn Asp Ile Ser Glu Leu Thr Ser Thr Leu Gly Lys |      |           |
| 1570  | 1575 | 1580      |
| His Phe Lys Asp Ser Ala Thr Thr Lys Met Leu Ala Ala Leu Lys Glu |      |           |
| 1585  | 1590 | 1595 1600 |
| Leu Asp Asp Ala Lys Pro Ala Glu Gln Leu His Ile Leu Gln Gln His |      |           |
| 1605  | 1610 | 1615      |
| Phe Ser Ala Lys Asp Val Val Gly Asp Glu Arg Tyr Glu Ala Val Arg |      |           |
| 1620  | 1625 | 1630      |
| Asn Leu Lys Lys Leu Val Ile Arg Gln Gln Ala Ala Asp Ser His Ser |      |           |
| 1635  | 1640 | 1645      |
| Met Glu Leu Gly Ser Ala Ser His Ser Thr Thr Tyr Asn Asn Leu Ser |      |           |
| 1650  | 1655 | 1660      |
| Arg Ile Asn Asn Asp Gly Ile Val Glu Leu Leu His Lys His Phe Asp |      |           |
| 1665  | 1670 | 1675 1680 |
| Ala Ala Leu Pro Ala Ser Ser Ala Lys Arg Leu Gly Glu Met Met Asn |      |           |
| 1685  | 1690 | 1695      |
| Asn Asp Pro Ala Leu Lys Asp Ile Ile Lys Gln Leu Gln Ser Thr Pro |      |           |
| 1700  | 1705 | 1710      |
| Phe Ser Ser Ala Ser Val Ser Met Glu Leu Lys Asp Gly Leu Arg Glu |      |           |
| 1715  | 1720 | 1725      |
| Gln Thr Glu Lys Ala Ile Leu Asp Gly Lys Val Gly Arg Glu Glu Val |      |           |

**THIS PAGE BLANK (USPTO)**

<210> 29  
<211> 420  
<212> DNA  
<213> *Erwinia amylovora*

| <b>&lt;400&gt; 29</b> |            |            |             |            |                 |
|-----------------------|------------|------------|-------------|------------|-----------------|
| atgacatcgt            | cacagcagcg | ggttgaaagg | tttttacagt  | atttctccgc | cgggtgtaaa 60   |
| acgccatac             | atctgaaaga | cggggtgtgc | gccctgtata  | acgaacaaga | tgaggaggcg 120  |
| gcggtgctgg            | aagtaccgca | acacagcgac | agcctgttac  | tacactgccg | aatcattgag 180  |
| gctgaccac             | aaacttcaat | aaccctgtat | tcgatgctat  | tacagctgaa | ttttgaaatg 240  |
| gcggccatgc            | gcggtctgtg | gctggcgctg | gatgaactgc  | acaacgtgcg | tttatgtttt 300  |
| cagcagtcgc            | tggagcatct | ggatgaagca | agtttttagcg | atatcgttag | cggcttcatac 360 |
| gaacatgcgg            | cagaagtgcg | tgagtatata | gcgcaattag  | acgagagtag | cgcggcataa 420  |

```
<210> 30
<211> 139
<212> PRT
<213> Erwinia amylovora
```

```

<400> 30
Met Thr Ser Ser Gln Gln Arg Val Glu Arg Phe Leu Gln Tyr Phe Ser
  1              5              10              15
Ala Gly Cys Lys Thr Pro Ile His Leu Lys Asp Gly Val Cys Ala Leu
      20              25              30

```

Tyr Asn Glu Gln Asp Glu Glu Ala Ala Val Leu Glu Val Pro Gln His

**THIS PAGE BLANK (USPTO)**



35                                      40                                      45  
 Ser Asp Ser Leu L u Leu His Cys Arg Ile Ile Glu Ala Asp Pro Gln  
     50                                      55                                      60  
 Thr Ser Ile Thr Leu Tyr Ser Met Leu Leu Gln Leu Asn Phe Glu Met  
     65                                      70                                      75                                      80  
 Ala Ala Met Arg Gly Cys Trp Leu Ala Leu Asp Glu Leu His Asn Val  
                                     85                                      90                                      95  
 Arg Leu Cys Phe Gln Gln Ser Leu Glu His Leu Asp Glu Ala Ser Phe  
                                     100                                      105                                      110  
 Ser Asp Ile Val Ser Gly Phe Ile Glu His Ala Ala Glu Val Arg Glu  
                                     115                                      120                                      125  
 Tyr Ile Ala Gln Leu Asp Glu Ser Ser Ala Ala  
                                     130                                      135

<210> 31  
 <211> 341  
 <212> PRT  
 <213> *Pseudomonas syringae*

<400> 31  
 Met Gln Ser Leu Ser Leu Asn Ser Ser Ser Leu Gln Thr Pro Ala Met  
     1                                      5                                      10                                      15  
 Ala Leu Val Leu Val Arg Pro Glu Ala Glu Thr Thr Gly Ser Thr Ser  
                                     20                                      25                                      30  
 Ser Lys Ala Leu Gln Glu Val Val Val Lys Leu Ala Glu Glu Leu Met  
                                     35                                      40                                      45  
 Arg Asn Gly Gln Leu Asp Asp Ser Ser Pro Leu Gly Lys Leu Leu Ala  
                                     50                                      55                                      60  
 Lys Ser Met Ala Ala Asp Gly Lys Ala Gly Gly Gly Ile Glu Asp Val  
                                     65                                      70                                      75                                      80  
 Ile Ala Ala Leu Asp Lys Leu Ile His Glu Lys Leu Gly Asp Asn Phe  
                                     85                                      90                                      95  
 Gly Ala Ser Ala Asp Ser Ala Ser Gly Thr Gly Gln Gln Asp Leu Met  
                                     100                                      105                                      110

**THIS PAGE BLANK (USPTO)**

Thr Gln Val Leu Asn Gly Leu Ala Lys Ser Met L u Asp Asp Leu Leu  
 115 120 125

Thr Lys Gln Asp Gly Gly Thr Ser Phe Ser Glu Asp Asp Met Pro Met  
 130 135 140

Leu Asn Lys Ile Ala Gln Phe Met Asp Asp Asn Pro Ala Gln Phe Pro  
 145 150 155 160

Lys Pro Asp Ser Gly Ser Trp Val Asn Glu Leu Lys Glu Asp Asn Phe  
 165 170 175

Leu Asp Gly Asp Glu Thr Ala Ala Phe Arg Ser Ala Leu Asp Ile Ile  
 180 185 190

Gly Gln Gln Leu Gly Asn Gln Gln Ser Asp Ala Gly Ser Leu Ala Gly  
 195 200 205

Thr Gly Gly Gly Leu Gly Thr Pro Ser Ser Phe Ser Asn Asn Ser Ser  
 210 215 220

Val Met Gly Asp Pro Leu Ile Asp Ala Asn Thr Gly Pro Gly Asp Ser  
 225 230 235 240

Gly Asn Thr Arg Gly Glu Ala Gly Gln Leu Ile Gly Glu Leu Ile Asp  
 245 250 255

Arg Gly Leu Gln Ser Val Leu Ala Gly Gly Gly Leu Gly Thr Pro Val  
 260 265 270

Asn Thr Pro Gln Thr Gly Thr Ser Ala Asn Gly Gly Gln Ser Ala Gln  
 275 280 285

Asp Leu Asp Gln Leu Leu Gly Gly Leu Leu Leu Lys Gly Leu Glu Ala  
 290 295 300

Thr Leu Lys Asp Ala Gly Gln Thr Gly Thr Asp Val Gln Ser Ser Ala  
 305 310 315 320

Ala Gln Ile Ala Thr Leu Leu Val Ser Thr Leu Leu Gln Gly Thr Arg  
 325 330 335

Asn Gln Ala Ala Ala  
 340

<210> 32

<211> 1026

**THIS PAGE BLANK (USPTO)**

&lt;212&gt; DNA

<213> *Pseudomonas syringae*

&lt;400&gt; 32

```

atgcagagtc tcagtccttaa cagcagctcg ctgcaaacc cggcaatggc ccttgtcctg 60
gtacgtcctg aagccgagac gactggcagt acgtcgagca aggcgcttca ggaagtgtgc 120
gtgaagctgg ccgaggaact gatgcgcaat ggtcaactcg acgacagctc gccattggga 180
aaactgttgg ccaagtcgat ggccgcagat ggcaaggcgg gcggcggtat tgaggatgtc 240
atcgctgcgc tggacaagct gatccatgaa aagctcgggtg acaacttcgg cgcgtctgcg 300
gacagcgcc cgggtaccgg acagcaggac ctgatgactc aggtgctcaa tggcctggcc 360
aagtcgatgc tcgatgatct tctgaccaag caggatggcg ggacaagctt ctccgaagac 420
gatatgccga tgctgaacaa gatcgcgcag ttcattggatg acaatcccgc acagtttccc 480
aagccggact cgggctcctg ggtgaacgaa ctcaagggaag acaacttcct tgatggcgac 540
gaaacggctg cgttccgttc ggcactcgac atcattggcc agcaactggg taatcagcag 600
agtgcgctg gcagtctggc agggacgggt ggaggtctgg gactccgag cagtttttcc 660
aacaactcgt ccgtgatggg tgatccgctg atcgacgcca ataccgggtc cggtgacagc 720
ggcaataccc gtggtgaagc ggggcaactg atcggcgagc ttatcgaccg tggcctgcaa 780
tcggtattgg ccggtggtgg actgggcaca ccgtaacaa cccgcagac cggtagctcg 840
gcgaatggcg gacagtccgc tcaggatctt gatcagttgc tggcgcgctt gctgctcaag 900
ggcctggagg caacgctcaa ggatgccggg caaacaggca ccgacgtgca gtcgagcgct 960
gcgcaaatcg ccaccttgct ggtcagtacg ctgctgcaag gcacccgcaa tcaggctgca 1020
gcctga 1026

```

&lt;210&gt; 33

&lt;211&gt; 1729

&lt;212&gt; DNA

<213> *Pseudomonas syringae*

&lt;400&gt; 33

```

tccacttcgc tgattttgaa attggcagat tcatagaaac gttcaggtgt ggaaatcagg 60
ctgagtgcgc agatttcggt gataaggggt tgggtactgg cattgttgg catttcaagg 120
cctctgagtg cgggtgcggag caataccagt ctctctgctg gcgtgtgcac actgagtcgc 180
aggcataggc atttcagttc cttgcgttgg ttgggcataa aaaaaaggga acttttamaa 240
acagtgcaat gagatgccgg caaaacggga accggctcgt gcgctttgcc actcacttcg 300
agcaagctca accccaacaa tccacatccc tatcgaacgg acagcgatac ggccacttgc 360
tctggtaaac cctggagctg gcgtcgggtc aattgcccac ttagcgaggt aacgcagcat 420
gagcatcggc atcacacccc ggccgcaaca gaccaccacg cactcagatt ttctggcgct 480
aagcggcaag agtcctcaac caaacacgtt cggcgagcag aacactcagc aagcgatcga 540
cccagtgca ctgttggttc gcagcgacac acagaaagac gtcaacttcg gcacgcccga 600
cagcaccgtc cagaatccgc aggacgccag caagcccaac gacagccagt ccaacatcgc 660
taaattgate agtgcatgta tcatgtcgtt gctgcagatg ctcaccaact ccaataaaaa 720
gcaggacacc aatcaggaa agcctgatag ccaggctcct ttccagaaca acggcgggct 780
cggtagaccg tcggccgata gcggggggcg cggtagaccg gatgcgacag gtggcggcgg 840
cgggtatacg ccaagcgcaa caggcgggtg cggcgggtgat actccgaccg caacaggcgg 900
tggcggcagc ggtggcggcg gcacacccac tgcaacagggt ggcggcagcg gtggcacacc 960
cactgcaaca ggcgggtggc aggggtggcgt aacaccgcaa atcactccgc agttggccaa 1020
ccctaaccgt acctcaggta ctggctcggg gtcggacacc gcaggttcta ccgagcaagc 1080
cggcaagatc aatgtggtga aagacaccat caaggctcgg gctggcgaag tctttgacgg 1140

```

**THIS PAGE BLANK (USPTO)**

ccacggcgca accttcactg ccgacaaatc tatgggtaac ggagaccagg gcgaaaatca 1200  
gaagcccatg ttcgagctgg ctgaaggcgc tacgttgaag aatgtgaacc tgggtgagaa 1260  
cgaggtcgat ggcattccacg tgaagccaa aaacgctcag gaagtcacca ttgacaacgt 1320  
gcatgcccag aacgtcgggtg aagacctgat tacgggtcaaa ggcgagggag gcgcagcggt 1380  
cactaatctg aacatcaaga acagcagtgc caaagggtgca gacgacaagg ttgtccagct 1440  
caacgccaac actcacttga aaatcgacaa cttcaaggcc gacgatttcg gcacgatgggt 1500  
tcgcaccaac ggtggcaagc agtttgatga catgagcatc gagctgaacg gcacggaagc 1560  
taaccacggc aagttcgccc tgggtgaaaag cgacagtgc gatctgaagc tggcaacggg 1620  
caacatcgcc atgaccgacg tcaaacacgc ctacgataaa acccaggcat cgacccaaca 1680  
caccgagctt tgaatccaga caagtagctt gaaaaaaggg ggtggactc 1729

<210> 34

<211> 424

<212> PRT

<213> *Pseudomonas syringae*

<400> 34

Met Ser Ile Gly Ile Thr Pro Arg Pro Gln Gln Thr Thr Thr Pro Leu  
1 5 10 15

Asp Phe Ser Ala Leu Ser Gly Lys Ser Pro Gln Pro Asn Thr Phe Gly  
20 25 30

Glu Gln Asn Thr Gln Gln Ala Ile Asp Pro Ser Ala Leu Leu Phe Gly  
35 40 45

Ser Asp Thr Gln Lys Asp Val Asn Phe Gly Thr Pro Asp Ser Thr Val  
50 55 60

Gln Asn Pro Gln Asp Ala Ser Lys Pro Asn Asp Ser Gln Ser Asn Ile  
65 70 75 80

Ala Lys Leu Ile Ser Ala Leu Ile Met Ser Leu Leu Gln Met Leu Thr  
85 90 95

Asn Ser Asn Lys Lys Gln Asp Thr Asn Gln Glu Gln Pro Asp Ser Gln  
100 105 110

Ala Pro Phe Gln Asn Asn Gly Gly Leu Gly Thr Pro Ser Ala Asp Ser  
115 120 125

Gly Gly Gly Gly Thr Pro Asp Ala Thr Gly Gly Gly Gly Asp Thr  
130 135 140

Pro Ser Ala Thr Gly Gly Gly Gly Gly Asp Thr Pro Thr Ala Thr Gly  
145 150 155 160

Gly Gly Gly Ser Gly Gly Gly Gly Thr Pro Thr Ala Thr Gly Gly Gly

**THIS PAGE BLANK (USPTO)**



|   |     |     |
|---|-----|-----|
| 165   | 170 | 175 |
| Ser Gly Gly Thr Pro Thr Ala Thr Gly Gly Gly Glu Gly Gly Val Thr |     |     |
| 180   | 185 | 190 |
| Pro Gln Ile Thr Pro Gln Leu Ala Asn Pro Asn Arg Thr Ser Gly Thr |     |     |
| 195   | 200 | 205 |
| Gly Ser Val Ser Asp Thr Ala Gly Ser Thr Glu Gln Ala Gly Lys Ile |     |     |
| 210   | 215 | 220 |
| Asn Val Val Lys Asp Thr Ile Lys Val Gly Ala Gly Glu Val Phe Asp |     |     |
| 225   | 230 | 235 |
| Gly His Gly Ala Thr Phe Thr Ala Asp Lys Ser Met Gly Asn Gly Asp |     |     |
| 245   | 250 | 255 |
| Gln Gly Glu Asn Gln Lys Pro Met Phe Glu Leu Ala Glu Gly Ala Thr |     |     |
| 260   | 265 | 270 |
| Leu Lys Asn Val Asn Leu Gly Glu Asn Glu Val Asp Gly Ile His Val |     |     |
| 275   | 280 | 285 |
| Lys Ala Lys Asn Ala Gln Glu Val Thr Ile Asp Asn Val His Ala Gln |     |     |
| 290   | 295 | 300 |
| Asn Val Gly Glu Asp Leu Ile Thr Val Lys Gly Glu Gly Gly Ala Ala |     |     |
| 305   | 310 | 315 |
| Val Thr Asn Leu Asn Ile Lys Asn Ser Ser Ala Lys Gly Ala Asp Asp |     |     |
| 325   | 330 | 335 |
| Lys Val Val Gln Leu Asn Ala Asn Thr His Leu Lys Ile Asp Asn Phe |     |     |
| 340   | 345 | 350 |
| Lys Ala Asp Asp Phe Gly Thr Met Val Arg Thr Asn Gly Gly Lys Gln |     |     |
| 355   | 360 | 365 |
| Phe Asp Asp Met Ser Ile Glu Leu Asn Gly Ile Glu Ala Asn His Gly |     |     |
| 370   | 375 | 380 |
| Lys Phe Ala Leu Val Lys Ser Asp Ser Asp Asp Leu Lys Leu Ala Thr |     |     |
| 385   | 390 | 395 |
| Gly Asn Ile Ala Met Thr Asp Val Lys His Ala Tyr Asp Lys Thr Gln |     |     |
| 405   | 410 | 415 |
| Ala Ser Thr Gln His Thr Glu Leu                                 |     |     |

**THIS PAGE BLANK (USPTO)**

420

&lt;210&gt; 35

&lt;211&gt; 344

&lt;212&gt; PRT

&lt;213&gt; Pseudomonas solanacearum

&lt;220&gt;

<223> Description of Unknown Organism: Pseudomonas  
solanacearum

&lt;400&gt; 35

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ser | Val | Gly | Asn | Ile | Gln | Ser | Pro | Ser | Asn | Leu | Pro | Gly | Leu | Gln |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Leu | Asn | Leu | Asn | Thr | Asn | Thr | Asn | Ser | Gln | Gln | Ser | Gly | Gln | Ser |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Gln | Asp | Leu | Ile | Lys | Gln | Val | Glu | Lys | Asp | Ile | Leu | Asn | Ile | Ile |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Ala | Leu | Val | Gln | Lys | Ala | Ala | Gln | Ser | Ala | Gly | Gly | Asn | Thr | Gly |
|     | 50  |     |     |     |     | 55  |     |     |     |     |     | 60  |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Thr | Gly | Asn | Ala | Pro | Ala | Lys | Asp | Gly | Asn | Ala | Asn | Ala | Gly | Ala |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Asp | Pro | Ser | Lys | Asn | Asp | Pro | Ser | Lys | Ser | Gln | Ala | Pro | Gln | Ser |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Asn | Lys | Thr | Gly | Asn | Val | Asp | Asp | Ala | Asn | Asn | Gln | Asp | Pro | Met |
|     |     |     | 100 |     |     |     |     | 105 |     |     |     |     | 110 |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Ala | Leu | Met | Gln | Leu | Leu | Glu | Asp | Leu | Val | Lys | Leu | Leu | Lys | Ala |
|     | 115 |     |     |     |     |     | 120 |     |     |     |     | 125 |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Leu | His | Met | Gln | Gln | Pro | Gly | Gly | Asn | Asp | Lys | Gly | Asn | Gly | Val |
|     | 130 |     |     |     |     | 135 |     |     |     |     | 140 |     |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Gly | Ala | Asn | Gly | Ala | Lys | Gly | Ala | Gly | Gly | Gln | Gly | Gly | Leu | Ala |
| 145 |     |     |     |     | 150 |     |     |     |     | 155 |     |     |     | 160 |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Ala | Leu | Gln | Glu | Ile | Glu | Gln | Ile | Leu | Ala | Gln | Leu | Gly | Gly | Gly |
|     |     |     | 165 |     |     |     |     | 170 |     |     |     |     |     | 175 |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Ala | Gly | Ala | Gly | Gly | Ala | Gly | Gly | Gly | Val | Gly | Gly | Ala | Gly | Gly |
|     |     |     | 180 |     |     |     |     | 185 |     |     |     |     | 190 |     |     |

**THIS PAGE BLANK (USPTO)**

Ala Asp Gly Gly Ser Gly Ala Gly Gly Ala Gly Gly Ala Asn Gly Ala  
195 200 205

Asp Gly Gly Asn Gly Val Asn Gly Asn Gln Ala Asn Gly Pro Gln Asn  
210 215 220

Ala Gly Asp Val Asn Gly Ala Asn Gly Ala Asp Asp Gly Ser Glu Asp  
225 230 235 240

Gln Gly Gly Leu Thr Gly Val Leu Gln Lys Leu Met Lys Ile Leu Asn  
245 250 255

Ala Leu Val Gln Met Met Gln Gln Gly Gly Leu Gly Gly Gly Asn Gln  
260 265 270

Ala Gln Gly Gly Ser Lys Gly Ala Gly Asn Ala Ser Pro Ala Ser Gly  
275 280 285

Ala Asn Pro Gly Ala Asn Gln Pro Gly Ser Ala Asp Asp Gln Ser Ser  
290 295 300

Gly Gln Asn Asn Leu Gln Ser Gln Ile Met Asp Val Val Lys Glu Val  
305 310 315 320

Val Gln Ile Leu Gln Gln Met Leu Ala Ala Gln Asn Gly Gly Ser Gln  
325 330 335

Gln Ser Thr Ser Thr Gln Pro Met  
340

<210> 36

<211> 1035

<212> DNA

<213> *Pseudomonas solanacearum*

<400> 36

atgtcagtcg gaaacatcca gagcccgctg aacctcccgg gtctgcagaa cctgaacctc 60  
aacaccaaca ccaacagcca gcaatcgggc cagtcctgtc aagacctgat caagcaggtc 120  
gagaaggaca tcctcaacat catcgagcc ctcgtgcaga aggccgcaca gtcggcgggc 180  
ggcaacaccg gtaacaccgg caacgcgccc gcgaaggacg gcaatgccaa cgcgggcgcc 240  
aacgaccgga gcaagaacga cccgagcaag agccaggctc cgcagtcggc caacaagacc 300  
ggcaacgtcg acgacgcaa caaccaggat ccgatgcaag cgctgatgca gctgctggaa 360  
gacctggtga agctgctgaa ggccggccctg cacatgcagc agcccgccgg caatgacaag 420  
ggcaacggcg tggcggtgc caacggcgcc aagggtgccg gcggccaggc cggcctggcc 480  
gaagcgctgc aggagatoga gcagatcctc gcccgctcg gcggcgccgg tgctggcgcc 540  
ggcgccgcgg gtggcggtgt cggcggtgct ggtggcgccg atggcgccgc cggcgcggt 600

**THIS PAGE BLANK (USPTO)**

ggcgaggcg gtgcgaacgg cgccgacggc ggcaatggcg tgaacggcaa ccaggcgaac 660  
 ggcccgcaga acgcaggcga tgtcaacggg gccaacggcg cggatgacgg cagcgaagac 720  
 cagggcgggc tcaccggcgt gctgcaaaag ctgatgaaga tcctgaacgc gctgggtgcag 780  
 atgatgcagc aaggcggcct cggcgggcggc aaccaggcgc agggcgggctc gaagggtgcc 840  
 ggcaacgcct cgccgggttc cggcgcggaac ccggggcgcg accagcccggt ttcggcggtat 900  
 gatcaatcgt ccggccagaa caatctgcaa tcccagatca tggatgtggt gaaggaggctc 960  
 gtccagatcc tgcagcagat gctggcgggcg cagaacggcg gcagccagca gtccacctcg 1020  
 acgcagccga tgtaa 1035

<210> 37

<211> 26

<212> PRT

<213> *Xanthomonas campestris* pv. *glycines*

<400> 37

Thr Leu Ile Glu Leu Met Ile Val Val Ala Ile Ile Ala Ile Leu Ala  
 1 5 10 15

Ala Ile Ala Leu Pro Ala Tyr Gln Asp Tyr  
 20 25

<210> 38

<211> 20

<212> PRT

<213> *Xanthomonas campestris* pv. *pelargonii*

<400> 38

Ser Ser Gln Gln Ser Pro Ser Ala Gly Ser Glu Gln Gln Leu Asp Gln  
 1 5 10 15

Leu Leu Ala Met  
 20

<210> 39

<211> 13

<212> PRT

<213> *Phytophthora megasperma*

<400> 39

Val Trp Asn Gln Pro Val Arg Gly Phe Lys Val Tyr Glu  
 1 5 10

**THIS PAGE BLANK (USPTO)**



## INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/US 99/23181

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/195 C12N15/31 C12N1/21 C12N5/10 A01H5/00  
A01H5/10 C12N15/82

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.           |
|------------|---|---------------------------------|
| X          | NÜRNBERGER T, ET AL. : "High Affinity Binding of a Fungal Oligopeptide Elicitor to arseley Plasma Membranes Triggers Multiple Defense Responses" CELL, vol. 78, no. 3, 12 August 1994 (1994-08-12), pages 449-460, XP000882736 Cambridge, Mass. cited in the application the whole document | 1,2,10, 11, 19-23, 30-32, 36-38 |
| A          | WO 98 32844 A (CORNELL RES FOUNDATION INC) 30 July 1998 (1998-07-30) the whole document   |                                 |
|            | -/-   |                                 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

6 March 2000

Date of mailing of the international search report

03/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 6816 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Billang, J

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/US 99/23181

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| A          | WO 98 24297 A (CORNELL RES FOUNDATION INC)<br>11 June 1998 (1998-06-11)<br>the whole document  |                       |
| A          | WEI Z-M, ET AL.: "Harpin, an HR elicitor,<br>activates both defense and growth systems<br>in many commercially important crops"<br>PHYTOPATHOLOGY,<br>vol. 88, September 1998 (1998-09), page<br>S96 XP000882741<br>abstract |                       |
| A          | NIGGEMEYER J, ET AL.: "Characterization<br>of the functional domains of harpin"<br>PHYTOPATHOLOGY,<br>vol. 88, September 1998 (1998-09), page<br>S67 XP000882740<br>abstract   |                       |

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Inventor Application No

PCT/US 99/23181

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| WO 9832844 A                              | 30-07-1998          | AU 6043198 A               | 18-08-1998          |
| WO 9824297 A                              | 11-06-1998          | AU 5693598 A               | 29-06-1998          |
|   |                     | EP 0957672 A               | 24-11-1999          |

**THIS PAGE BLANK (USPTO)**